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Abstract 
 
C-Terminal amidated peptide hormones regulate numerous physiological process and 
are associated with many pathological conditions. Their C-terminal amidation 
isexclusively catalysed by the enzyme peptidylglycine α-amidating monooxygenase 
(PAM), which has two subunits: peptidylglycine α-hydroxylating monooxygenase 
(PHM; EC 1.14.17.3) and peptidyl-α-hydroxyglycine α-amidating lyase (PAL; EC 
4.3.2.5). In the present study, the substrate specificity and inhibition of the PAM 
sourced from DMS53 human small cell lung cancer cells were investigated. A peptide 
consensus sequence N-Ac-Gly-(S)-Pro-Gln-(S)-Arg-(S)-Phe-Gly-COOH was 
constructed from the human amidated peptide hormone database, and a library of 
peptide substrates was designed by varying the amino acids located at the penultimate 
and antepenultimate positions from the C-terminus. These peptides were synthesised 
by solid phase peptide synthesis and studied in a competitive PHM binding assay. The 
results indicated that human glycine-extended hormone precursors having -Arg-Phe-
Gly-COOH are likely to bind to PHM effectively in living bodies with IC50 values 
around 20 µM and those having –Asp-Phe-Gly-COOH and -Ala-Phe-Gly-COOH are 
likely to bind with IC50 values around 70 µM. The results also show that 
antepenultimate amino acids affect binding to PHM but to a lesser degree than the 
effect of penultimate amino acids. 
 
In a prodrug study, the anti-cancer drug bexarotene was synthetically extended with a 
glycine to obtain a derivative that was expected to be cleaved by PAM and then deliver 
a cytotoxic drug. However, the derivative compound showed poor binding to PHM at 
xii 
 
the millimolar level, but had a similar cytotoxic activity against DMS53 cells to its 
parent agent. Unlike bexarotene, a previous study showed that the glycine derivative 
of temozolomide (another anti-cancer drug) has strong binding to PHM at micromolar 
concentration, but somehow does not convert to temozolomide by PAM. One possible 
reason is that the glycine derivative possessing an imidazole moiety could inhibit PHM 
by metal chelation. To investigate this, a structurally-similar molecule N-Ac-(S)-His-
Gly-COOH was tested and found to be processed by PAM and not undergo copper 
coordination. This implies that the glycine derivative of temozolomide is unlikely to 
chelate the copper of the PHM active site. 
 
To investigate PHM and PAL activity simultaneously, a new PAM assay with a direct, 
rapid and sensitive HPLC-MS system was established. With this new assay the PAL 
inhibitor N-Ac-Phe-pyruvate and analogues were evaluated in terms of PAM 
inhibition through isolated enzyme competitive assays. This demonstrated that N-Ac-
Phe-pyruvate is a PAL inhibitor at the nanomolar level against the medium PAM from 
DMS53 cells and deprotonation of its enol form results in a decrease of PAL inhibition. 
 
By using the established HPLC-MS detection system, the intermediate of the C-
terminal amidation of calcitonin-Gly (CTG), α-hydroxyglycine-extended calcitonin 
(HO-CTG), was detected in the culture medium of DMS53 cells. This is the first time 
HO-CTG produced by cells has been detected. With and without a PAL inhibitor, the 
concentration of the HO-CTG in the medium sample was found to be more than two 
orders of magnitude lower than those of the corresponding substrate and amidated 
xiii 
 
product, suggesting the PAL catalysis is much faster than PHM catalysis, and PHM 
catalysis is the rate-limiting step of amidation of calcitonin in human cells.  
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Chapter One 
Introduction 
 
1.1 C-Terminal Amidated Peptide Hormones 
 
Peptide hormones play many important roles in biological activities in living bodies. 
Their roles include but are not limited to digestion,[1] body temperature control,[2] 
growth,[3] uterine contractions,[4] cardiovascular function,[5] and antidiuretic 
regulation.[6] Through regulated secretory pathways, peptide hormones are synthesised 
from larger, inactive precursors by a set of co- and post-translational modifications to 
become biologically active. As illustrated in Figure 1.1 below, some prohormones 
have paired basic sites containing arginine (R) or lysine (K) which can undergo 
endoproteolysis by prohormone convertases (PCs). The cleaved residue extensions are 
then recognised and removed by carboxypeptidase E (CPE) and aminopeptidase to 
produce active hormones.[7] However, some hormones will not be biologically active 
unless they are treated with an additional modification including glycosylation, 
acetylation, sulfation, phosphorylation, or C-terminal amidation. Among them, C-
terminal amidation is the most important because around 50% of mammalian peptide 
hormones and more than 80% of insect hormones require amidation at the C-terminus 
for biological activity.[8] This process is accomplished through a sequential reaction 
of two enzymes encoded by a single bifunctional enzyme - peptidylglycine α-
amidating monooxygenase (PAM, EC 1.14.17.3).[7] 
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Figure 1.1 Biosynthesis of C-terminal amidated peptide hormones.[7] 
 
The sequences of all known human α-amidated peptide hormones are listed in Table 
1.1. These peptides have a vast range of functions. For instance, kisspeptin stimulates 
the secretion of aldosterone and the release of insulin;[9] vasopressin serves as an 
antidiuretic regulator[6] and helps to alleviate pulmonary inflammation[10] as well as 
influence pair-bonding in voles for its various neurological effect on brains;[11] 
Cholecystokinin plays a key role in a number of physiological processes including 
digestion,[12] satiety,[13] and anxiety;[14-15] and calcitonin participates in regulation of 
calcium and phosphorus metabolism,[16] which may induce cancer growth.[17-18] 
Therefore, from the above mentioned it is inferred that some correlation may exist 
between peptide hormone amidations and pathological conditions (e.g. chronic pain, 
inflammation, asthma or cancer).  
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Table 1.1 Human α-amidated peptide hormones. 
 
 
No. Name Sequence 
1 Adrenomedullin[19] YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVAPRSKISPQ
GY-NH2 
2 Adrenomedullin-2[20] TQAQLLRVGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-
NH2 
3 Arg-vasopressin[6] CYFQNCPRG-NH2 
4 Big gastrin[21] QLGPQGPPHLVADPSKKQGPWLEEEEEAYGWMDF-NH2 
5 Calcitonin[22] CGNLSTCMLGTYTQDFNKFHTFPQTAIGVGAP-NH2 
6 Calcitonin gene-related peptide[23] ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2 
7 Calcitonin gene-related peptide 2[24] ACNTATCVTHRLAGLLSRSGGMVKSNFVPTNVGSKAF-NH2 
8 Cholecystokinin-5[25] GWMDF-NH2 
9 Cholecystokinin-7[26] YMGWMDF-NH2 
10 Cholecystokinin-8[27] DYMGWMDF-NH2 
11 Cholecystokinin-12[28] ISDRDYMGWMDF-NH2 
12 Cholecystokinin-18[29] LDPSHRISDRDYMGWMDF-NH2 
13 Cholecystokinin-25[29] YIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDF-NH2 
14 Cholecystokinin-58[27] VSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRD
YMGWMDF-NH2 
15 Corticoliberin[30] SEEPPISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII-NH2 
16 Endokinin-A[31] DGGEEQTLSTEAETWVIVALEEGAGPSIQLQLQEVKTGKASQFFGLM-NH2 
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17 Endokinin-A/B[31] GKASQFFGLM-NH2 
18 Endokinin-C[31] KKAYQLEHTFQGLL-NH2 
19 ER-37[32] EEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRR-NH2 
20 Gastrin[33] QGPWLEEEEEAYGWMDF-NH2 
21 Gastrin-6[34] YGWMDF-NH2 
22 Gastrin-14[33] WLEEEEEAYGWMDF-NH2 
23 Gastrin-52[35] DLELPWLEQQGPASHHRRQLGPQGPPHLVADPSKKQGPWLEEEEEAYGW
MDF-NH2 
24 Gastrin-71[36] SWKPRSQQPDAPLGTGANRDLELPWLEQQGPASHHRRQLGPQGPPHLVA
DPSKKQGPWLE-NH2 
25 Gastrin-releasing peptide[37] VPLPAGGGTVLTKMYPRGNHWAVGHLM-NH2 
26 Glucagon-like peptide 1(7-36)[38] HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR-NH2 
27 Gonadoliberin-1[39] QHWSYGLRPG-NH2 
28 Gonadoliberin-2[40] QHWSHGWYPG-NH2 
29 GR-44[32] GYPEEKKEEEGSANRRPEDQELESLSAIEAELEKVAHQLQALRR-NH2 
30 Intermedin-short[41] VGCVLGTCQVQNLSHRLWQLMGPAGRQDSAPVDPSSPHSY-NH2 
31 Intestinal peptide PHM-27[42] HADGVFTSDFSKLLGQLSAKKYLESLM-NH2 
32 Islet amyloid polypeptide[43] KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY-NH2 
33 Kisspeptin[44] GTSLSPPPESSGSPQQPGLSAPHSRQIPAPQGAVLVQREKDLPNYNWNSFGL
RF-NH2 
34 Kisspeptin-10[45] YNWNSFGLRF-NH2 
35 Kisspeptin-13[45] LPNYNWNSFGLRF-NH2 
36 Kisspeptin-14[45] DLPNYNWNSFGLRF-NH2 
37 Melanotropin alpha[46] SYSMEHFRWGKPV-NH2 
38 Melanotropin gamma[47] YVMGHFRWDRF-NH2 
39 Neurokinin A[48] HKTDSFVGLM-NH2 
40 Neurokinin-B[49] DMHDFFVGLM-NH2 
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41 Neuromedin-B[50] GNLWATGHFM-NH2 
42 Neuromedin-B-32[51] APLSWDLPEPRSRASKIRVHSRGNLWATGHFM-NH2 
43 Neuromedin-C[37] GNHWAVGHLM-NH2 
44 Neuromedin-S[52] ILQRGSGTAAVDFTKKDHTATWGRPFFLFRPRN-NH2 
45 Neuromedin-U-25[53] FRVDEEFQSPFASQSRGYFLFRPRN-NH2 
46 Neuropeptide gamma, 2nd part[54] GHGQISHKRHKTDSFVGLM-NH2 
47 Neuropeptide-glutamic 
acid-isoleucine[55] 
EIGDEENSAKFPI-NH2 
48 Neuropeptide AF[56] AGEGLNSQFWSLAAPQRF-NH2 
49 Neuropeptide FF[57] FLFQPQRF-NH2 
50 Neuropeptide K[54] DADSSIEKQVALLKALYGHGQISHKRHKTDSFVGLM-NH2 
51 Neuropeptide NPSF[58] SLNFEELKDWGPKNVIKMSTPAVNKMPHSFANLPLRF-NH2 
52 Neuropeptide NPVF[57] VPNLPQRF-NH2 
53 Neuropeptide RFRP-1[57] MPHSFANLPLRF-NH2 
54 Neuropeptide SF[59] SQAFLFQPQRF-NH2 
55 Neuropeptide Y[60-61] YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
56 Obestatin[62] FNAPFDVGIKLSGVQYQQHSQAL-NH2 
57 Orexin-A[63] QPLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 
58 Orexin-B[64] RSGPPGLQGRLQRLLQASGNHAAGILTM-NH2 
59 Osteocrin[65] SFSGFGSPLDRLSAGSVDHKGKQRKVVDHPKRRFGIPMDRIGRNRLSNSR-
NH2 60 Oxytocin[4] CYIQNCPLG-NH2 
61 Pancreastatin[66] GESRSEALAVDGAGKPGAEEAQDPEGKGEQEHSQQKEEEEEMAVVPQGL
FRG-NH2 
62 Pancreatic hormone[67] APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
63 Peptide YY[68] YPIKPEAPREDASPEELNRYYASLRHYLNLVTRQRY-NH2 
64 Peptide YY(3-36)[69] IKPEAPREDASPEELNRYYASLRHYLNLVTRQRY-NH2 
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65 Pituitary adenylate cyclase-activating 
polypeptide 27[70] 
HSDGIFTDSYSRYRKQMAVKKYLAAVL-NH2 
66 Pituitary adenylate cyclase-activating 
polypeptide 38[70] 
HSDGIFTDSYSRYRKQMAVKKYLAAVLGKRYKQRVKNK-NH2 
67 Pneumadin[71] AGEPKLDAGV-NH2 
68 Potential peptide[72] EDVSAGEDCGPLPEGGPEPRSDGAKPGPRE-NH2 
69 Proadrenomedullin N-20 terminal 
peptide[73] 
ARLDVASEFRKKWNKWALSR-NH2 
70 Prolactin-releasing peptide PrRP31[74] SRTHRHSMEIRTPDINPAWYASRGIRPVGRF-NH2 
71 Prolactin-releasing peptide PrRP20[75] TPDINPAWYASRGIRPVGRF-NH2 
72 QRF-amide[76] QDEGSEATGFLPAAGEKTSGPLGNLAEELNGYSRKKGGFSFRF-NH2 
73 Salusin-alpha[77] SGALPPAPAAPRPALRAQRAGPAGPGAK-NH2 
74 Secretin[78] HSDGTFTSELSRLREGARLQRLLQGLV-NH2 
75 Somatoliberin[79] YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2 
76 Spexin[80] NWTPQAMLYLKGAQ-NH2 
77 Substance P[5] RPKPQQFFGLM-NH2 
78 Thyroliberin[81] QHP-NH2 
79 Urocortin[82] DNPSLSIDLTFHLLRTLLELARTQSQRERAEQNRIIFDSV-NH2 
80 Urocortin-3[83] FTLSLDVPTNIMNLLFNIAKAKNLRAQAAANAHLMAQI-NH2 
81 Vasoactive intestinal peptide[84] HSDAVFTDNYTRLRKQMAVKKYLNSILN-NH2 
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1.2 General Introduction to PAM Enzyme 
 
PAM is the only known enzyme that catalyses C-terminal amidation both in mammals 
and insects.[85] It exists not only in neuroendocrine tissues, but also in endothelial cells, 
smooth muscle cells, airway, brain ependymal cells, and astrocytes.[8, 86-88] In an adult 
human body, high levels of PAM activity have been found in the central nervous 
system,[89] endocrine cells of the pituitary,[85] and at atrium cordis.[90] PAM consists of 
two subunits: peptidylglycine α-hydroxylating monooxygenase (PHM; EC 1.14.17.3) 
and peptidyl-α-hydroxyglycine α-amidating lyase (PAL; EC 4.3.2.5). PHM catalyses 
stereospecific hydroxylation of the glycine α-carbon of all the peptidyglycine 
substrates; then PAL catalyses N-dealkylation of the α-hydroxyglycine intermediates 
to produce amidated hormones and glyoxylate (Scheme 1.1).[85] Since some 
pathological conditions can be attributed to dysfunction of α-amidated peptides, there 
has been a constant interest in developing PAM inhibitors that could moderate α-
amidated peptide hormone levels. 
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Scheme 1.1 Mechanism of PAM Catalysis. 
 
1.2.1 Mechanistic Insight of PHM 
 
The first subunit of PAM enzyme, PHM, is copper-, molecular oxygen- and ascorbate-
dependent. Figure 1.2 shows the X-ray crystal structure of the active pocket of PHM 
with encapsulated substrate. PHM catalytic core consists of two β-sandwich domains, 
of which one binds to an active site cupric ion  (CuA) with three histidine residues 
(H107, H108, and H172); and another binds to the second cupric ion (CuB) with H242, 
H244, and M314.[91] The distance between these two coppers is 11 Å and is not 
affected by the binding of the peptide. The CuA site has been identified as an electron 
transfer site,[91] while the CuB site is close to the substrate binding site.[91] This 
structural analysis is consistent with the results attained in several kinetic and 
structural studies.[92-95] It is worth noting that the key structural change for peptide 
binding is hydrogen bond formation between the glycyl NH of the peptide substrate 
and the carbonyl group of N316 through rotation of N316 side chain, which leads to 
the breaking of a hydrogen bond between N316 and Y318. Further, the carboxylate of 
the substrate forms not only an ion-ion interaction with the guanidiunium group of 
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R240 but also a hydrogen bond with the hydroxyl group of Y318. Additionally, some 
hydrophobic residues like the CuB ligand M314 have good contact with the 
hydrophobic side chain of the substrate, anchoring it in the PHM active site[91]. 
 
 
Figure 1.2 Crystal structure of an oxidised PHM-substrate complex.[91] The substrate 
is N-Ac-l-3,5-diiodotyrosylglycine. (From Prigge et al., Science 1997, 278, 1300. 
Reprinted with permission from American Association for the Advancement of 
Science.) 
 
The two PHM copper ions cycle between Cu(I) and Cu(II) during the hydroxylation 
of the C-terminal glycine residue of a peptide substrate.[96-98] This redox reaction as 
part of PHM activity requires the participation of ascorbic acid.[8] Ascorbate reduces 
the two PHM copper atoms from Cu(II) to Cu(I) through two single-electron transfers 
and itself is oxidised to semidehydroascorbate at the same time.[99] The reduced Cu(I) 
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binds to molecular oxygen as the glycine-extended substrate binds to the enzyme,[100] 
followed by abstraction of H· and formation of C-OH bond in the substrate.[92, 101-102] 
However, to date, it has not been confirmed what the abstracting species are[92-93, 95, 
103] and how formation of C-OH bond is performed.[92-93]  
 
1.2.2 Mechanistic Insight of PAL 
 
PAL, a zinc-dependent enzyme, catalyses the cleavage of the α-hydroxyglycine 
extended intermediate produced by PHM to the corresponding amidated product and 
glyoxylate at physiological pH.[104] The PAL enzyme active site consists a Zn(II) 
coordinated by H585, H690 and H786.[105-106] Based on the analysis of the X-ray 
crystal structure of a PAL-substrate complex, as shown in Figure 1.3, several 
interactions between the substrate and the enzyme are considered important.[105] For 
example, an important tyrosine residue, Y654, concerved in all known PAL enzymes, 
and is proposed to be first deprotonated as the catalytic base through the interaction 
with R706 and Zn(II).[106-107] Afterwards, Y654 deprotonates the α-hydoxyl group of 
the PAL substrate already bound to the active site through coordination of the α-OH 
to the Zn(II). Finally, it transfers the proton to the leaving –NH group which triggers 
the formation of the amidated peptide and glyoxylate (Scheme 1.2).[105] In addition, 
R533 anchors the terminal carboxylate of the substrate by ion-ion interactions, while 
M784 anchors the carbonyl of the substrate via sigma-hole bond and determines the 
stereo specificity of the PAL reaction.[105] 
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Figure 1.3 Crystal structure of a PAL-substrate complex.[105] The substrate is HO-Ala-
Ala-(S)-Gly-COOH. (From Chufan et al., Structure 2009, 17, 965. Reprinted with 
permission from Cell Press.)  
 
 
Scheme 1.2 PAL catalytic reaction mechanism.[105] 
 
1.2.3 PAM Cofactors  
 
The PAM reaction mainly depends on PHM cofactors, which are oxygen, copper and 
ascorbate, lacking one of them can lead to inactivation of PAM activity.[8, 104, 108] For 
example, loss of oxygen in tissue-related experiments can completely inhibit 
amidation,[108] and acute hypoxia in cell assay can significantly restrain production of 
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amidated peptides.[109] Copper ion is the only metal ion present in the PHM structure 
and crucial for monoxygenase activity.[110] PAM-catalysed amidation can be inhibited 
by copper chelation. For instance, copper chelator, N,N-diethyldithiocarbamate, 
reduces the production of adrenocorticotropic hormone (ACTH) and α-melanocyte-
stimulating hormone (α-MSH);[108] bathocuproinedisulfonic acid, a cell impermeant 
copper chelator specific for Cu(I), inhibits the formation of peptide YY and 
neuromedin U in Chinese hamster ovary cell medium.[111] Activity can only be 
restored by addition of copper ion.[110, 112] Its oxidizing agent, ascorbate, is another 
important factor for PAM activity. In cultured pituitary cells, the lack of ascorbate can 
lead to the loss of amidated peptide α-MSH while the addition of ascorbate can re-
establish α-amidation.[113] Pre-incubating AtT-20 cells (a type of pituitary corticotrope 
tumor from mouse) with medium containing ascorbate for 24 h can increase 
intracellular concentration of ascorbate as well as levels of amidated joining 
peptide.[114] A similar  scenario can also be seen with thyrotropin-releasing hormone 
(TRH) in the cultures of hypothalamic cells.[113]  
 
1.2.4 Substrate Specificity of PAM 
 
PAM has a high substrate specificity for C-terminal glycine-extended peptide 
prohormones,[115-117] and especially has a preference for those with a hydrophobic 
amino acid with (S)-α-configuration in the penultimate position at the C-terminus, 
adjacent to the glycine.[115, 118-119] In the binding affinity study by Tamburini et al.,[118] 
all twenty natural amino acids were one by one put at the position X of N-dansyl-
(Gly)4-X-Gly-COOH for binding affinity test and a 130-fold variation in apparent Km 
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values were observed. The broad range in Km values indicates that the interaction of a 
side chain at the penultimate position from the C-terminus with the enzyme active site 
can play an important role to the stabilization of the enzyme-substrate complex. Its 
positive effect on binding to PAM decreases sequentially through four groups which 
are sulphur containing or planar aromatic, neutral aliphatic, polar and basic, and cyclic 
aliphatic or acidic.[118] More specifically, Table 1.2 illustrates the effect of each of the 
twenty amino acids at the penultimate position of the hexapeptide substrate on the 
binding affinity with PAM.[118]  
Table 1.2 Kinetic parameters for enzymatic α-amidation of peptides of the form 
N-dansyl-(Gly)4-X-Gly-OH.[118]  
Group X Km (µM) Vmax (nmol min-1 mg-1) 
Planar aromatic Phe 4 50 
or sulphur containing Tyr 5 40 
 Met 7 23 
 Cys 11 10 
Neutral aliphatic Ile 20 55 
 His 41 10 
 Ala 46 6 
 Val 49 48 
 Leu 54 22 
 Trp 58 58 
Polar and basic Asn 83 7 
 Ser 196 9 
 Arg 200 15 
 Lys 206 4 
 Gln 308 17 
 Thr 334 50 
Cyclic aliphatic or acidic Glu 449 5 
 Pro 618 22 
 Gly - (< 1 at 240 µM) 
 Asp - No detectable activity 
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In addition, the length of peptide substrate sequence is another factor that affects 
binding affinity. Recognition of peptide substrate extends to about five amino acids 
from the C-terminus, as displayed by the study of Morris et al.[120] showing that Km 
values for tri-, tetra-, and pentapeptide analogues of procalcitonin, and of mono-, di-, 
tri, and tetrapeptide analogues of prooxytocin decrease accordingly and are all higher 
than the Km values of the corresponding natural prohormones. It is worth noting that 
peptides with C-terminal (R)-Ser or (R)-Ala can also be processed by PAM but the 
enzyme binding affinities are less than one percent of those with C-terminal Gly.[117]  
 
Apart from peptides, several types of non-peptide compounds can also be competitive 
substrates for PAM. As shown in Scheme 1.3A, PAM can catalyse amine N-
dealkylation, for example, converting N-(4-nitrobenzyl)glycine (1-1) to 4-
nitrobenzylamine.[102] However, their PAM binding affinities are relatively low with 
millimolar Km values.[102] Sulphide (4-nitrobenzy1)thioacetic acid (1-3) is also 
oxidatively cleaved by bovine PAM, with the Km value of 340 µM, yielding mainly 
sulfoxide through formation of sulphur cation radical and thus sulfoxidation (Scheme 
1.3B).[104] In addition, some hydrazones and semicarbazones of glyoxylic acid 1-6 - 1-
16 are well recognised and oxidised by porcine PAM (Scheme 1.3C).[121] 
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Scheme 1.3 Variety of non-peptide substrates accommodated by PAM. (A): N-
dealkylation of amine compounds;[102] (B): Sulfoxidation of sulphide;[104] (C) PAM-
catalysed reaction of hydrazones and semicarbazones of glyoxylic acid.[121] 
 
1.3 PAM Inhibition 
 
As mentioned before, overexpression of α-amidated peptide hormones may contribute 
to inflammation, disease recurrence, cancer cell proliferation, or tumour growth etc.[17, 
87, 122-123] For instance, calcitonin secreted by prostate carcinoma cell lines can 
stimulate cell growth in the tumour;[17] substance P and calcitonin gene-related peptide 
(CGRP) give rise to acute inflammation including rheumatoid arthritis.[87] The 
disease-promoting role of some amidated peptides makes PAM a promising target for 
therapeutic strategies.[87] Furthermore, the fact that PAM activity is the rate-limiting 
B 
A 
C 
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and final step in the production of α-amidated peptide hormones in vivo,[110] makes the 
regulation of amidated peptide hormones possible through the regulation of PAM. 
Hence, many studies focus on drug development through the production of inhibitors 
that regulate PAM both in vivo and in vitro.[87, 104, 124-127] 
 
1.3.1 PHM Inhibitors 
 
Considerable effort has been made on studying compounds, which can be processed 
by PHM and that result in inactivation of the enzyme. E-4-phenyl-3-butenoic acid 
(PBA) (1-17), is an irreversible mechanism-based PHM inhibitor. Michael 
addition/Cu(I) chelation is thought to be the main chemistry for PHM inhibition by 
PBA, which occurs via formation of a delocalised radical prior to hydroxylation, 
producing an inactivated copper-oxygen species (Scheme 1.4).[128] PBA shows anti-
inflammatory and analgesic effects in animal models of acute and chronic 
inflammation, probably by reducing the level of the amidated peptide substance P, 
which is linked to inflammation.[87] In addition, PBA (1-17) exhibits anti-tumorigenic 
potential in that PBA (1-17) reduces lung cancer cell proliferation by inhibiting 
amidated growth factors: gastin-releasing peptide (GRP).[129-130] Apart from PBA, the 
PBA derivatives 1-18 - 1-21 containing methyl, methoxy and benzyloxy substituents 
on their phenyl rings also show similar PHM inhibitory potency.[128] 
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Scheme 1.4 Radical formation and hydroxylation of PBA by PHM.[128]   
 
α,β-Unsaturated acids such as cinnamate and its analogues 1-25 - 1-34 have different 
chemistry for the inactivation of PHM via a reversible Michael addition of an active 
site nucleophile at the α,β-unsaturated carbonyl of cinnamate and corresponding 
analogues (Figure 1.4).[124] Among them, trans-benzoylacrylic acid (1-37) shows 
approximately eight times better PHM inactivation than that of monoethyl fumarate 
(1-36), indicating that aromatic ring enhances the binding affinity with PHM.[102] 
Further, compounds more closely resembling PHM substrates such as enantiomeric 
compounds (R)- and (S)-5-acetamido-4-oxo-6-phenyl-2-henxenoic acid (1-38) - (1-39) 
have similar PHM inhibitory effects, illustrating that the binding mode of α,β-
unsaturated γ keto acids is different to those of peptide substrates and peptidyl 
competitive inhibitors, for which PHM exhibits subsite stereospecificity.[131-132]  
 
 
Figure 1.4 Proposed mechanism for cinnamate-mediated inactivation of PHM.[124] 
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Glycolates such as compounds 1-45 - 1-58 are a type of reversible and competitive 
PHM inhibitor.[102, 119, 127, 133-134] In terms of structure, glycolates and PHM substrates 
are alike and the only difference is that the NH of glycine in substrates is replaced with 
O in glycolates. This change blocks enzyme catalysis because of the inability to 
perform an α-hydroxylation.[135] A study by Cao et al.[133] shows that fatty acid 
derivatives of glycolates 1-45 - 1-49 are efficient inhibitors against enzyme extracted 
from frog and human small cell lung carcinoma (H889 and DMS53). Compared with 
the corresponding glycine substrate with Km,app values of 30 µM, the decanoate 1-47 
has an IC50 of only 40 nM against PAM extracted from DMS53 Cells.[133] Similar to 
glycine-extended substrates of PAM, glycolate analogues also show high enzyme 
affinity when an α-(S)-amino acid is present at the penultimate position. For example, 
(S)-phenylalanine and leucine derivatives 1-57 and 1-58 have KI values of 45 and 60 
µM, respectively, while the corresponding enantiomers 1-59 and 1-60 have much 
higher KI values of 2250 and 2100 µM, respectively.[119]  
 
The unsaturated thioacetic acid, trans-styrylthioacetic acid (1-109), behaves as an 
irreversible mechanism-based PHM inhibitor.[136] Two possible pathways of PHM-
catalysed reaction of compound 1-109 were proposed as shown in Scheme 1.6. Since 
synthesised compound 1-140 was tested (used up to 3 mM) and shows no inhibitory 
effect,[136] it is thus more likely that, after delocalization, benzylic radical in compound 
1-141 is formed according to pathway b (Scheme 1.5), followed by reaction with a 
radical residue of PHM, leading to inactivation. The corresponding cis isomer 1-110 
shows no inhibition, indicating that the configurational isomerism affects PHM 
inactivation significantly and only trans-form is active.[136]  
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Scheme 1.5 Two possible pathways of PHM oxidation of trans-styrylthioacetic 
acid.[136] 
 
Some non-peptide N-formyl amides 1-131 - 1-137 are recognised as moderate 
mechanism-based irreversible inactivators of PHM.[137] N-formyl amides 1-133 - 1-
137 with phenyl groups show better PHM inhibition than those with aliphatic ones, 
among which compound 1-137 that mimics phenylalanine is the most potent one. 
Table 1.3 summarises all reported PHM substrates and inhibitors. 
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Table 1.3 PHM substrates and inhibitors. 
Structure and Binding Data Structure and Binding Data 
 
1-1 
Km = 1800 µM(bovine)[102] 
 
1-2 
Km = 160 µM(bovine)[102] 
 
1-3 
Km= 340 µM(bovine)[102] 
 
1-4 
KI = 380 ± 40 µM (rat)[127] 
 
1-5 
KI = 29 µM (rat)[127] 
 
1-6 
KI = 15 µM (96% inhibition with 100 
µM; porcine)[121] 
 
1-7 
0% inhibition with 100 µM (porcine)[121] 
 
1-8 
93% inhibition with 100 µM 
(porcine)[121] 
 
1-9 
45% inhibition with 100 µM 
(porcine)[121] 
 
1-10 
8% inhibition with 100 µM 
(porcine)[121] 
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1-11 
46% inhibition with 100 µM 
(porcine)[121] 
 
1-12 
94% inhibition with 100 µM[121] 
 
1-13 
52% inhibition with 100 µM 
(porcine)[121] 
 
1-14 
50% inhibition with 100 µM 
(porcine)[121] 
 
1-15 
33% inhibition with 100 µM 
(porcine)[121] 
 
1-16 
KI = 110 µM (83% inhibition with 100 
µM; porcine)[121] 
 
1-17 
KI = 1 µM (bovine)[102] 
KI = 19 ± 2 µM (porcine)[128] 
KI = 0.096 ± 0.028 µM (human)[138] 
 
 
1-18 
KI = 5.7 ± 0.9 µM (porcine)[128] 
 
1-19 
KI = 15 ± 2 µM (porcine)[128] 
 
1-20 
KI = 19 ± 2 µM (porcine)[128] 
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1-21 
KI = 3.9 ± 0.7 µM (porcine)[128] 
 
1-22 
KI > 700 µM (porcine)[128] 
 
1-23 
IC50 = 1000 µM (rat)[139] 
 
1-24 
IC50 = 1500 µM (rat)[139] 
 
1-25 
KI = 4000 ± 200 µM (rat)[124]  
 
1-26 
KI = 200 ± 20 µM (rat)[124] 
 
1-27 
KI = 300 ± 40 µM (rat)[124] 
 
1-28 
KI = 600 ± 40 µM (rat)[124] 
 
1-29 
KI = 500 ± 60 µM (rat)[124] 
 
1-30 
KI = 2000 ± 300  µM (rat)[124] 
 
1-31 
KI = 3000 ± 500 µM (rat)[124] 
 
1-32 
KI = 6000 ± 600 µM (rat)[124] 
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1-33 
KI = 10000 ± 2000 µM (rat)[124] 
 
1-34 
KI = 10 ± 1 µM (rat)[124] 
 
1-35 
KI = 131 ± 26 µM (porcine)[128] 
 
1-36 
KI = 1300 µM (bovine)[102] 
 
1-37 
KI = 160 µM (bovine)[102] 
KI = 440 ± 50 µM (porcine)[128] 
 
1-38 
KI = 60 µM  (frog)[131] 
 
1-39 
KI = 54 µM (frog)[131] 
 
1-40 
KI = 26 ± 2 µM (L) (frog)[140] 
KI = 60 ± 3 µM (racemate) (frog)[140] 
 
1-41 
KI = 57 µM (frog)[131] 
 
1-42 
KI = 2900 ± 480 µM (rat)[127] 
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1-43 
IC50 = 3000 µM (frog)[135] 
 
1-44 
IC50 = 6000 µM (frog)[135] 
 
1-45 
IC50 = 780 µM (frog)[133]  
 
1-46 
IC50 = 250 µM (frog)[133] 
 
1-47 
IC50 = 40 µM (frog)[133]  
IC50 = 0.04 µM (human)[133] 
 
1-48 
IC50 = 35 µM (frog)[133] 
IC50 = 0.06 µM (human)[133] 
 
1-49 
IC50 = 30 µM (frog)[133] 
 
1-50 
IC50 = 250 µM (frog)[134] 
 
1-51 
IC50 = 510 µM (frog)[133] 
IC50 = 2.0 µM (human)[133] 
 
1-52 
KI = 54 ± 4 µM (rat)[127] 
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1-53 
KI = 480 µM (bovine)[102] 
 
1-54 
IC50 = 50 µM (frog)[134] 
 
1-55 
IC50 = 500 µM (frog)[134] 
 
1-56 
KI = 52 µM (bovine)[119] 
 
1-57 
KI = 45 µM (bovine)[119] 
IC50 > 2000 µM (frog)[133] 
IC50 = 6 µM (human)[133] 
 
1-58 
KI = 60 µM (bovine)[119] 
 
1-59 
KI = 2250 µM (bovine)[119] 
 
1-60 
KI = 2100 µM   (bovine)[119] 
 
1-61 
KI = 1250 µM (bovine)[119] 
 
1-62 
KI = 1000 ± 60 µM (rat)[127] 
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1-63 
KI = 18000 ± 5100 µM (rat)[127] 
 
1-64 
IC50 = 440 µM (frog)[133]  
IC50 = 330 µM (human)[133] 
 
1-65 
KI = 8100 µM (bovine)[119] 
 
1-66 
KI = 2.0 µM (bovine)[119] 
IC50 = 170 µM (frog)[133] 
IC50 = 15 µM (human)[133] 
 
1-67 
KI = 1300 µM (bovine)[119] 
 
1-68 
Km = 82 ± 11 µM (rat)[141] 
 
1-69 
IC50 = 440 µM (frog)[133]  
IC50 = 200 µM (human)[133] 
 
1-70 
Km = 33 ± 5 µM (rat)[141] 
 
1-71 
KI = 110 ± 20 µM (rat)[127] 
 
1-72 
KI = 1500 ± 150 µM (rat)[127] 
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1-73 
17% inhibition with 100 µM 
(porcine)[121] 
 
1-74 
KI = 7.2 ± 0.9 µM (rat)[127] 
 
1-75 
KI = 3.6 ± 0.4 µM (rat)[127] 
 
1-76 
KI = 20 µM (porcine)[142] 
 
1-77 
KI > 5000 µM (porcine)[142] 
 
1-78 
IC50 = 300 µM (rat)[139] 
 
1-79 
IC50 = 5000 µM (frog)[135] 
 
1-80 
KI = 1400 ± 110 µM (rat)[127] 
 
1-81 
KI = 7900 ± 980 µM (rat)[127] 
 
1-82 
KI = 100 µM (rat)[143] 
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1-83 
KI = 66 ± 8 µM (rat)[127] 
 
1-84 
KI = 330 nM (rat)[16] 
 
1-85 
KI = 340 nM (rat)[16] 
 
1-86 
KI = 7500 nM (rat)[16] 
 
1-87 
KI = 29 ± 4 nM (rat)[16] 
 
1-88 
KI = 53 ± 12 nM (rat)[16] 
 
1-89 
KI = 15 ± 3 nM (rat)[16] 
 
1-90 
KI = 10 ± 1 µM (rat)[16] 
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1-91 
KI = 610 ± 80 nM (rat)[16] 
 
1-92 
KI = 14 ± 3 nM (rat)[16] 
 
1-93 
KI = 55 ± 5 nM (rat)[16] 
 
1-94 
KI = 10 ± 3 µM (rat)[16] 
 
1-95 
KI = 8 ± 1 nM (rat)[16] 
 
1-96 
KI = 39 ± 8 nM (rat)[16] 
 
1-97 
KI = 18 ± 3 nM (rat)[16] 
 
1-98 
 
KI = 160 ± 30 nM (rat)[16] 
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1-99 
KI = 23 ± 2 nM (rat)[16] 
 
1-100 
KI = 18 ± 2 nM (rat)[16] 
 
1-101 
KI = 300 ± 17 nM  (rat)[16] 
 
1-102 
KI > 10000 nM (rat)[16] 
 
1-103 
KI > 10000 nM (rat)[16] 
 
1-104 
KI > 10000 nM (rat)[16] 
 
1-105 
KI = 1600 nM (rat)[16] 
 
 
1-106 
KI > 10000 nM (rat)[16] 
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1-107 
KI > 10000 nM (rat)[16] 
 
1-108 
KI = 2 µM (whole cell inhibition)[144] 
 
1-109 
KI = 100 µM (horse)[136] 
 
1-110 
No Inhibition (horse)[136] 
 
1-111 
KI = 190 µM (horse)[136] 
 
1-112 
IC50 = 150 µM (frog)[133] 
 
1-113 
IC50 = 20 µM (frog)[133] 
IC50 = 45 µM (human)[133] 
 
1-114 
IC50 = 25 µM (frog)[133] 
IC50 = 45 µM (human)[133] 
 
1-115 
IC50 = 260 µM (frog)[133] 
 
1-116 
IC50 = 50 µM (frog)[133] 
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1-117 
IC50 = 9 µM (frog)[133]  
IC50 = 7 µM (human)[133] 
 
1-118 
KI = 0.54 ± 0.05 µM (rat)[127] 
 
1-119 
KI = 39 ± 5 µM (rat)[127] 
 
1-120 
KI = 58 ± 9 µM (rat)[127] 
 
1-121 
KI = 3.5 ± 0.4 µM (rat)[127] 
 
1-122 
KI = 5.7 ± 0.4 µM (rat)[127] 
 
1-123 
KI = 110 ± 10 µM (rat)[127] 
 
1-124 
KI = 7.9 ± 1.8 µM  (rat)[127] 
 
1-125 
KI = 8.6 ± 1.4 µM (rat)[127] 
 
1-126 
KI = 9.4 ± 0.8 µM (rat)[127] 
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1-127 
KI = 2.6 ± 0.7 µM (rat)[127] 
 
1-128 
KI = 66 ± 8 µM (rat)[127] 
 
1-129 
KI = 20 µM (rat)[127] 
 
 
1-130 
KI = 35 ± 4 µM (rat)[127] 
 
 
1-131 
IC50> 2500 µM (honeybee)[137] 
 
1-132 
IC50> 2500 µM (honeybee)[137] 
 
1-133 
IC50 = 890 µM (honeybee)[137] 
 
1-134 
IC50 = 820 µM (honeybee)[137] 
 
1-135 
IC50 = 570 µM (honeybee)[137] 
 
1-136 
IC50 = 800 µM (honeybee)[137] 
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1-137 
IC50 = 400 µM (porcine)[137] 
 
 
1-138 
KI = 300 µM (rat)[127] 
 
 
1-139 
KI = 1000 µM (rat)[127] 
 
 
1.3.2 PAL Inhibitors 
 
Compared with the wide range of PHM inhibitors investigated, fewer studies focus on 
inhibitors specific for PAL. The first relevant publication was reported by Mounier et 
al. finding that PAL substrate analogues, 2-hydroxy-2-((R)-2-
phenylbutanamido)acetic acid (1-140) and 2-hydroxy-2-((S)-2-
phenylbutanamido)acetic acid (1-141), are both competitive PAL inhibitors with KI  
values of 280 µM and 310 µM, respectively.[119] Afterwards, they reported that 
pyruvate-extended N-acylamino acid derivatives are potent PAL inhibitors that 
resemble transient substrate species along the catalytic pathway of PAL.[126] Among 
them, N-Ac-Phe-pyruvate (1-143), with a KI value of 0.24 µM, is the most potent PAL 
inhibitor known so far.[126] Table 1.4 summarises all reported PAL inhibitors. 
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Table 1.4 PAL substrates and inhibitors. 
Structure and Binding Data Structure and Binding Data 
 
1-140 
KI = 280 µM (bovine)[119] 
 
1-141 
KI = 310 µM (bovine)[119]  
 
1-142 
KI = 770 µM (bovine)[119] 
 
1-143 
KI = 0.24 ± 0.03 µM (bovine)[126]  
 
1-144 
KI = 0.52 ± 0.06 µM (bovine)[126] 
 
1-145 
KI = 1.0 ± 0.1 µM (bovine)[126] 
 
1-146 
KI = 10 ± 1 µM (bovine)[126] 
 
1-147 
KI = 15 ± 2 µM (bovine)[126] 
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1-119 
40% inhibition with 750 µM (rat)[127] 
 
 
1.4 Summary 
 
Regulation of amidated peptide hormone production is of great interest due to their 
crucial role in intercellular communication as well as the link between a variety of 
pathological conditions and imbalances in the expression of peptide hormones. PAM 
as the only enzyme that catalyses amidation of peptide hormones is therefore an 
important target for hormone regulation. Hence, the aim of thesis is to investigate 
features that govern the binding of substrates and inhibitors to PHM and PAL. The 
first part in this thesis is to study PHM binding. In Chapter 2, the recognition of a 
peptide substrate consensus sequence by PHM is investigated, while Chapter 3 
describes the evaluation of glycolate and glycine derivatives as medicinal agents. The 
rest of the work, shown in Chapters 4 - 6, focuses on PAL activity. In Chapter 4, a 
new PAM assay was developed using HPLC-MS allowing simultaneous observation 
of PHM and PAL activities. The new assay was then employed in Chapter 5 for the 
assessment of compounds as PHM and PAL inhibitors. In Chapter 6, natural α-
hydroxyglycine peptide from human cancer cell line was attempted to be detected and 
quantified to explore the importance of PAL activity of PAM activity in cells. 
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Chapter Two 
Study of Peptide Sequence Recognition by Peptidylglycine α-
Amidating Monooxygenase 
 
2.1 Introduction 
 
In this Chapter, the focus was the amidation of human peptide hormone precursors 
that are the substrates of the amidating enzyme PAM. Peptide hormone levels are very 
low in tissues and cells, normally at picomolar or nanomolar levels.[145] However, the 
peptide binding affinities are usually micromolar, and different prohormones have 
quite different values with the processing enzyme. For example, the Ki values of 
prohormones such as adrenomedullin-Gly and Peptide-YY-Gly are about 20 µM with 
the medium PAM from the DMS53 cell line, while the Ki value of Thyroliberin (TRH)-
Gly is 1235 µM under identical test conditions.[146] Therefore amidation of peptide 
prohormones is significantly dependent on the binding affinity with PAM, where a 
prohormone with better binding affinity is likely to be amidated in preference to one 
with lower binding affinity. It follows that factors which affect the binding affinity of 
peptide hormones are of considerable importance. 
 
As mentioned in Chapter 1, Tamburini et al.[118] investigated the effect of the C-
terminal penultimate amino acid on the peptide substrate binding affinity with PAM 
by using a synthetic hexapeptide model, and found that penultimate amino acids with 
a planar aromatic group had highest binding affinity while cyclic aliphatic or acidic 
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ones gave rise to lower binding affinities. Further to this, Easton et al.,[120] studied 
substrate recognition by PAM by utilizing natural prohormones such as prooxytocin 
(oxytocin-Gly) and its analogues. They found that the binding affinities of N-
acetylated di-, tri-, and tetra-peptide prooxytocin analogues, along with prooxytocin, 
with the PAM enzyme from the DMS53 cell line, increase in order. The phenomenon 
that increasing the length of the prohormone sequence increases the binding affinity 
again highlights the importance of the peptide sequence on recognition by the 
amidating enzyme. However, when they substituted Gly at the penultimate position of 
analogues of the peptide with Phe, the binding affinities of all tested peptides increased 
significantly, but no further increase was then observed with increased peptide 
sequence length. Comparison between the above results demonstrates that Phe 
changes the binding mode from one where recognition depends on the peptide 
sequence to another where recognition by the amidating enzyme is predominantly 
dependent on the penultimate Phe.[120] However, prooxytocin does not naturally have 
Phe at the C-terminus. These observations attracted us to investigate in more details 
the binding affinities of natural prohormones having Phe at the penultimate position 
from the C-terminus and see whether there is sequence recognition of these natural 
prohormones with PAM 
 
With this aim, a statistical analysis was performed of the human amidated peptide 
hormone database. From Table 1.1 in Chapter 1, among all eighty one peptide 
hormones, there are twenty eight having Phe at the amidated end, which corresponds 
to the C-terminal penultimate position (P1) in their respective Gly-extended 
prohormones. Since investigating the binding affinities of all twenty eight full-length 
peptide prohormones would be impractical, instead consensus sequence models that 
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cover all the possibilities of amino acids at the antepenultimate position (P2) were 
studied. As shown in Table 2.1 and Table 2.2, there are three possibilities of –X-Phe-
Gly-COOH in natural human Gly-extended peptide prohormones, of which X can only 
be one of Arg (R), Asp (D) or Ala (A). Specifically, fourteen out of twenty eight 
peptide prohormones containing Phe at P1, including those of kisspeptin, prolactin-
releasing peptide, QRF-amide, and some neuropeptides, have the fragment –Arg-Phe-
Gly-COOH. Another twelve prohormones, cholecystokinin and gastrin related-
hormones, have the fragment –Asp-Phe-Gly-COOH. The remaining two prohormones 
with –Ala-Phe-Gly-COOH at the C-terminus, are calcitonin gene-related peptide and 
calcitonin gene-related peptide 2.  
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Table 2.1 Human Gly-extended prohormones having penultimate Phe at the C-
terminus, divided into three groups in terms of the amino acids at P2. 
Group Name Sequence 
RFG 
Neuropeptide NPVF-Gly VPNLPQRFG 
Neuropeptide FF-Gly FLFQPQRFG 
Neuropeptide SF-Gly SQAFLFQPQRFG 
Neuropeptide AF-Gly AGEGLNSQFWSLAAPQRFG 
Kisspeptin-10-Gly YNWNSFGLRFG 
Kisspeptin-13-Gly LPNYNWNSFGLRFG 
Kisspeptin-14-Gly DLPNYNWNSFGLRFG 
Kisspeptin-Gly GTSLSPPPESSGSPQQPGLSAPHSRQIPA
PQGAVLVQREKDLPNYNWNSFGLRFG 
Melanotropin gamma-Gly YVMGHFRWDRFG 
Neuropeptide RFRP-1-Gly MPHSFANLPLRFG 
Prolactin-releasing peptide 
PrRP20-Gly 
TPDINPAWYASRGIRPVGRFG 
Prolactin-releasing peptide 
PrRP31-Gly 
SRTHRHSMEIRTPDINPAWYASRGIRPV
GRFG 
Neuropeptide NPSF-Gly SLNFEELKDWGPKNVIKMSTPAVNKMP
HSFANLPLRFG 
QRF-Gly QDEGSEATGFLPAAGEKTSGPLGNLAE
ELNGYSRKKGGFSFRFG 
DFG 
Cholecystokinin-5-Gly GWMDFG 
Cholecystokinin-7-Gly YMGWMDFG 
Cholecystokinin-8-Gly DYMGWMDFG 
Cholecystokinin-12-Gly ISDRDYMGWMDFG 
Cholecystokinin-18-Gly LDPSHRISDRDYMGWMDFG 
Cholecystokinin-25-Gly YIQQARKAPSGRMSIVKNLQNLDPSHRI
SDRDYMGWMDFG 
Cholecystokinin-58-Gly VSQRTDGESRAHLGALLARYIQQARKA
PSGRMSIVKNLQNLDPSHRISDRDYMG
WMDFG 
Gastrin-6-Gly YGWMDFG 
Gastrin-14-Gly WLEEEEEAYGWMDFG 
Gastrin-Gly QGPWLEEEEEAYGWMDFG 
Big gastrin-Gly QLGPQGPPHLVADPSKKQGPWLEEEEE
AYGWMDFG 
Gastrin-52-Gly DLELPWLEQQGPASHHRRQLGPQGPPH
LVADPSKKQGPWLEEEEEAYGWMDFG 
AFG 
Calcitonin gene-related 
peptide-Gly 
ACDTATCVTHRLAGLLSRSGGVVKNNF
VPTNVGSKAFG 
Calcitonin gene-related 
peptide 2-Gly 
ACNTATCVTHRLAGLLSRSGGMVKSNF
VPTNVGSKAFG 
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Table 2.2 Proportion analysis of amino acids at the C-terminal antepenultimate 
position of human Gly-extended prohormones having penultimate Phe. 
 Total Arg (R) Asp (D) Ala (A) 
Number of peptide prohormones 28 14 12 2 
Number of sequence types 12 8 2 2 
 
Since the sequence fragment -Arg-Phe-Gly-COOH appears most frequently, these 
amino acids were chosen as the first three of the basic consensus sequence, then being 
extended with three more amino acids at P3, P4, and P5. Selecting the amino acids at 
P3-P5 was dependent on extended sequence analysis to represent the widest variety of 
peptide prohormones. In the first case, after further statistical analysis, Gln (Q), Pro 
(P), and Gly (G) were chosen for P3-P5, respectively. N-Acetylation was performed 
at the N-terminus of the designed peptide sequences due to concerns that a free amino 
group at the N-terminus would be protonated under the assay conditions and hence be 
likely to significantly impact the binding affinity with PAM.[120] Therefore, as 
illustrated in Figure 2.1, the peptide sequence N-Ac-Gly-(S)-Pro-(S)-Glu-(S)-Arg-(S)-
Phe-Gly-COOH (2-14) was designed to be the basic consensus sequence in the present 
study. 
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Figure 2.1 According to the human amidated peptide hormone database, N-Ac-Gly-
(S)-Pro-(S)-Glu-(S)-Arg-(S)-Phe-Gly-COOH (2-14) was identified as the consensus 
sequence via mathematical analysis (the greater proportion of each amino acid at a 
particular position represents the more frequent occurrence of that amino acid 
appearing at that position, with the amino acid listed on the top of each column having 
the most frequent occurrence). 
 
On the basis of the initial hexapeptide 2-14, modifications such as decreasing the 
length of the sequence and substitution of Arg or Phe at P2 or P1 with amino acids 
representative of those found in prohormones were considered to generate nine more 
peptide sequences as shown in Figure 2.2 below. Compared to consensus sequence 2-
14, its three related peptides, the penta-, tetra-, and tri-peptide prohormones 2-15 - 2-
17, with lengths decreased by one amino acid from the N-terminus each time, were 
chosen to examine the effect of extended sequence recognition on binding affinity of 
natural prohormones with PAM. In addition, covering the other two possibilities of -
X-Phe-Gly-COOH in natural human prohormones, peptide sequences 2-18 and 2-19 
were tested, to help understand the effect of antepenultimate amino acids on the 
binding affinity with the amidating enzyme. Though not existing in the nature, -Gly-
Phe-Gly-COOH within peptide 2-20 was also examined as a control. Substitution of 
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Phe at P1 of the basic consensus sequence 2-14 with Pro and Gly was chosen to 
generate sequences 2-21 and 2-22. The results of testing these two peptides were to be 
compared with the results of Easton et al.[120] related to the binding affinity of 
procalcitonin and prooxytocin that have Pro and Gly at their respective P1 positions. 
Sequence fragment -Arg-Gly-Gly-COOH of peptide 2-22 also exists in two natural 
human peptide prohormones, Arg-vasopressin and pancreastatin. There are in total 
five prohormones having -Gly-Gly-COOH as shown in Table 2.3. Apart from -Arg-
Gly-Gly-COOH possessed by two human peptides, as discussed above, a third is 
prooxytocin which has already been studied in the Easton Group. The other two, 
gonadoliberin-1 and gonadoliberin-2, both have Pro at P2. Therefore, peptide 2-23 
having the -Pro-Gly-Gly-COOH fragment was also selected so that the binding 
affinities of all the human prohormones having –X-Gly-Gly-COOH would be covered.  
 
 
Figure 2.2 Peptide sequences chosen to test. 
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Table 2.3 Human Gly-extended prohormones having penultimate Gly. 
Group Name Sequence 
LGG Oxytocin-Gly CYIQNCPLGG 
PGG Gonadoliberin-1-Gly QHWSYGLRPGG 
Gonadoliberin-2-Gly QHWSHGWYPGG 
RGG 
Arg-vasopressin-Gly CYFQNCPRGG 
Pancreastatin-Gly GESRSEALAVDGAGKPGAEEAQDPEGK
GEQEHSQQKEEEEEMAVVPQGLFRGG 
 
The amidating enzyme PAM from the growth medium of the human small cell lung 
carcinoma (SCLC), DMS53 cell line, was chosen for comparison with earlier studies 
of peptide prohormones of calcitonin and oxytocin.[145] 
 
2.2 Synthesis of Peptide Substrates 
 
In order to obtain the selected Gly-extended peptide sequences, solid phase peptide 
synthesis (SPPS) was chosen as the method. SPPS, first established by Bruce 
Merrifield in 1963,[147] is a convenient and universally adopted method for production 
of peptides. Its continual development related to racemisation suppression, protection 
group chemistry, and resin selection has made the build-up of peptide sequences more 
efficient and timesaving.[148-150] In general, there are two main approaches of SPPS; 
one is the Boc approach, and the other is the Fmoc approach. In the former approach, 
the acid-labile Boc-group is well suited for temporary protection of the amino group 
of amino acids and is able to be removed using some acidic agents such as TFA under 
mild conditions; however, under these circumstances, protecting groups used for 
protection of the side chains of amino acids during peptide elongation and peptide-
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resin linkers need to be resistant to acid hydrolysis. By contrast, when the Fmoc group 
is used for protecting amino groups, it is removed with base, which allows the use of 
more acid-labile side-chain protecting groups that may then be removed under mild 
acidic conditions.[151] There are many kinds of side-chain protecting groups including 
Tos,[152] Mts,[153] and Pbf for (S)-Arg. The Pbf group is more acid-labile than the other 
two and the best Arg-protecting group for Fmoc-SPPS.[154] Xan, Mbh and Trt can be 
used for protecting (S)-Gln. Among them, Xan and Mbh are mainly used for the Boc 
method[155-156] while Trt is the best for the Fmoc method because it is more acid-
labile.[157] Therefore, the Fmoc-based SPPS method was chosen in the present 
synthesis.  
 
Resins commonly used with the Fmoc approach are hydroxymethyl-based, which 
leads to coupling of the first amino acid by forming an ester link. Among these resins, 
Wang resin, as shown in Figure 2.3, was selected in this project because it is an 
unhindered one that forms esters more easily than other candidates such as Sasrin or 
HMPB resin.[151] In general, aggregation of peptides can complicate coupling, 
therefore when preparing long peptide sequences it is better to choose a resin with low 
substitution to increase the yield of coupling.[158] For instance, to prepare a long 
peptide (30 to 50 amino acids), a resin with a low substitution (0.1-0.4 mmol/g) is 
appropriate. By contrast, to prepare a short one (<10 amino acids), a higher 
substitution resin (1.2-2.0 mmol/g) may be used. Therefore, to make peptides 2-14 - 
2-23, the Wang resin whose estimated substitution is 1.18 mmol/g was purchased from 
Sigma-Aldrich Corporation and used.  
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Figure 2.3 The structures of Wang resin, Sasrin resin and HMPB resin. 
 
The peptides were built up by the stepwise SPPS method on Wang resin as a solid 
support, which is exemplified with the synthesis of hexapeptide 2-14 via Scheme 2.1. 
Specifically, commercial dry Wang resin was suspended in organic solvent to swell 
the beads. The swelling step is essential because most of coupling sites of dry resin 
are not on the surface but inside the resin beads. Swelling enlarges the beads and 
exposes the hydroxyl groups of the Wang resin in order to maximise the coupling 
efficiency.[151] The swollen Wang resin was coupled with Fmoc-Gly-COOH (2.5 eq) 
to produce Fmoc-Gly-Wang resin (2-1) using standard ester forming conditions with 
DIC, HOBt, and a catalytic amount of DMAP in DMF.[158] Excess reagents at high 
concentration are used to drive coupling reactions, and the excess reagents and by-
products are then removed simply by filtration and washing. DIC is commonly used 
to prepare amides or esters from carboxylic acids in SPPS, with the urea by-product 
being soluble in standard solvents such as DMF and washing out easily. HOBt 
enhances reactivity of ester or amide formation with carbodiimides.[159] Only a small 
amount of DMAP was used to avoid deprotecting the Fmoc group because of its basic-
lability. After the first coupling, a small amount of resin was used to determine the 
loading efficiency via Fmoc release and measurement by UV-Vis spectroscopy.[151] 
The absorbance of samples was measured at 278 nm, from which the loading 
efficiency was calculated according to the following Eq 2.1:[158] 
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            S (mmol/g) = (1000 × A)/(M × 7800 × D)                     (Eq 2.1) 
                     S = substitution of the resin in mmol/g 
                     A = absorbance of the sample – absorbance of the blank 
                     M = mass of the resin used in mg 
                     D = dilution factor 
 
The loading efficiency test for peptide 2-1 in the synthesis of peptide 2-14 was 65% 
(all other target peptides were also synthesised starting by making compound 2-1 and 
the loading efficiencies were between 65-83%), which indicated that 35% of the 
hydroxyl groups were still free. Therefore, the whole resin was agitated with Ac2O 
and pyridine to acetylate unreacted hydroxyl groups and hence reduce the possibility 
of generating undesired peptide sequences from coupling other amino acids used later 
in the sequence directly to the resin. Afterwards, the Fmoc-protected amino acid 2-1 
underwent Fmoc deprotection by adding piperidine in DMF.  
 
Subsequently, the resulting amine 2-2 was treated with the next Fmoc-protected amino 
acid, Fmoc-(S)-Phe-COOH, using HBTU, HOBt, and DIPEA.[158] These reagents are 
more efficient than DIC/DMAP in terms of amide coupling.[160-161] HBTU is reported 
to form amides rapidly with little racemisation,[162] but requires the presence of large 
amounts of base such as DIPEA. After the standard Fmoc deprotection that converted 
peptide 2-3 to peptide 2-4, peptide 2-4 was then elongated to the desired sequence with 
the following protected amino acids: Fmoc-(S)-Arg(Pbf)-COOH, Fmoc-(S)-Gln(Trt)-
COOH, Fmoc-(S)-Pro-COOH, and Fmoc-Gly-COOH. All these coupling procedures 
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and the reagent quantities were as described for the second coupling described above. 
After the elongation and the last Fmoc deprotection, an acetylation was performed on 
the N-terminus of peptide 2-12 with Ac2O to produce peptide 2-13. The N-acetylated 
peptide was then cleaved from the Wang resin, at the same time removing the two 
side-chain protecting groups (Pbf and Trt), under acid conditions.  
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                                                                           Continued on next page 
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Scheme 2.1 Synthesis of N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-
14). 
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A small amount of the crude peptide product was analysed by HPLC with detection 
using UV-Vis spectroscopy. The resulting HPLC chromatogram reproduced in Figure 
8.1 showed two dominant peaks. Separation of the materials corresponding to these 
peaks and MS analysis showed one corresponds to the peptide N-Ac-Gly-(S)-Pro-(S)-
Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-14) while the other one has mass 57 Da less. 
Separated compound 2-14 was analysed using high resolution MS and 1H NMR 
spectroscopy for further characterization. With the exception of compound 2-19, 
which was a gift from Dr. Tim Altamore, all the other peptides 2-15 - 2-18 and 2-20 - 
2-23 were prepared using the same approach as described for peptide 2-14. When 
preparing N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Asp-(S)-Phe-Gly-COOH (2-18), Fmoc-(S)-
Asp(tBu)-COOH was used, wherein the tBu group protects the side chain carboxylic 
acid group in order to avoid production of branched peptides. Although there are other 
kinds of side-chain protecting groups for Asp such as Bn, cHx, and Men,[163-164] tBu is 
the most used with the Fmoc method because it is the more acid-labile. In addition, 
the tBu group minimises side reactions because of its steric bulk.[165] Like peptide 2-
14, the other peptides 2-15 - 2-23 were also characterised using HPLC, low and high 
resolution MS and 1H NMR spectroscopy. All the NMR spectra are consistent with 
their structures and all the related details are shown in Chapter 8. 
 
As mentioned above, two peptide products were isolated during the synthesis of 
peptide 2-14, one being peptide 2-14 and the other having a mass 57 Da less. This 
difference is equal to loss of a glycine residue and indicates that the by-product is 
either N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-COOH or N-Ac-(S)-Pro-(S)-Gln-
(S)-Arg-(S)-Phe-Gly-COOH. A by-product was also isolated from the synthesis of N-
Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-15) (Figure 8.4); it also had a 
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mass 57 Da less than that of peptide 2-15, and is therefore likely to be  N-Ac-(S)-Pro-
(S)-Gln-(S)-Arg-(S)-Phe-COOH. Due to the similarity between peptides 2-14 and 2-
15, it is probable that the by-product of the synthesis of peptide 2-14 is N-Ac-Gly-(S)-
Pro-(S)-Gln-(S)-Arg-(S)-Phe-COOH. While these by-products could be the result of 
incomplete coupling of Fmoc-Gly-COOH to the resin, that seems unlikely since 
compound 2-1 was acetylated to avoid this potential problem. Further, analogous 
products were not observed in any of the other peptide syntheses. When analysing 
crude peptides 2-18 and 2-21, by-products of mass corresponding to loss of two amino 
acid residues (Phe+Gly or Pro+Gly) were seen from the MS analysis of species. A 
possible explanation is that acidic peptide hydrolysis occurs in the last step of the 
syntheses, where a high concentration (95%) of TFA is used.[166] Peptide hydrolysis 
shows a large dependence on amino acid sequence. 
 
2.3 Measurements of Binding Affinities of Peptide Substrates with PAM 
 
Peptides 2-14 - 2-23 were to be evaluated in terms of their binding affinities with PAM. 
The basic way for evaluation is to determine a Km value, a kinetic constant, which is 
used widely in enzyme kinetics to determine substrate binding affinity for the enzyme. 
For this, the PAM assay is repeated over a range of concentrations of each peptide 2-
14 - 2-23, which is impractical and unnecessary for a simple comparative evaluation. 
Alternatively, an IC50 value, the concentration of an inhibitor that reduces the turnover 
of a substrate by half, was determined in a competitive PAM assay by monitoring the 
effect of each inhibitor on reaction of the substrate (R)-Tyr-(S)-Val-Gly-COOH. This 
is a more simple and convenient method, where each peptide of interest competes for 
binding to the active site of the PAM enzyme against the tripeptide (R)-Tyr-(S)-Val-
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Gly-COOH that is converted to the corresponding product (R)-Tyr-(S)-Val-NH2 by 
PAM as shown in Scheme 2.2.[167-168] In this assay, the peptide of interest slows down 
or prevents the amidation of the above mentioned tripeptide substrate, where the 
relative binding affinities of the inhibitors and substrates are reflected in this 
competition. 
 
 
 
Scheme 2.2 The tripeptide (R)-Tyr-(S)-Val-Gly-COOH catalysis by PAM to give the 
amidated product (R)-Tyr-(S)-Val-NH2. 
 
An IC50 value is dependent on the experimental conditions. However, testing all 
candidates under identical conditions makes it possible to compare their binding 
affinities directly. The current competition assay was carried out on the basis of the 
reported isolated PAM assay conditions established in the Easton group.[120, 133] To be 
specific, the assay sample was initially prepared with the tripeptide substrate (R)-Tyr-
(S)-Val-Gly-COOH and the peptide of interest. The latter is treated in this analysis as 
an inhibitor though it is also expected to be a substrate. A consistent concentration of 
50 mM of tripeptide substrate was used in each sample, which is smaller than the Km 
value (360 ± 40 µM) of this tripeptide with PAM from DMS53 cell medium.[146] Under 
this condition, an inhibitor or competitive substrate effectively competes for binding 
(R)-Tyr-(S)-Val-Gly-COOH (R)-Tyr-(S)-Val-NH2 
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the active site of PAM. In addition, PAM cofactors (ascorbic acid and copper sulphate) 
with bovine liver catalase were added into samples for assisting the enzyme catalysis; 
the function of bovine liver catalase in the assay is for stabilizing ascorbate and 
protecting the enzyme from damage by decomposed ascorbate.[8, 169] Organic solvents 
EtOH and DMSO (a small amount) were used to increase substrate and inhibitor 
solubility,[120, 133] and to maintain conditions so that these results could be compared 
directly with reported ones. The PAM enzyme used was from concentrated growth 
medium of the DMS53 cell line[145] and was used in the binding affinity assay without 
further purification because PAM is the only enzyme known for catalysing the 
amidation of glycine-extended prohormones.[85] The samples were incubated for 2 h 
at 37 ºC, followed by being treated with base to quench the PAM activity, converting 
all the hydroxyglycine-extended intermediates to the corresponding amidated products. 
After being neutralised with acid, the sample mixtures were filtered with Amicon® 
Ultra YM-3 filters that removes compounds having molecular weights over 3000. In 
this case, PAM enzyme and other proteins were removed due to their high molecular 
weights while peptides 2-14 - 2-23, the tripeptide (R)-Tyr-(S)-Val-Gly-COOH, and 
amidated products having molecular weights below 3000, passed through the 
membrane. The filtrates were subsequently injected onto HPLC for separation and 
analysis. 
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Figure 2.4 HPLC setup for the detection of (R)-Tyr-(S)-Val-Gly-COOH and its 
amidated product (R)-Tyr-(S)-Val-NH2.[133] 
The detection and quantification method of HPLC used was also established in the 
Easton group.[133, 146] This detection system, as illustrated in Figure 2.4 above, consists 
of a Waters Alliance 2695 separation module, a Waters 600E Pump, a solid-phase 
extraction (SPE) column, a reverse-phase column, a cation-exchange column, a 
Waters reagent manager controlling the flow of fluorescamine solution, and a Waters 
2475 fluorescence detector. Specifically, the prepared sample was loaded onto the SPE 
column and then washed with water to get rid of salts but retained peptides on the 
column. After that, the residual peptide material was eluted with MeCN and AccQ-
Tag buffer to be separated by the C18 reverse-phase column and the cation-exchange 
column, followed by being labelled with fluorescamine for fluorescence detection, 
which gave rise to a chromatogram with the separation of (R)-Tyr-(S)-Val-Gly-COOH 
and (R)-Tyr-(S)-Val-NH2. The ratio between the tripeptide substrate and the amidated 
product was obtained via Waters Empower 3 software. On this basis, the concentration 
of peptide of interest against the percentage of tripeptide turnover was plotted to 
generate an activity-concentration curve for determining an IC50 value. An example 
HPLC trace with standard compounds is shown in Figure 2.6 below.  
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Figure 2.6 Example of HPLC trace, with commercial standards of (R)-Tyr-(S)-Val-
Gly-COOH and (R)-Tyr-(S)-Val-NH2. 
 
Starting with the shortest peptide 2-17, the concentration used in the assay ranged from 
600 to 0 µM at 2X serial dilution, which is based on the study by Easton et al.[120] that 
apparent Km values of prooxytocin analogues having –Phe-Gly-COOH at the C-
terminus are between 9-38 µM. The assay was duplicated, and two sets of experiment 
data were obtained as shown in Table 2.4. On the basis of these data, an activity-
concentration curve was fitted with SciDAVis 0.2.4 software[120] using a sigmodial-
dose response equation: y=b+(t-b)/(1+(x/IC50)n) where y is percentage tripeptide 
turnover (after two hours), x is the peptide concentration, b is the baseline response, t 
is the maximum response, and n is the hill slope. All numbers calculated were 
corrected to two significant figures.  
 
 
 
(R)-Tyr-(S)-Val-Gly-COOH 
(R)-Tyr-(S)-Val-NH2 
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Table 2.4 Experiment data of binding affinity test of 2-17 from the competition assay. 
Concentration of 2-17 
(µM) 
(R)-Tyr-(S)-Val-Gly-COOH turnover (%) 
Experiment A Experiment B 
0 16 16 
19 11 9.4 
38 6.3 6.4 
75 3.5 2.7 
150 1.6 1.5 
300 1.3 0.98 
600 0.41 0.18 
 
Experiments A and B in Table 2.4 correspond to the competition assay using peptide 
2-17. The resulting activity-concentration curves, shown in Figure 8.34, had 
R2 values above 0.99 and IC50 values in good agreement with one another; 27 ± 1 µM 
and 26 ± 2 µM. The low uncertainty and R2 values close to 0.99 indicate the data are 
well matched to the predicted values. The combined activity-concentration curve of 
these two experiments is illustrated in Figure 2.7A. The error bars, which are the 
differences between the two measurements, are relatively small. Since the most 
relevant part of the activity-concentration curve is from about 10-50 µM of peptide 2-
17, the high concentration data point, at 600 µM, possibly could distort the IC50 value 
calculation. Therefore, the data were reanalysed without this value at 600 µM. After 
recalculation, however, experiments A and B gave IC50 = 26 ± 1 µM and IC50 = 26 ± 
2 µM and the combined IC50 value of 26 ± 2 µM, as shown in Figure 2.8B. The 
uncertainty is below 10% of the measured IC50 value, which is comparable with 
previous measurements by Easton et al., [120] indicating an accurate measurement of 
IC50.  
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Figure 2.7 Example of the determination of an IC50 value, with the peptide N-Ac-(S)-
Arg-(S)-Phe-Gly-COOH (2-17). The activity-concentration curve was generated by 
plotting the tripeptide substrate turnover percentage and inhibitor concentration 
ranging (A) from 600 to 0 µM at 2X serial dilution; and (B) from 300 to 0 µM at 2X 
serial dilution. 
IC50 = 27 ± 2 µM 
 R2 > 0.99 
 
µM 
A 
IC50 = 26 ± 2 µM 
R2 > 0.99 
 
B 
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All other peptide candidates were tested in the same manner as described for peptide 
2-17. For peptides 2-14 - 2-16, since their structures are similar to that of peptide 2-
17, 300 to 0 µM was used to perform the binding affinity assays and their IC50 values 
were also similar to that of peptide 2-17, which were all below 30 µM. For peptides 
2-18 and 2-19, by reason that whether Ala or Asp at P2 would moderate IC50 values 
was not clear, the original concentration range used was 600 to 0 µM. The calculated 
IC50 values of peptides 2-18 and 2-19 were both around 70 µM, showing that the 
concentrations used were appropriate for the IC50 value calculations. For peptide 2-20, 
the initial concentration range of 300 to 0 µM was used for the assay. Since 300 µM 
of peptide 2-20 had decreased the tripeptide turnover by over 95%, no larger 
concentration was required. By contrast, for peptides 2-21 - 2-23, 600 was not enough. 
For example, as shown in Figure 2.8A below, the maximum concentration of 600 µM 
of peptide 2-22, only reduced the tripeptide substrate turnover by around 30%. This 
indicated that more peptide 2-22 should be used in the assay. Therefore, a range from 
6000 to 0 µM of peptide 2-22 was used and the combined IC50 value was determined 
as 1200 ± 190 µM as shown in Figure 2.8B. For peptides 2-21 and 2-23, a 
concentration range of 2000 to 0 µM, not higher due to the lack of material. In the 
assay of peptide 2-21, even the maximum concentration, 2 mM, only reduced the 
tripeptide substrate turnover by around 40%. This is not enough to accurately calculate 
the IC50, but it is clear that the value must be over 2 mM. Under the same conditions, 
the IC50 value of peptide 2-23 was calculated as 1500 ± 210 µM. All the data related 
to these ten target peptides are illustrated in Chapter 8. 
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Figure 2.8 Example of the determination of an IC50 value, with the peptide N-Ac-Gly-
(S)-Pro-(S)-Gln-(S)-Arg-Gly-Gly-COOH (2-22). The activity-concentration curve 
was generated by plotting the tripeptide substrate turnover percentage and inhibitor 
concentration ranging  (A) from 600 to 0 µM at 2X serial dilution; and (B) from 6000 
to 0 µM at 2X serial dilution (different batches of concentrated PAM used caused 
different substrate turnovers for these two experiments). 
A 
B 
IC50 = 1200 ± 190 µM 
R2 > 0.98 
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Table 2.5 IC50 values of the peptide substrates (all assays were duplicated). 
 
From Table 2.5, the IC50 values of peptides 2-14 - 2-17 having -Arg-Phe-Gly-COOH 
were all between 10-30 µM, which is similar to those of prooxytocin analogues with 
penultimate Phe in the early study.[120] The similar values of peptides 2-14 - 2-17 
illustrate that when Phe is at the penultimate position from the C-terminus, there is 
little sequence recognition of amino acids at P3 - P5. Therefore, these natural 
prohormone models show the same trend as observed previously with unnatural 
peptides,[120] that there is negligible sequence recognition of amino acids from P3 to 
the N-terminus of peptide substrates having penultimate Phe.[120] Based on this 
consensus sequence study, it is anticipated that, the first group of human prohormones 
shown in Table 2.1, having -Arg-Phe-Gly-COOH, are likely to bind to PAM 
effectively in living bodies with IC50 values around 20 µM.  
 
Considering then the effect of different amino acids at P2 on the binding affinities of 
human prohormones having penultimate Phe, based on Table 2.5, compared to peptide 
2-14 with Arg at P2, the IC50 values of peptides 2-18 and 2-19 with Asp and Ala, 
respectively, were around four times higher (70 µM) while the value of peptide 2-20 
No.             Peptide of interest IC50 (μM) 
2-14       N-Ac-Gly-(S)-Pro-Gln-(S)-Arg-(S)-Phe-Gly-COOH 16 ± 3  20 ± 1  
2-15       N-Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH 17 ± 2  21 ± 5  
2-16        N-Ac-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH 20 ± 2  17 ± 1  
2-17        N-Ac-(S)-Arg-(S)-Phe-Gly-COOH 26 ± 1  26 ± 2  
2-18       N-Ac-Gly-(S)-Pro-Gln-(S)-Asp-(S)-Phe-Gly-COOH 69 ± 9 62 ± 8 
2-19       N-Ac-Gly-(S)-Pro-Gln-(S)-Ala-(S)-Phe-Gly-COOH 69 ± 10  71 ± 8  
2-20       N-Ac-Gly-(S)-Pro-Gln-Gly-(S)-Phe-Gly-COOH 10 ± 1  12 ± 1  
2-21       N-Ac-Gly-(S)-Pro-Gln-(S)-Arg-(S)-Pro-Gly-COOH > 2000  > 2000  
2-22       N-Ac-Gly-(S)-Pro-Gln-(S)-Arg-Gly-Gly-COOH 1200 ± 200 1300 ± 200 
2-23       N-Ac-Gly-(S)-Pro-Gln-(S)-Pro-Gly-Gly-COOH 1400 ± 160 1500 ± 260 
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with Gly was slightly lower (10 µM). This indicates that Asp and Ala at P2 slightly 
disrupt binding affinity with PAM compared to Arg. By contrast, Gly at P2 helps 
binding. The contributions from these antepenultimate amino acids probably reflect 
their properties. Among these four amino acids (Arg, Asp, Ala, and Gly), Gly gives 
the highest binding affinity and is the smallest. The marginal decrease with Arg 
indicates that its positive charged side chain fits the active site of the enzyme. By 
contrast, negatively charged Asp and uncharged Ala give lower binding affinity. The 
trend found in the present study is supported by Caron[146] who found that the Ki value 
(25 µM) of γ-MSH with –Arg-Phe-Gly-COOH was 3.5 times lower than that (85 µM) 
of CCK8-Gly with –Asp-Phe-Gly-COOH. Based on the results above, it is expected 
that human prohormones having –Asp-Phe-Gly-COOH and -Ala-Phe-Gly-COOH, 
shown in the second and third groups of Table 2.1, are likely to have slightly lower 
binding with PAM than those having –Arg-Phe-Gly-COOH, but are still likely to bind 
to PAM effectively with IC50 values around 70 µM.  
 
Further to this, the P1 amino acid was considered. The peptide substrates 2-21 - 2-23 
having penultimate Pro and Gly had IC50 values all at the millimolar level. Their IC50 
values were all over 60 times higher than peptide 2-14, indicating that penultimate Pro 
or Gly, compared with Phe, gives much poorer binding affinities with PAM. So in the 
current study modification of the natural prohormone sequence  –Arg-Phe-Gly-COOH, 
by replacing the Phe with Pro or Gly disrupts binding, just as substitution of the 
penultimate Pro and Gly in the natural sequences of the prohormones procalcitonin 
and prooxytocin with Phe increases binding.[120] The combined results indicate that 
the penultimate amino acids predominantly determine the binding affinities with PAM.  
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The fact that Km values of natural prohormones are usually much higher than their 
concentrations implies that amidation significantly depends on the binding affinity 
with PAM. The study in this Chapter suggests that penultimate amino acid of human 
prohormones mainly determines the binding affinity with PAM. Therefore, 
penultimate amino acid is likely to be an important factor of the selectivity of 
amidation of peptide hormones. To further inverstigate this, literature research was 
performed on the correlation between the penultimate amino acids and the functions 
of hormones. It was found that hormones having -Arg-Phe-NH2 are mostly 
neuropeptides that play important role in body temperature homeostasis, pain 
modulation, and the control of transmission of nociceptive information.[170-171] Asp-
Phe-amides are either cholecystokinin (CCK) or gastrin, and their main functions are 
both related to dietary digestion in stomach.[172-174] While the Ala-Phe-amide, 
calcitonin gene-related peptide, is a potent peptide vasodilator that also plays a vital 
role in the transmission of pain.[175-176] These reivews suggest that hormones with Phe-
NH2 are produced rapidly in bodies. By contrast, amidated hormones having -Pro-NH2 
or -Gly-NH2 serve as growth hormones in humans and show relatively low preference 
on release. For example, calcitonin (Pro-NH2) plays a role in blood calcium 
regulation,[22] and oxytocin (Gly-NH2) mainly plays a role in sexual reproduction.[177] 
Combining the current results and the literature work, it is concluded that there might 
be a corraltion between penultimate amino acid and the release rate of amidated 
peptide hormones. It is likely that prohormones having penultimate amino acid that 
enhance binding are possibly amidated by PAM relatively preferentially and vice 
versa. In future, new models related to human prohormones with other penultimate 
amino acids should be studied to further investigate this.
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Chapter Three 
Synthesis and Evaluation of Interactions of Glycine Derivatives 
of Medicinal Agents with Peptidylglycine α-Amidating 
Monooxygenase 
 
3.1 Introduction 
 
PAM is found in many types of tumours and has potential in cancer therapy.[178-180] 
Anti-sense expression of PAM in tumour cell lines is reported to inhibit tumour growth 
efficiently.[180] Moreover, the potent PAM inhibitor, PBA (1-17), is reported to reduce 
the growth of some particular types of cancer cells.[129-130, 181] On this basis, the work 
in this Chapter involves derivatives of antineoplastic drugs which were considered to 
be potential PAM substrates or inhibitors. The hypothesis was that these compounds 
would not only inhibit PAM activity, but also undergo reaction to produce a cytotoxic 
agent. The aim of this work was to examine some modified anticancer drugs and see 
whether an improvement in the anticancer effect was achieved. As shown in Figure 
3.1, the cytotoxic agents, bexarotene (3-1) and temozolomide (3-2), which are 
clinically available, were chosen for investigation. 
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Figure 3.1 Structures of bexarotene (3-1) and temozolomide (3-2). 
 
Bexarotene (Bex, 3-1) is a selective retinoid type-X receptor (RXR) agonist,[182] where 
activation of RXR gives rise to the formation of homodimeric (RXR-RXR) or 
heterodimeric complexes (RXR-RAR (retinoic acid receptors)).[183] The RXR-RAR 
heterodimeric complexes can bind DNA and hence induce apoptosis and 
differentiation of tumours,[184] which indicates that Bex (3-1) might play an important 
role in cancer prevention or treatment. Therapeutically, Bex (3-1) has already been 
widely used in the treatment of cutaneous T-cell lymphoma,[185] and also has 
promising effects on the treatment of non-small cell lung cancer (NSCLC).[186]  
 
The glycolate analogue of Bex (Bex-glycolate, 3-3) is a competitive PAM inhibitor 
(IC50 value = 17.7 µM) and no significant reaction was observed during the PAM assay 
(Scheme 3.1).[187] It was also evaluated in terms of cytotoxicity for DMS53 cells and 
its LD50 value (40 µM) was slightly better than that (60 µM) of the parent cytotoxic 
agent 3-1, indicating that it is also a promising cytotoxic agent for SCLC.[187] 
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Scheme 3.1 Bex-glycolate (3-3) and its potential hydrolysis to produce Bex (3-1).  
 
In the present study, another analogue of Bex (3-1), Bex-glycine (3-4), was assessed 
in the same way as Bex-glycolate (3-3). It was expected that Bex (3-1) could be 
synthetically extended as a glycine derivative to operate as a PAM substrate, the intent 
being that the PAM would recognise and cleave it to produce the amide (Scheme 3.2) 
which hopefully would have similar cytotoxicity to Bex (3-1). In this case, compound 
3-4 would not only inhibit the PAM, but also react to produce a cytotoxic drug. The 
PAM source, the DMS53 cell strain (a human SCLC), was used as the cancer cell 
candidate for cytotoxicity assays.  
  
 
Scheme 3.2 Bex-glycine (3-4) and its expected amidated PAM product. 
 
Another antineoplastic agent, temozolomide (Tmz, 3-2), is a methylating agent used 
for cancer treatment that works through DNA damage.[188] Recent studies have shown 
that Tmz (3-2) is a very effective agent in recurrent metastatic SCLC,[189] where all 
standard therapies operate via DNA damage. However, both Tmz (3-2) and its glycine-
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extended analogue (Tmz-glycine, 3-5) were found to be ineffective against DMS53 
cells (LD50 value > 2 mM).[187] More surprisingly, Tmz-glycine (3-5), with a good 
binding affinity (IC50 value = 17.7 µM) to medium PAM, did not undergo PAM-
mediated cleavage (Scheme 3.3), and it could be recovered after the assay.[187] This 
suggests that Tmz-glycine (3-5) serves as a PAM inhibitor rather than a PAM substrate.  
 
 
Scheme 3.3 No Tmz (3-2) was produced in the PAM assay using Tmz-glycine (3-5). 
 
Based on this, another aim of the work in this Chapter was to attempt to find out why 
Tmz-glycine (3-5) is not converted into Tmz (3-2) by PAM. Recent studies suggest 
that the reaction of Tmz with CdCl2·2H2O produces the complex [Cd(Tmz)Cl2]n,[190] 
as Tmz is an organic ligand with abundant coordinating sites. Therefore, the working 
hypothesis for the inability of PAM to process Tmz-glycine (3-5) is that it may 
coordinate to the enzyme cofactor Cu(II) during the assay, resulting in inactive enzyme. 
In order to test this, a structurally-similar molecule N-Ac-(S)-His-Gly-COOH (3-6) 
was prepared. Both compound 3-6 and Tmz-glycine (3-5) have the imidazole moiety,  
for copper coordination.[191] Hence, it was of interest to examine whether N-Ac-(S)-
His-Gly-COOH (3-6) would be converted to N-Ac-(S)-His-NH2 (3-7) through 
enzyme-mediated cleavage. 
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Scheme 3.4 N-Ac-(S)-His-Gly-COOH (3-6) and the corresponding possible amidated 
product N-Ac-(S)-His-NH2 (3-7). 
 
3.2 Synthesis of Bex-glycine (3-4) 
 
It was anticipated that tert-butyl glycine could be installed onto Bex (3-1) through 
coupling in the presence of the BOP and DIPEA reagents, followed by deprotection 
of the tert-butyl group with TFA (Scheme 3.5).  
 
 
Scheme 3.5 Synthesis of Bex-glycine (3-4). 
 
As expected, Bex (3-1) coupled with tert-butyl glycine hydrochloride in the presence 
of BOP and DIPEA at room temperature to produce the ester 3-8, which was indicated 
by the appearance of a singlet peak at δH 1.50 and a doublet peak at δH 4.13 in the 1H 
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NMR spectrum, corresponding to the tert-butyl and glycine methylene protons, 
respectively. Deprotection of the ester 3-8 under acidic condition was performed to 
produce Bex-glycine (3-4), as evident from the loss of the singlet peak related to tert-
butyl protons in the 1H NMR spectrum. The product was purified by preparative HPLC. 
More synthesis details are presented in Chapter 8.  
 
3.3 Interaction of Bex-glycine (3-4) with Medium PAM 
 
Initially the binding affinity of Bex-glycine (3-4) with PAM was examined by 
determining the IC50 value in a competitive assay with the tripeptide (R)-Tyr-(S)-Val-
Gly-COOH as discussed in Chapter 2. This way, the present results are comparable 
with the earlier study of the analogue Bex-glycolate (3-3), wherein the binding affinity 
assay was performed using the same assay conditions. Due to the similarity of the 
structures of compounds 3-3 and 3-4, they were expected to have similar binding 
affinities. Since the IC50 value of compound 3-3 is reported to be 17.7 µM with the 
medium PAM from DMS53 cells,[187] the initial concentration range for testing 
compound 3-4 in the competitive assay was from 300-0 µM and the corresponding 
experimental data are shown in Table 3.1 below.  
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Table 3.1 Preliminary experimental data of binding affinity of Bex-glycine (3-4) from 
a competition assay. 
Concentration of Bex-
glycine (3-4) (µM) 
(R)-Tyr-(S)-Val-Gly-COOH turnover (%) 
Experiment A Experiment B 
0 20 18 
19 19 18 
38 17 17 
75 17 17 
150 15 14 
300 14 14 
 
From the Table above, up to 300 µM of compound 3-4 only reduced turnover of (R)-
Tyr-(S)-Val-Gly-COOH by around 20%. Therefore, higher concentrations (4800-0 
µM) were used in the competitive assay and the data are provided in Table 3.2. After 
plotting the concentration of compound 3-4 against the percentage turnover of the 
tripeptide, the activity-concentration curve (Figure 3.2) gave the IC50 value as 1300 ± 
300 µM. 
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Table 3.2 Second experimental data of binding affinity of Bex-glycine (3-4) from a 
competition assay. 
Concentration of Bex-
glycine (3-4) (µM) 
(R)-Tyr-(S)-Val-Gly-COOH turnover (%) 
Experiment A Experiment B 
0 20 19 
75 19 18 
150 16 16 
300 16 16 
600 14 13 
1200 9.2 10 
2400 5.4 5.1 
4800 4.0 3.5 
 
  
Figure 3.2 Activity-concentration curve for the assessment of binding affinity of 
Bex-glycine (3-4) with medium PAM. 
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The millimolar IC50 value shows that this Bex analogue 3-4 has poor binding affinity 
with PAM and it is therefore anticipated that when doped into cancer cells no 
significant amount of corresponding amidated product would form. However, it was 
still of interest to test its cytotoxicity profile because of its structural similarity with 
the medicinal agent Bex (3-1). 
 
3.4 Cytotoxicity Profile of Bex (3-1) and Bex-glycine (3-4) 
 
To evaluate the cytotoxicity of Bex (3-1) and Bex-glycine (3-4) with the DMS53 cell 
line, their LD50 values were to be determined. LD stands for lethal dose and the LD50 
value is the concentration of the tested compound required to produce a fifty percent 
decrease in cell viability.[192] In the present work, this value was calculated by plotting 
the concentration of the test compound against the fraction of cell viability using 
SciDAVis 0.2.4 software. The method used a Cell Counting Kit-8 (CCK-8), which 
provides convenient and sensitive colorimetric assays for determination of cell 
viability in cell proliferation and cytotoxicity assays. It relies on Dojindo’s highly 
water-soluble tetrazolium salt, WST-8 [2-(2-methoxy-4-nitrophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt]. This salt, as 
shown in Scheme 3.6, is reduced by dehydrogenase activities in cells to give an 
orange-colour formazan dye, which is soluble in the tissue culture medium and 
proportional to the numbers of living cells.[193] The detection sensitivity of WST-8 is 
higher than that of other tetrazolium salts such as MTT, XTT, MTS or WST-1.[194]  
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Scheme 3.6 WST-8 is reduced by dehydrogenase activities to give formazan dye. 
 
The assay involved pre-incubated DMS53 cells in a 96-well plate. Each well was 
treated with various concentrations of compounds 3-1 or 3-4 and incubated in a 
humidified incubator, followed by the addition of CCK-8 solution and further 
incubation. The concentration range was chosen from 160-0 µM at 2X serial dilution 
and 640 µM due to the fact that the LD50 value of compound 3-1 in an early study was 
found to be 60 µM.[187] The plate was finally analysed using a microplate reader. Each 
compound was tested twice, and the averaged results are presented in Figure 3.3. The 
data provided LD50 values for compounds 3-1 and 3-4 of 60 ± 9 µM and 80 ± 9 µM, 
respectively. As discussed in Chapter 2, the error was generated from the software 
program. This analysis indicates that the relative cytotoxic efficacies of Bex (3-1) and 
Bex-glycine (3-4) are not substantially different.  
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Figure 3.3 Antiproliferation effects of Bex (3-1) and Bex-glycine (3-4) on DMS53 
cells.  
 
3.5 Synthesis of N-Ac-(S)-His-Gly-COOH (3-6) and N-Ac-(S)-His-NH2 (3-7) 
 
Another aspect of the work described in this Chapter was to examine whether the 
potential PAM substrate 3-6 would be converted to compound 3-7 through enzyme-
mediated cleavage to attempt to find an explanation for why Tmz-glycine (3-5) is not 
converted to Tmz (3-2) by PAM. To obtain the peptide 3-6, solid phase peptide 
synthesis was carried out using standard Fmoc protocols (Scheme 3.7) with Wang 
resin in a similar manner as described for the synthesis of peptide 2-14. The swollen 
resin was treated with Fmoc-Gly-COOH in the presence of DIC and DMAP to give 
peptide 2-1 with 70% loading efficiency, followed by deprotection of the Fmoc group 
to give peptide 2-2. The resulting resin was then coupled with Fmoc-(S)-His(Bom)-
COOH. After Fmoc deprotection, an acetylation was performed with Ac2O and 
pyridine, followed by cleavage from the resin under acidic conditions, to give 
compound 3-11. It is noteworthy that the side-chain Bom group, attached to the 
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imidazole moiety, is stable to TFA but would be removed by a stronger acid such as 
HF. Considering HF is extremely hazardous and requires particular equipment to 
conduct deprotection of the Bom group, instead a mild method was chosen, that is 
hydrogenation using palladium on carbon under hydrogen.[195] After hydrogenation, a 
small amount of the crude peptide product was analysed by HPLC with detection using 
UV-Vis spectroscopy. The resulting HPLC chromatogram reproduced in Figure 8.46 
showed two dominant peaks. Separation of the materials corresponding to these peaks 
and MS analysis showed one corresponds to compound 3-6. The other one has mass 
120 Da more, which corresponds to compound 3-11. Separated compound 3-6 was 
analysed using high resolution MS and 1H NMR spectroscopy. 
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Scheme 3.7 Synthesis of N-Ac-(S)-His-Gly-COOH (3-6) 
 
In order to get a standard sample for HPLC detection, compound 3-7 was also 
synthesised. As shown in Scheme 3.8, esterification of N-Ac-(S)-His-COOH (3-12) 
was performed to produce the ester 3-13. Then, ammonia was used to convert the ester 
3-13 to the amide 3-7 at room temperature. The crude product was purified using 
HPLC and analysed using high resolution MS and 1H NMR spectroscopy before use. 
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Scheme 3.8 Synthesis of N-Ac-(S)-His-NH2 (3-7) 
 
3.6 Interaction of N-Ac-(S)-His-Gly-COOH (3-6) with Medium PAM 
 
Before examining whether compound 3-6 would be converted to compound 3-7 
through enzyme-mediated oxidative cleavage, the binding affinity of compound 3-6 
was measured in a competitive assay under the same conditions as described for 
peptide 2-14, because this is a relatively quick way to check whether N-Ac-(S)-His-
Gly-COOH (3-6) binds to PAM. The concentration of compound 3-6 and the 
tripeptide substrate turnover percentage were plotted to generate the activity-
concentration curve (Figure 3.4) and the average IC50 value of compound 3-6 was 
calculated as 70 ± 11 µM. This establishes that N-Ac-(S)-His-Gly-COOH (3-6) binds 
to PAM tightly. To determine if it is also a PAM substrate, standard assays were 
performed with N-Ac-(S)-His-Gly-COOH (3-6). 
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Figure 3.4 PAM binding affinity assay of N-Ac-(S)-His-Gly-COOH (3-6).  
 
The investigation of 3-6 as a possible substrate of PAM was performed under the same 
conditions as described for the above competitive assay, but with no tripeptide (R)-
Tyr-(S)-Val-Gly-COOH. The concentration of 3-6 used was 75 µM because this is 
close to the IC50 value determined above and hence enzyme binding occurs. After 
incubation, the solution was passed through an Amicon® Ultra YM-3 filter, then it 
was analysed using analytical HPLC, with detection and quantification of N-Ac-(S)-
His-Gly-COOH (3-6) and N-Ac-(S)-His-NH2 (3-7) by UV-Vis spectroscopy. The 
analytical standards had retention times of 10.8 min for compound 3-7 and 11.8 min 
for compound 3-6 (Figure 3.5A). The analysis of the PAM assay sample shown in 
Figure 3.5B shows a peak at 10.8 min corresponding to N-Ac-(S)-His-NH2 (3-7). It 
was thus concluded that N-Ac-(S)-His-Gly-COOH (3-6) is converted to the amidated 
product N-Ac-(S)-His-NH2 (3-7) by PAM. 
IC50 = 70 ± 11 µM 
 R2 > 0.99 
 
µM 
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Figure 3.5 (A) HPLC trace of 100 µM N-Ac-(S)-His-Gly-COOH (3-6) and N-Ac-(S)-
His-NH2 (3-7) standards; (B) HPLC trace of the sample from the PAM assay with 75 
µM N-Ac-(S)-His-Gly-COOH (3-6) (the small variation in retention time is likely due 
to the different solvents used, which were water (A) and MES buffer containing EtOH 
and DMSO (B), respectively).  
 
3.7 Discussion 
 
Bex-glycine (3-4) had an IC50 value at the micromolar level in the competition assay, 
indicating that it is a poor PAM substrate with weak enzyme binding. Therefore, 
compound 3-4 would not have dual activity as proposed, i.e. inhibiting PAM and then 
producing a cytotoxic drug for cancer cells. However, the cytotoxicity assay showed 
that compound 3-4 itself had good activity against DMS53 cells, similar to its analogue 
A 3-7 
B 
3-7 
3-6 
3-6 
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3-3 and the parent agent 3-1. This indicates that compound 3-4 still has potential in 
cancer therapy but not through the dual activity anticipated. 
 
The fact that the reaction of N-Ac-(S)-His-Gly-COOH (3-6) is catalysed by PAM 
shows that its imidazole moiety does not inactivate the enzyme through copper 
coordination. Therefore, it is unlikely that Tmz-glycine (3-5) possessing the similar 
imidazole moiety inhibits PAM by metal chelation. Instead, other possibilities should 
be considered to explain why Tmz-glycine (3-5) is not converted to Tmz (3-2) by PAM. 
For example, compound 3-5 might bind to the active site of PAM in a different 
orientation other than that required for reaction. 
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Chapter Four 
Investigation of the Subunit Activity of Peptidylglycine α-
Amidating Monooxygenase 
 
4.1 Introduction 
 
PAM consists of two subunits, PHM and PAL. As shown in Scheme 4.1(which is 
reproduced from Scheme 1.1 in Chapter 1), PHM catalyses reaction of glycine-
extended peptides to give α-hydroxyglycine intermediates, and PAL then catalyses 
cleavage of the intermediates to give amidated products. The latter step also occurs 
through non-enzyme-catalysed hydrolysis, particularly on treatment with base.[196] In 
the work described in the previous Chapters, base was used in the work-up of PAM 
assays, so any PAL activity was masked and the activity being measured was actually 
that of the PHM subunit. In this Chapter, the aim was to unmask the PAL activity. 
Without non-enzymatic hydrolysis, PHM activity corresponds to the amount of the 
glycine-extended peptide reacted and the sum of the quantities of the hydroxylated 
intermediate and amidated product formed, while PAL activity corresponds only to 
the amount of formation of the amidated product. 
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Scheme 4.1 Mechanism of PAM catalysis. 
 
Within the past thirty years, a number of groups have studied both PHM activity and 
PAL activity using various assay conditions and detection methods. Eipper and her 
colleagues performed radioactivity assays with 125I-labelled N-Ac-(R)-Tyr-(S)-Val-
Gly-COOH and N-Ac-(R)-Tyr-(S)-Val-α-hydroxyglycine as distinct substrates to 
determine PHM and PAL activities, respectively.[125] This assay had a few 
shortcomings. Apart from involving radioactivity, separate investigations of PHM and 
PAL activities complicated the experiment. Furthermore, hydroxyglycine derivatives 
are hard to synthesise and store due to chemical instability.[196]  
 
The Merkler group also conducted separate assays of PHM and PAL activities.[127] In 
their study, PHM activity was determined by measuring either oxygen consumption, 
using aceturic acid as an oxidisable substrate, or measuring N-dansyl-Tyr-Val-Gly 
amidation. PAL activity was determined by measuring glyoxylate production from 
(R,S)-α-hydroxyhippuric acid by the spectrophotometric method of Christman et 
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al.,[197] modified by Katopodis and May.[102] The drawbacks mentioned above 
encouraged us to consider a single assay to investigate both PHM and PAL at the same 
time. Mounier et al. monitored PHM and PAL activities in a time-dependent assay 
with the PAM from X. laevis,[126] using HPLC with a UV-Vis detector. We instead 
developed an assay based on HPLC-MS. 
 
4.2 Investigation of PHM and PAL Activities Using HPLC-MS 
 
To develop an efficient method for detecting universal PAM substrates, intermediates, 
and amidated products at the same time, HPLC-MS was considered because it involves 
rapid method development. The HPLC-MS setup, as illustrated in Figure 4.1 below, 
consists of a Waters Alliance 2695 separation module, a reverse-phase C18 column, a 
Waters flow splitter, a Waters TQD mass detector (ESI), and a Waters Fraction 
Collector. For analysis, samples are injected onto the reverse-phase column, eluted 
with MeCN, water and formic acid, followed by detection with the ESI mass detector. 
The percent conversion from peptide substrates to intermediates and products is then 
calculated via MassLynx 4.1 software.  
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Figure 4.1 HPLC-MS setup for detection of PAM substrates, intermediates, and 
products. 
 
The PAM enzyme used in this work was medium PAM as used in Chapter 2 and 
Chapter 3, which is most relevant to humans. In this work, the first PAM substrate 
studied was the tripeptide (R)-Tyr-(S)-Val-Gly-COOH, which had already been used 
before where it was detected by fluorescence after labelling the free amine group with 
fluorescamine. The second substrate selected was N-Ac-(S)-Phe-Gly-COOH (1-66). 
This compound was expected to bind PAM better than the tripeptide because it has 
Phe at its penultimate position from the C-terminus. Compound 1-66 was synthesised 
through a coupling reaction between N-Ac-(S)-Phe-COOH (4-1) and glycine methyl 
ester hydrochloride, followed by ester deprotection, as described in the literature 
(Scheme 4.2A).[133] The corresponding amidated product 4-3 was also made to 
facilitate the development of the detection method. As shown in Scheme 4.2B, it was 
synthesised through an esterification, followed by adding ammonia. 
 
 
Analysis (Out) 
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Scheme 4.2 Synthesis of (A) N-Ac-(S)-Phe-Gly-COOH (1-66) and (B) N-Ac-(S)-Phe-
NH2 (4-3). 
 
PAM assays in this Chapter were performed under the same conditions as described 
in Chapter 2 except that no base was used after the sample incubation. Both compound 
1-66 and the tripeptide substrate were used with the same concentration so that the 
data can be compared directly. Under these circumstances, the hydroxylated 
intermediate produced by PHM catalysis but not yet processed by PAL should be 
detectable. The substrates, hydroxylated intermediates and amidated products are 
shown in Scheme 4.3.  
 
 
 
 
 
A 
B 
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Scheme 4.3 PAM processing of (A) (R)-Tyr-(S)-Val-Gly-COOH and (B) N-Ac-(S)-
Phe-Gly-COOH (1-66).  
 
After being incubated and filtered, assay mixtures were injected on to the HPLC-MS 
system. The substrates, intermediates and products were successfully separated by 
HPLC and quantified by the mass detector (ESI). The quantification was conducted 
through Multiple Reaction Monitoring (MRM) mass spectrometry (Figure 4.2 and 
Figure 4.3) comparing peak areas of the three components. PHM activity is reflected 
by the sum of hydroxylated intermediate and amidated product while PAL activity 
plus chemical hydrolysis of hydroxylated intermediate are reflected by only the 
amount of amidated product. 
 
 
A 
B 
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Figure 4.2 Representative HPLC-MS analysis of HO-(R)-Tyr-(S)-Val-Gly-COOH, 
(R)-Tyr-(S)-Val-NH2 and (R)-Tyr-(S)-Val-Gly-COOH. 
 
 
Figure 4.3 Representative HPLC-MS analysis of HO-N-Ac-(S)-Phe-Gly-COOH, N-
Ac-(S)-Phe-NH2 (4-3) and N-Ac-(S)-Phe-Gly-COOH (1-66). 
 
HO-(R)-Tyr-(S)-Val-Gly-COOH 
N-Ac-(S)-Phe-Gly-COOH (1-66) 
(R)-Tyr-(S)-Val-NH2 
(R)-Tyr-(S)-Val-Gly-COOH 
N-Ac-(S)-Phe-Gly-NH2 (4-3) 
HO-N-Ac-(S)-Phe-Gly-COOH 
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The relative amounts of substrates, intermediates, and products in the samples with 
(R)-Tyr-(S)-Val-Gly-COOH and N-Ac-(S)-Phe-Gly-COOH (1-66) are illustrated in 
Figure 4.4. The substrate and hydroxylated intermediate turnovers were calculated 
and are shown in Table 4.1. Under identical assay conditions, the substrate turnover 
of 1-66 was 10% higher than that of (R)-Tyr-(S)-Val-Gly-COOH, reflecting that PHM 
activity for compound 1-66 was higher than for the tripeptide. This is likely due to the 
Phe at the penultimate position from the C-terminus which increases the binding 
affinity with PAM as described in Chapter 2. Additionally, the free amino group at the 
N-terminus of (R)-Tyr-(S)-Val-Gly-COOH would be protonated under the assay 
conditions, which likely negatively impacts the binding affinity;[120] in contrast, N-Ac-
(S)-Phe-Gly-COOH (1-66) is N-acetylated so is neutral/uncharged. Hydroxylated 
intermediate turnover in the case of compound 1-66 was 9% higher than that of the 
tripeptide. The HPLC-MS detection method is rapid and efficient. 
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Figure 4.4 Ratios of substrates, intermediates, and products in assays using (R)-Tyr-
(S)-Val-Gly-COOH and N-Ac-(S)-Phe-Gly-COOH (1-66) with PAM (both assays 
were duplicated).  
 
Table 4.1 Substrate and hydroxylated intermediate turnover in assays using (R)-Tyr-
(S)-Val-Gly-COOH and N-Ac-(S)-Phe-Gly-COOH (1-66). 
Substrate Substrate Turnover (%) 
Hydroxylated 
Intermediate Turnover 
(%) 
(R)-Tyr-(S)-Val-Gly-COOH 7 5 
N-Ac-(S)-Phe-Gly-COOH 17 14 
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Having established a method for assessing intermediate turnover, it was now feasible 
to further investigate the hydrolysis of hydroxylated intermediates during the PAM 
reaction. As discussed in Section 4.1, the hydrolysis occurs due to PAL catalysis and 
chemical instability. However, the proportion of these two processes was unknown. 
Chemical instability of hydroxyglycine derivatives increases with increasing pH (from 
pH 5),[196] and a kinetic study by Mounier et al. reported chemical hydrolysis of 
hydroxyglycine derivatives increases approximately 2 fold from pH 5.0 to 6.5.[126] 
Considering this, the effect of pH on the PAM assay was investigated. The PAM assay 
was conducted across the effective pH range (5.5 - 6.7) of MES buffer.[198] It was 
expected that, if chemical hydrolysis dominates the conversion of hydroxylated 
intermediates, the amount of amidated product would increase with increasing pH. 
 
The pH-dependent assays using (R)-Tyr-(S)-Val-Gly-COOH and N-Ac-(S)-Phe-Gly-
COOH (1-66) were performed under the same conditions as described above except 
the pH was varied. Relative amounts of substrates, intermediates, and products with 
(R)-Tyr-(S)-Val-Gly-COOH and N-Ac-(S)-Phe-Gly-COOH (1-66) are illustrated in 
Figure 4.5 and Figure 4.6, respectively. Figure 4.5 shows the relative amounts of 
each component in the assays with (R)-Tyr-(S)-Val-Gly-COOH are similar from pH 
5.5 to 6.7. This indicates that, for (R)-Tyr-(S)-Val-Gly-COOH, PHM activity is 
constant across this pH range. The similar amounts of product and intermediate across 
the pH range suggest that chemical hydrolysis is at least not solely responsible for the 
conversion of hydroxylated intermediate. Otherwise, the amount of intermediate at pH 
5.5 would be expected to be around double the amount at pH 6.7 due to the pH 
dependency of chemical hydrolysis.[126] Based on this, either PAL activity is mostly 
responsible for conversion of the hydroxylated intermediate, or a decrease of PAL 
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activity with increasing pH offsets the expected increase in chemical hydrolysis. Based 
on the kinetic study by Mounier et al.[126] that half-lives of hydroxyglycine derivatives 
are typically several days, it is more likely but not proven that PAL activity is mostly 
responsible for hydrolysis of the intermediate. 
 
 
 
Figure 4.5 Ratios of substrates, intermediates, and products in pH-dependent assays 
using (R)-Tyr-(S)-Val-Gly-COOH with PAM. 
 
As shown in Figure 4.6 and Table 4.2, N-Ac-(S)-Phe-Gly-COOH (1-66) turnover 
decreased with increasing pH, showing a decreasing PHM activity. So after the first 
step of the PAM reaction, more hydroxylated intermediate is produced at lower pH. 
But the observed relative amounts of hydroxylated intermediate were constant and the 
observed relative amounts of amidated product decreased with increasing pH, 
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demonstrating that hydrolysis of intermediate (PAL activity plus chemical hydrolysis) 
decreases with increasing pH. As discussed above, chemical hydrolysis would be 
expected to increase with increasing pH from pH 5, which again means that PAL 
activity is likely to be much greater than chemical hydrolysis.  
 
 
 
Figure 4.6 Ratios of substrates, intermediates, and products in pH-dependent assays 
using N-Ac-(S)-Phe-Gly-COOH (1-66) with PAM. 
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Table 4.2 Substrate and hydroxylated intermediate turnover in pH-dependent assays 
using N-Ac-(S)-Phe-Gly-COOH with PAM. 
pH Substrate Turnover (%) Hydroxylated Intermediate Turnover (%) 
5.5 20 18 
5.8 17 14 
6.1 14 11 
6.4 11 9 
6.7 7 5 
 
4.3 Conclusion 
 
In the present study, an efficient and rapid HPLC-MS method was developed, which 
enables the detection and quantification of substrate, hydroxylated intermediate and 
product in PAM catalysis and hence investigation of both substrate turnover and 
hydroxylated intermediate turnover simultaneously. With this new method, the 
proportion of PAL catalysis and chemical hydrolysis of hydroxylated intermediates 
were investigated through pH-dependent assays. It was found that no increase of 
amidated product was observed with increasing pH, showing that PAL activity is 
likely to be mostly responsible for the hydrolysis of hydroxylated intermediate while 
the proportion of chemical hydrolysis is expected to be quite low. Nevertheless, to 
assess this more accurately, PAL inhibition assays were considered. 
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Chapter Five 
 
Structure-Activity Relationship Study for Peptidyl-α-
Hydroxyglycine α-Amidating Lyase Inhibition 
 
5.1 Introduction 
 
The work described in the previous Chapter comprised a bifunctional PAM assay 
using HPLC-MS which enables simultaneous investigation of PHM activity and PAL 
activity. With this newly established assay, it is feasible to investigate the inhibition 
of both PHM and PAL activities at the same time with PAM inhibitors. Considerable 
effort has been made to develop PAM inhibitors with potential to treat diseases 
associated with amidated peptide production imbalances. To date, many studies have 
focused on PHM inhibition,[16, 102, 121, 124-125, 127-128, 131, 133-139, 142-144] but only a few PAL 
inhibitors have been reported.[119, 126-127] With two components, PHM and PAL, there 
are several possible modes of inhibition for a PAM inhibitor: (1) only PHM inhibition; 
(2) only PAL inhibition; or (3) inhibition of PAL and PHM. To find out which mode 
of inhibition is applicable for a range of candidate molecules, PAM inhibitory potency 
is assessed in this Chapter. Specifically, a known PAL inhibitor 1-143 was 
investigated alongside a number of structural analogues, as shown in Figure 5.1, to 
build a structure activity relationship revealing the modes of inhibition and which 
structural elements are responsible for PAL inhibition. 
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Figure 5.1 Compounds for structure-activity relationship study in PAM inhibition. 
 
5.2 Synthesis of Candidate Molecules for PAM Inhibition Assay 
 
N-Ac-Phe-pyruvate (1-143) was prepared on the basis of the protocol described by 
Mounier et al.[126]  As shown in Scheme 5.1, (S)-Phe-COOH reacted with acetic 
anhydride through a Dakin-West reaction using pyridine as the base at elevated 
temperature delivering a racemic ketone mixture 5-1 upon liberation of CO2.[199] The 
proposed mechanism[200-201] is that acylation of (S)-Phe-COOH on the carboxylic acid 
group as well as the amine forms an anhydride, which then cyclises to give an 
oxazolone intermediate. Deprotonation of the oxazolone by the base leads to a 
resonance-stabilised 1,3-oxazol-5-olate. Subsequent acetylation followed by ring 
opening gives rise to a racemic anhydride. After transacylation decarboxylation finally 
furnishes the product 5-1. Its structure was confirmed by 1H NMR spectroscopy which 
showed two singlets at d 1.98  and d 2.15 corresponding to the methyl groups. ESI-
MS showed an [M+H]+ ion at m/z 206.2. The resulting product 5-1 then reacted with 
diethyl oxalate through condensation in sodium ethoxide solution as the base at room 
temperature overnight.[126] The crude product was treated with decolorizing carbon to 
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remove a yellowish impurity, and then further purified by silica-gel chromatography 
to yield compound 5-4 as a colourless oil. The structure of compound 5-4 was 
confirmed by 1H NMR spectroscopy which showed a triplet and a quartet at d 1.37 
and d 4.35 with coupling constants of 7.1 Hz. These two peaks were attributed to the 
ester group in compound 5-4. A singlet peak at d 6.40 corresponds to an olefinic proton, 
with an integration for one proton, indicating that compound 5-4 in this solvent CDCl3 
is mainly the enol form of the keto-enol tautomerism, as shown in Scheme 5.2. It is 
worth noting that Mounier et al. reported the synthesis of compound 5-4 and their 1H 
NMR spectrum in CDCl3 showed peaks related to every proton in compound 5-4 
except the olefinic proton for the enol form (or the methylene protons for the keto 
form). The structure of compound 5-4 was also confirmed by ESI-MS which showed 
an [M+H]+ ion at m/z 306.2. Hydrolysis of the ester 5-4 using lithium hydroxide in 
THF mixed with water gave the acid form of compound 1-143,[202] which was finally 
converted to the sodium salt using sodium hydroxide. The 1H NMR spectrum of the 
final product 1-143 (sodium form) in D2O showed a singlet peak at d 1.82, 
corresponding to the methyl group. Two doublets of doublets at d 2.79 and d 3.21 with 
coupling constants of 14.0 Hz correspond to the benzylic methylene. The methine 
resonance of the phenylalanine moiety is expected to be masked by the HOD peak at 
d 4.79. The fact that the two protons of the benzylic methylene both show doublets of 
doublets instead of simply doublets suggests they are both affected by a proton on an 
adjacent carbon. The phenyl resonances centre around d 7.36. The methylene 
resonance of the pyruvate moiety was not seen, which is expected to be due to 
deuterium exchange through keto-enol equilibration. ESI-MS of compound 1-143 
showed an [M-H]- ion at m/z 276.4. Both the 1H NMR and MS spectra are consistent 
with data reported by Mounier et al.[126]  
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Scheme 5.1 Synthesis of N-Ac-Phe-Pyruvate (1-143).  
 
 
Scheme 5.2 Keto-enol tautomerism. 
 
The α-hydroxy acid 5-2 was previously unreported. Its synthesis was accomplished in 
six steps from phenylacetic acid as shown in Scheme 5.3. The first step involved 
activation of phenylacetic acid with EDCI and cross-coupling with N,O-
dimethylhydroxylamine to give the amide 5-5.[203] ESI-MS showed an [M+H]+ ion at 
m/z 180.1. Then compound 5-5 underwent a Grignard reaction delivering the ketone 
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5-6,[204] wherein the Grignard reagent formed via the reaction of 4-bromo-1-butene 
with magnesium metal, functioned as a nucleophile, substituting at the electrophilic 
carbon of the carbonyl group of compound 5-5. The product structure was confirmed 
by 1H NMR spectroscopy which showed a triplet peak at d 2.55, corresponding to a 
methylene in the butenyl group of compound 5-6. EI-MS showed an M+ ion at m/z 
174.1. The ketone 5-6 then underwent reductive amination to deliver the primary 
amine 5-7.[205] In the reaction, ammonium acetate first reacts with compound 5-6 to 
form an imine losing a molecule of H2O. Under the acidic conditions, the imine is 
protonated as the iminium ion, which is reduced to give the amine 5-7 by the reducing 
agent, NaBH3CN. The singlet at d 3.69 in the 1H NMR spectrum of compound 5-6 in 
CDCl3, corresponding to the benzylic methylene, is completely missing from the 1H 
NMR spectrum of compound 5-7 in CDCl3. Instead, two doublets of doublets appear 
at d 2.78 and d 2.91, and a broad singlet appears at d 3.60, corresponding to the 
benzylic methylene and amino group, indicating that the amine 5-7 is obtained. The 
product structure was further confirmed by ESI-MS which showed an [M+H]+ ion at 
m/z 176.2. Since no stereoselective reagents were used, the resulting compound 5-7 is 
expected to be a racemic mixture. After acetylation of the amine 5-7 to form the amide 
5-8, dihydroxylation was performed using osmium tetroxide as a catalyst and a 
stoichiometric amount of NMO as oxidant to convert the amide 5-8 to the 1,2-diol 5-
9.[206] Peaks corresponding to olefinic protons in the 1H NMR spectrum of compound 
5-8 in CDCl3 are completely missing from the 1H NMR spectrum of the diol 5-9 in 
CDCl3, suggesting the olefin group in compound 5-8 was oxidised. Many peaks in the 
spectrum are duplicated, suggesting the compound is a mixture of diastereomers as 
compound 5-9 has two chiral centres. Two singlets at d 1.91 and d 1.92 are attributed 
to the N-acetyl methyl group, the equal height of which indicated the ratio of 
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diastereomers is 1:1. This can be explained by the reaction mechanism that after the 
cycloaddtion of osmium tetroxide to the olefinic bond in compound 5-8, water attacks 
the epoxy intermediate from both sides with equal chance to give the mixture of 
diastereomers in the ratio 1:1. ESI-MS showed an [M+H]+ ion at m/z 252.2. The 
terminal alcohol of the diol 5-9 was later oxidised, catalysed by TEMPO, to achieve 
the target product 5-2.[207] The 1H NMR spectrum of the final product in D2O shows 
resonances of α-carboxy and α-acetamido methine groups, at d 4.21 and d 4.03, 
respectively. Four doublets of doublets with the same coupling of 13.4 Hz are all 
attributed to benzylic methylenes, again suggesting the product is a mixture of 
diastereomers. The product structure was also confirmed by 13C NMR spectroscopy 
and ESI-MS which showed an [M+Na]+ ion at m/z 344.2. 
 
 
Scheme 5.3 Synthesis of the α-hydroxy acid 5-2. 
 
The glycolate 1-57 was prepared according to the protocol described by Easton et 
al.[133] As shown in Scheme 5.4, an alkylation of N-Ac-(S)-Phe-COOH (4-1) was 
performed to give compound 5-10, involving dissolving compound 4-1 and tert-butyl 
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bromoacetate in acetone with excess K2CO3 added as an insoluble component. The 
reaction was run at reflux. The product structure was confirmed by ESI-MS which 
showed an [M+Na]+ ion at m/z 344.2. The final product 1-57 was obtained through 
removal of the tert-butyl group using strong acid at room temperature. The product 
structure was confirmed by 1H NMR spectroscopy, which showed a singlet at d 1.99, 
corresponding to the N-acetyl methyl group, and the ESI-MS which showed an [M-
H]- ion at m/z 264.1. 
 
 
Scheme 5.4 Synthesis of the glycolate 1-57. 
 
The α,β-unsaturated γ-keto acid 1-39 was prepared according to the protocol described 
by Mounier et al.[140] As shown in Scheme 5.5, N-Ac-(S)-Phe-COOH (4-1) was 
esterified using acid and EtOH at reflux to give the ester 5-11. The resulting ester then 
reacted with n-BuLi and dimethyl methylphosphonate (DMMP, CH₃PO(OCH₃)₂) to 
give a ketophosphonate.[208-209] This reaction involves the deprotonation of DMMP 
using n-BuLi at -78 ºC to give LiCH2PO(OCH₃)₂, which then reacts with the ester 5-
11 through a condensation to give the product 5-12. This product structure was 
confirmed by 1H NMR spectroscopy which showed two multiplets at d 3.23 and d 3.75 
with an integration value of two protons for each. These two multiplets are attributed 
to the overlapping of two methylene groups, i.e. phosphate methylene and benzylic 
methylene groups, suggesting that the phosphate methylene has two magnetically 
nonequivalent protons. ESI-MS showed an [M+Na]+ ion at m/z 336.1. A Horner–
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Wadsworth–Emmons (HWE) reaction between ethyl glyoxalate and compound 5-12, 
using K2CO3 as the base at 5 ºC, was then performed to give the alkene 5-13.[140] This 
reaction involves deprotonation of the phosphonate 5-12 to give a phosphonate 
carbanion. Nucleophilic addition of the carbanion onto ethyl glyoxalate, followed by 
elimination, produces the E-alkene 5-13. This reaction produces predominantly E-
alkenes due to the fact that bulky aldehydes and bulky electron-withdrawing groups 
enhance E-alkene selectivity of HWE reactions.[210] The structure of the ester 5-13 was 
confirmed by 1H NMR spectroscopy which showed two doublets at d 6.77 and d 7.13 
with coupling constants of 15.8 Hz, corresponding to trans-olefinic protons. ESI-MS 
showed an [M+Na]+ ion at m/z 312.1. Following the reported procedure[140] which 
conveniently converts the ester 5-13 to the carboxylic acid 1-39 using pig liver esterase 
in phosphate buffer that maintains the pH around 7, crude compound 1-39 was 
obtained then purified by preparative HPLC to afford the final the product as a 
colourless powder. ESI-MS showed an [M-H]- ion at m/z 260.2. Both the 1H NMR and 
MS spectra are consistent with data reported by Mounier et al.[140] 
 
 
Scheme 5.5 Synthesis of the α,β-unsaturated γ-keto acid 1-39. 
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Synthesis of the fumaric acid 5-3 was based on the method by Ekici et al.[211] As shown 
in Scheme 5.6, ester coupling was performed between fumaric acid and benzyl alcohol 
using NMM as a coupling reagent and EDC as an activating reagent for ester formation 
in DMF solvent. The product structure was confirmed by 1H NMR spectroscopy which 
showed two doublets at d 6.88 and d 6.98 with coupling constants of 15.8 Hz, 
corresponding to the trans-olefinic protons. ESI-MS showed an [M+Na]+ ion at m/z 
229.1. 
 
 
Scheme 5.6 Synthesis of the fumaric acid 5-3. 
 
5.3 Measurements of PAM Inhibition Potencies of Molecules 
 
N-Ac-Phe-pyruvate (1-143) was chosen as the first candidate to test for PAM 
inhibition potency because it has the most potent PAL inhibition ever reported and has 
relatively weak PHM inhibition.[126] Therefore, evaluating the pyruvate 1-143 was to 
check whether the HPLC-MS system works for investigation of PHM and PAL 
inhibition potencies of PAM inhibitors. The evaluation was performed through a PAM 
inhibition assay using the substrate (R)-Tyr-(S)-Val-Gly-COOH with the addition of 
varying concentrations of the compound 1-143. The assay conditions were the same 
as described in Section 4.2. The concentrations of compound 1-143 used initially were 
from 0.4 to 0 µM at 2X serial dilution and 4 µM, based on the report by Mounier et 
al.[126] of a Ki value of compound 1-143 for competitive PAL inhibition of 0.24 µM. 
103 
 
The ratios of substrate, intermediate and product of the PAM catalysis are shown in 
Table 5.1. The Table shows increasing percentage of hydroxylated intermediate and 
decreasing percentage of amidated products with increasing concentrations of 
compound 1-143, consistent with compound 1-143 having PAL inhibition. The 
constant percentages of substrate show that compound 1-143 has no PHM inhibition 
in this concentration range. 
 
Table 5.1 Ratios of substrate, intermediate, and product in PAM assays using (R)-Tyr-
(S)-Val-Gly-COOH with concentrations of N-Ac-Phe-pyruvate (1-143) ranging from 
0-4 µM.  
Concentration of 
N-Ac-Phe-
pyruvate (1-143) 
(µM) 
Substrate (%) Intermediate (%) Product (%) 
0 91.5 5.0 3.5 
0.012 91.6 5.6 2.9 
0.025 91.1 6.2 2.7 
0.05 91.4 6.1 2.4 
0.1 92.0 6.4 1.6 
0.2 92.6 6.3 1.1 
0.4 91.6 7.6 0.8 
4 92.7 7.0 0.3 
 
In this assay, the inhibitor-free sample is the control, and the hydroxylated 
intermediate turnover (percentage of amidated product) of the control, reflecting PAL 
activity, is therefore set as one hundred percent. The IC50 value for PAL inhibition was 
then calculated as the concentration of compound 1-143 that reduced hydroxylated 
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intermediate turnover of the control by 50%. The activity-concentration curves were 
generated by plotting the hydroxylated intermediate turnover (percentage of control) 
and compound 1-143 concentration. The activity-concentration curves for duplicate 
PAL inhibition assays are shown in Figure 5.2. As a result, compound 1-143 was 
found to show good PAL inhibition with an IC50 value of 0.09 ± 0.02 µΜ, in the same 
range as the Ki value of 0.24 µM reported by Mounier et al.[126] 
 
  
 
IC50 = 0.09 ± 0.02 µM 
R2 > 0.99 
 
IC50 = 0.08 ± 0.01 µM 
R2 > 0.99 
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Figure 5.2 Determination of IC50 values of N-Ac-(S)-Phe-Gly-COOH (1-143) for PAL 
inhibition in duplicate assays.  
 
A PAM inhibition assay was then performed using concentrations of compound 1-143 
from 100 to 0 µM at 2X serial dilution for further investigation due to the fact that the 
Ki value of compound 1-143 toward PHM is known to be two orders of magnitude 
higher than that toward PAL.[126] The data, shown in Table 5.2, demonstrate that the 
percentage of hydroxylated intermediate increases going from 0-6.25 µM of 
compound 1-143 and then goes down with further increasing concentration of 
compound 1-143. This indicates compound 1-143 shows mainly PAL inhibition at low 
concentration but also shows PHM inhibition with further increasing concentration. 
The percentage of amidated product keeps decreasing till to zero with increasing 
compound 1-143 due to PAL inhibition, confirming that PAL activity is indeed mostly 
responsible for the hydrolysis of the intermediate and little chemical hydrolysis occurs 
in this two-hour PAM assay.   
 
Table 5.2 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of N-Ac-Phe-pyruvate (1-143) ranging from 0-
100 µM.  
Concentration of 
N-Ac-Phe-
pyruvate (1-143) 
(µM) 
Substrate (%) Intermediate (%) Product (%) 
0 92.2 4.7 3.1 
6.25 93.5 6.3 0.2 
12.5 95.2 4.6 0.2 
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25 96.9 3.0 0.1 
50 97.4 2.5 0.1 
100 98.3 1.7 0 
 
 
Like the determination of IC50 values for PAL inhibition, the substrate turnover 
(percentage of the sum of intermediate and product) of the control, reflecting PHM 
activity, was set as one hundred percent, and the IC50 value for PHM was then 
calculated as the concentration of compound 1-143 that reduced substrate turnover of 
the control by 50%. The activity-concentration curves generated by plotting the 
substrate turnover (percentage of control) and compound 1-143 concentration for 
PHM inhibition are shown in Figure 5.3. As a result, compound 1-143 was found to 
have micromolar PHM inhibition with an IC50 value of 14 ± 3 µM. The PHM and PAL 
inhibition results of compound 1-143 are consistent with the results by Mounier et 
al.,[126] indicating that the bifunctional PAM assay using the HPLC-MS system is 
suitable for the evaluation of PAM inhibitory potency of molecules. 
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Figure 5.3 Determination of IC50 values of N-Ac-(S)-Phe-Gly-COOH (1-143) for 
PHM inhibition in duplicate assays.  
After testing compound 1-143 and confirming that the HPLC-MS PAM assay is 
suitable for investigating PHM and PAL inhibitory potency simultaneously, the other 
inhibitor candidates in Figure 5.1 were then evaluated using the assay conditions as 
described for compound 1-143, except with different concentrations used for each 
molecule. PBA (1-17) was tested over the concentration range from 20 to 0 µM at 2X 
IC50 = 15 ± 3 µM 
R2 > 0.99 
 
IC50 = 12 ± 2 µM 
R2 > 0.99 
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serial dilution and 100 µM due to the fact that PBA (1-17) has reported PHM-
inhibition-related Ki values of 0.096 µM (human) and 19 µM (porcine).[128, 138] The 
data in Table 5.3 illustrate the increasing percentage of substrate and the deceasing 
percentage of intermediate and product with increasing concentration of PBA (1-17), 
indicating that PBA has PHM inhibition. At 20 µM PBA, the percentage of the 
intermediate is around 28% of the control while the percentage of the amidated product 
is around 57% of the control. This is expected when PHM activity is inhibited leading 
to less of the hydroxylated intermediate. This observation is consistent with the study 
by Eipper et al.[125] that PBA has only PHM inhibition and no PAL inhibition. Its IC50 
value for PHM inhibition was determined as 14 ± 5 µM through analysis of the 
activity-concentration curve. 
 
Table 5.3 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of PBA 1-17 ranging from 100-0 µM.  
Concentration of PBA 
1-17 (µM) Substrate (%) Intermediate (%) Product (%) 
0 94.7 2.5 2.8 
0.05 95.3 2.0 2.7 
0.5 95.7 1.6 2.7 
1 95.8 2.0 2.2 
5 96.1 1.9 2.0 
10 97.0 1.1 1.9 
20 97.7 0.7 1.6 
100 99.2 0.2 0.6 
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Compounds 5-1 and 5-2 were tested at 400-0 µM at 10X serial dilution to quickly 
assess any PAL and PHM inhibition since no related information was available. No 
reduction of substrate or intermediate turnover with increasing concentrations was 
observed with compounds 5-1 and 5-2, suggesting neither of these two compounds is 
a PHM or PAL inhibitor up to a concentration of 400 µM.  
 
Since its IC50 value for inhibition of PAM enzyme extracted from H889 small cell 
lung carcinoma cells is 6 µM,[133] the initial concentration of compound 1-57 used for 
this PAM inhibition assay was 100-0 µM at 2X serial dilution. Table 5.4 shows the 
ratios among substrate, intermediate and product are constant with compound 1-57 
concentrations from 0 to 20 µM. 100 µM N-Ac-Phe-glycolate (1-57) only reduced the 
tripeptide substrate turnover by 21%, suggesting compound 1-57 has PHM inhibition 
but requires higher concentrations for IC50 calculation. Therefore, higher 
concentrations, 0-2000 µM, were used and the data are shown in Table 5.5. 
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Table 5.4 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of N-Ac-Phe-glycolate (1-57) ranging from 0-
100 µM.  
Concentration of N-
Ac-Phe-glycolate (1-
57) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 94.7 2.4 2.9 
0.05 94.0 2.6 3.4 
0.5 94.1 2.6 3.3 
1 93.8 2.7 3.5 
5 94.3 2.3 3.4 
10 94.2 2.5 3.3 
20 95.0 2.1 2.9 
100 95.8 1.5 2.7 
 
 
The data in Table 5.5 show the increasing percentage of substrate and the deceasing 
percentage of intermediate and product with increasing concentrations of compound 
1-57. Similar to the scenario with PBA 1-17, the decrease of the intermediate is greater 
than that of the product, indicating that PHM inhibition by compound 1-57 is greater 
than its PAL inhibition. Under these circumstances, it is not practical to determine an 
IC50 value for PAL inhibition but that for PHM inhibition was determined to be 139 ± 
23 µM through analysis of the activity-concentration curve, and the PAL IC50 must be 
higher. 
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Table 5.5 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of N-Ac-Phe-glycolate (1-57) ranging from 0-
2000 µM.  
Concentration of N-
Ac-Phe-glycolate (1-
57) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 94.2 2.1 3.7 
100 96.9 1.0 2.1 
250 97.5 0.6 1.9 
500 98.4 0.3 1.3 
1000 99.0 0.2 0.8 
2000 99.4 0.1 0.5 
 
For compound 1-39, the concentration range used was 20-0 µM at 2X serial dilution 
and 100 µM since its IC50 value against frog PAM is 57 µM.[131] The data in Table 5.6 
show the increasing percentage of substrate and the deceasing percentage of 
intermediate and product with increasing concentrations of compound 1-39. At lower 
concentrations of compound 1-39 the decrease in the percentage of amidated product 
is greater than that of substrate turnover, showing selective PAL inhibition. Though 
the corresponding IC50 value could not be determined due to the complicated dual-
step assay, the IC50 value of compound 1-39 for PHM inhibition was determined 
through analysis of the activity-concentration curve to be 3 ± 1 µM.  
 
 
 
112 
 
Table 5.6 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of compound 1-39 ranging from 100-0 µM.  
Concentration of 
compound 1-39 (µM) Substrate (%) Intermediate (%) Product (%) 
0 94.6 1.7 3.7 
0.05 94.9 2.0 3.2 
0.5 95.8 1.7 2.5 
1 96.1 1.5 2.4 
5 97.7 0.8 1.5 
10 98.7 0.4 0.9 
20 99.4 0.1 0.5 
100 99.9 0 0.1 
 
 
Although there is no study related to PAM inhibition for the fumaric acid 5-3, 150-0 
µM at 2X serial dilution was used based on analogy to compound 1-39 because they 
are structurally similar. The data in Table 5.7 illustrate the increasing percentage of 
substrate and the deceasing percentage of intermediate and product with increasing 
concentrations of the fumaric acid 5-3, indicating that it has PHM inhibition. The 
decrease of the intermediate is greater than that of the product, showing that PHM 
inhibition is greater than PAL inhibition. The IC50 value for PHM inhibition was 
determined as 139 ± 23 µM, and the IC50 value for PAL inhibition is greater.  
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Table 5.7 Ratios of substrate, intermediate, and product in assays using (R)-Tyr-(S)-
Val-Gly-COOH with concentrations of the fumaric acid 5-3 ranging from 150-0 µM.  
Concentration of the 
fumaric acid 5-3 (µM) Substrate (%) Intermediate (%) Product (%) 
0 92.4 4.8 2.8 
1.9 92.4 4.6 3.0 
19 94.7 2.9 2.4 
38 96.7 1.6 1.7 
75 98.6 0.7 0.7 
150 100 0 0 
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Table 5.8 Summary of the assessment of PHM and PAL inhibition with selected 
compounds.  
Compound 
No. Compound Structure PHM Inhibition IC50 PAL Inhibition IC50 
1-143  14 ± 3 µM 0.09 ± 0.02 µM 
5-1  >> 400 µM >> 400 µM 
5-2  >> 400 µM >> 400 µM 
1-57  139 ± 23 µM > 139 µM 
1-39  3 ± 1 µM < 3 µM 
5-3  32 ± 1 µM    > 32 µM 
1-17  14 ± 5 µM  
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The PHM and PAL inhibition potencies are summarised in Table 5.8. Compound 1-
143 shows PAL inhibition at the nanomolar level and its pyruvate moiety must play 
an important role in this since compound 5-1 lacking the pyruvate moiety shows no 
PHM or PAL inhibition up to 400 µM. As discussed in Section 5.2, keto-enol 
tautomerism is likely for compound 1-143. Compound 1-143 is expected to be mainly 
the enol forms based on the study by Burdett et al.[212] that tautomeric equilibria for β-
diketones favours the enol tautomers. Intramolecular hydrogen bonding between a 
hydroxyl group and a carbonyl group stabilizes the enol forms, as shown in Scheme 
5.7. It is more likely that the enol forms of compound 1-143 instead of the keto form 
are responsible for PAL inhibition because the keto form of compound 1-143 is even 
less like α-hydroxyglycine PAM intermediates. Its enol forms have similar geometry 
(red parts in Scheme 5.7) to both the hydroxylated intermediate and the corresponding 
transition state in the PAL catalysed reaction as shown in Scheme 5.8. 
 
 
Scheme 5.7 Keto-enol tautomerism of N-Ac-(S)-Phe-Gly-COOH (1-143) in solution.  
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Scheme 5.8 PAL catalysis pathway.  
 
The glycolate 1-57 shows only PHM inhibition with an IC50 value of 139 ± 23 µM. 
No PAL inhibition is observed probably because compound 1-57 more closely 
resembles PHM substrates than PAL substrates. The α,β-unsaturated acids 1-39 and 
5-3 both show PHM inhibition at the micromolar level. This is consistent with the 
study by May et al.[131] of the Ki value for competitive PHM inhibition by compound 
1-39 of 54 µM. Their molecular docking studies illustrate that compound 1-39 docks 
and binds to the active site of PHM in a similar manner to the corresponding PAM 
substrate N-Ac-(S)-Phe-Gly-COOH.  
 
5.4 pH-Dependent PAM Inhibition Assays with N-Ac-Phe-Pyruvate 
 
Having confirmed that the diketone 1-143 is a PAL inhibitor and that the more active 
form is likely to be the enol rather than the ketone, this was further investigated by 
monitoring the effect of pH on PAL inhibition. The pH-dependent PAM inhibition 
competitive assay was conducted using (R)-Tyr-(S)-Val-Gly-COOH with various 
concentrations of compound 1-143 across the effective pH range (5.5 - 6.7) of MES 
buffer.[198] The concentrations used were from 0.4 to 0 µM at 2X serial dilution. 
Tables 5.9 – 5.12 show the ratios of substrate, intermediate, and product in PAM 
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inhibition assays at pH 5.5, 6.1, 6.4 and 6.7. The data for pH 5.8 have been shown 
above in Table 5.1.  
 
Table 5.9 Ratios of substrate, intermediate, and product in PAM assays at pH 5.5, 
using (R)-Tyr-(S)-Val-Gly-COOH with concentrations of N-Ac-(S)-Phe-Gly-COOH 
(1-143) ranging from 0-0.4 µM.  
Concentration of 
N-Ac-(S)-Phe-
Gly-COOH (1-
143) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 93.4 4.1 2.5 
0.012 93.2 4.4 2.4 
0.025 93.0 4.8 2.2 
0.05 93.2 5.1 1.7 
0.1 93.3 5.5 1.2 
0.2 93.5 5.6 0.9 
0.4 94.5 5.1 0.4 
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Table 5.10 Ratios of substrate, intermediate, and product in PAM assays at pH 6.1, 
using (R)-Tyr-(S)-Val-Gly-COOH with concentrations of N-Ac-(S)-Phe-Gly-COOH 
(1-143) ranging from 0-0.4 µM.  
Concentration of N-
Ac-(S)-Phe-Gly-
COOH (1-143) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 88.5 6.9 4.6 
0.012 89.3 6.7 4.0 
0.025 89.5 6.6 3.9 
0.05 89.9 7.1 3.0 
0.1 88.8 8.7 2.5 
0.2 88.9 9.5 1.6 
0.4 88.6 10.1 1.3 
 
Table 5.11 Ratios of substrate, intermediate, and product in PAM assays at pH 6.4, 
using (R)-Tyr-(S)-Val-Gly-COOH with concentrations of N-Ac-(S)-Phe-Gly-COOH 
(1-143) ranging from 0-0.4 µM.  
Concentration of N-
Ac-(S)-Phe-Gly-
COOH (1-143) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 85.7 8.5 5.8 
0.012 88.0 7.6 4.4 
0.025 87.5 8.4 4.1 
0.05 88.5 8.0 3.5 
0.1 87.6 9.4 3.0 
0.2 88.1 9.8 2.1 
0.4 86.9 11.7 1.4 
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Table 5.12 Ratios of substrate, intermediate, and product in PAM assays at pH 6.7, 
using (R)-Tyr-(S)-Val-Gly-COOH with concentrations of N-Ac-(S)-Phe-Gly-COOH 
(1-143) ranging from 0-0.4 µM.  
Concentration of N-
Ac-(S)-Phe-Gly-
COOH (1-143) (µM) 
Substrate (%) Intermediate (%) Product (%) 
0 88.6 6.0 5.4 
0.012 87.3 8.1 4.6 
0.025 87.5 8.0 4.5 
0.05 86.4 9.6 4.0 
0.1 86.9 9.6 3.5 
0.2 87.2 10.2 2.6 
0.4 87.7 10.7 1.6 
 
Table 5.1 and Tables 5.9 – 5.12 show that, in each data set, an increasing percentage 
of hydroxylated intermediate and a decreasing percentage of amidated product are 
seen with increasing concentrations of compound 1-143 from 0 to 0.4 µM. The 
activity-concentration curves were generated, as described in Section 5.3, by plotting 
the hydroxylated intermediate turnover and compound 1-143 concentration. The 
corresponding IC50 values for PAL inhibition at each pH were determined through 
analysis of the corresponding activity-concentration curves and are shown in Figure 
5.4. It was impractical to prepare and analyse all the assay samples on the same day. 
Therefore, compound 1-143-concentration-dependent PAM inhibition assays at 
different pH values were performed on different days. Since the enzyme activity 
decreases with the passage of time, it is not meaningful to compare the substrate and 
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intermediate turnovers at different pH values, but this does not affect the relative IC50 
values. 
 
 
Figure 5.4 The IC50 values for PAL inhibition of N-Ac-Phe-pyruvate (1-143) against 
the medium PAM from DMS53 cells at the pH ranging from 5.5 to 6.7. 
 
Figure 5.4 shows that the IC50 value increases by around two times on increasing the 
pH from 5.5 to 6.7, indicating that compound 1-143 shows decreasing PAL inhibition. 
This can be attributed to the increase in pH decreasing the amount of enol and 
increasing the amount of the corresponding enolate, A study by Bunting et al.[213] 
showed that the acidities of the enols (pKa) of β-diketones range from three to eight 
depending on the substituents. The corresponding pKa of compound 1-143, though 
unknown, is therefore expected to be in this range. On the basis of this, when the pH 
increases from 5.5 to 6.7, which is around the estimated pKa value, more deprotonation 
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of the enol form of compound 1-143 is expected. Presumably this binds less readily to 
PAL. 
 
5.5 Conclusion 
 
To summarise, the established HPLC-MS system enables simultaneous evaluation of 
PHM and PAL inhibition by molecules, which significantly facilitates structure-
activity relationship studies and the development of PAM inhibitors for 
pharmaceutical and medical applications. In the present study, N-Ac-Phe-pyruvate (1-
143) was confirmed to be a PAL inhibitor at the nanomolar level against the medium 
PAM from DMS53 cells. The PAM inhibition assay with compound 1-143 also 
confirms that PAL activity dominates the conversion of hydroxylated intermediates to 
amidated products within two hours. The pH-dependent PAM inhibition assay implies 
that the deprotonation of the enol form of compound 1-143 results in a decrease of 
PAL inhibition by compound 1-143. 
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Chapter Six 
 
Detection of an α-Hydroxyglycine-extended Peptide Hormone 
Produced by Human Small Cell Lung Cancer Cells 
 
6.1 Introduction 
 
To date, the role of α-hydroxyglycine-extended peptide hormones in humans is not 
well understood. To investigate this requires the detection and quantification of α-
hydroxyglycine-extended peptide hormones. So far, Eipper and her colleagues[214] are 
the only research group that has ever detected an α-hydroxyglycine peptide in a 
biological sample, wherein hydroxyglycine-extended joining peptide from mouse 
pituitary was measured. They reported that the level of hydroxylated joining peptide 
(HO-JPG) is around 70-fold lower than that of the corresponding precursor (JPG), 
which suggested that PAL catalysis is much faster than PHM catalysis in animals. In 
this Chapter, human α-hydroxyglycine-extended calcitonin (HO-CTG) was chosen as 
a candidate for detection. Its corresponding amidated product, calcitonin (CT) is a 
typical human amidated polypeptide hormone and mainly functions to reduce blood 
calcium (Ca2+).[215] In terms of medical science, CT is usually used for the treatment 
of osteoporosis or hypercalcemia.[216] Increased concentration of CT is closely 
associated with many human cancers such as lung cancer, breast cancer, and 
pancreatic cancer.[217-219] It is also used as an important clinical marker for monitoring 
medullary thyroid carcinoma.[220] Due to the biological and medical importance of CT, 
understanding the relationship between the precursor glycine-extended calcitonin 
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(CTG), intermediate α-hydroxyglycine-extended calcitonin (HO-CTG) and product 
CT is of considerable interest (Scheme 6.1).  
 
 
Scheme 6.1 Proposed PAM activity with CTG. 
 
In the present study, the cancer cell line selected was DMS53 due to its unusually high 
expression of CT (43 ng/mL).[145] Previously, CT and its glycine-extended precursor 
CTG secreted from the DMS53 cells were successfully identified by the Easton 
Group[221] via HPLC with a fluorescence detector. After incubation of DMS53 cells, 
they analysed the culture medium and found that two peaks matched those of 
commercial authentic CT and CTG standards on the HPLC trace. These two peaks 
were then identified as CT and CTG through collection and ESI-MS analysis. 
However, the intermediate HO-CTG had not been investigated. 
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Given the expected low level and chemical instability of hydroxylated 
intermediates,[196] PAL inhibition was considered as a possible strategy to cause the 
accumulation of HO-CTG in order to facilitate its detection and quantification. The 
work described in the previous Chapter demonstrated that N-Ac-Phe-pyruvate (1-143) 
is an effective PAL inhibitor with nanomolar potency against the medium PAM from 
the DMS53 cell line. Therefore, compound 1-143 was chosen in the present work to 
help the detection of HO-CTG. Further, to develop the analytical method, an authentic 
sample of HO-CTG was prepared through using isolated PAM and CTG, through 
HPLC and analysis by MS. 
 
The work in this Chapter has been published in Analytical Chemistry, and is copied 
on the following pages. My contribution to this multiauthored paper involved the 
preparation of an authentic sample of HO-CTG and the detection of HO-CTG 
produced by DMS53 cells. My work showed that concentrated medium from DMS53 
cells injected onto HPLC provided a sample that was positively identified by HPLC-
MS. However, with or without the PAL inhibitor 1-143 (up to 2 mM), analysis of the 
medium samples showed that the concentration of HO-CTG was below the 
fluorescence  detection limit (< 0.1 ng/mL), indicating that the concentration of HO-
CTG is more than two orders of magnitude lower than those of the CTG and CT. This 
means PAL catalysis is much faster than PHM catalysis, and PHM catalysis is the rate-
limiting step of amidation of calcitonin in human. The following pages are the copied 
paper and the contents highlighted with yellow are my work. 
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Chapter Seven 
 
Conclusions and Future Directions 
 
PAM is considered to be a key enzyme for regulation of amidated peptide hormones 
because more than a half of human peptide hormones are amidated peptide hormones, 
which are produced only through PAM catalysis. The consensus sequence study shows 
that C-terminal glycine-extended prohormone having penultimate Phe are expected to 
have strong binding affinity with PAM. It also shows amino acids at the 
antepenultimate position from the C-terminus has much smaller effect than those at 
the penultimate position on binding with PAM. The assay of Bex-glycine (3-4) 
illustrates that compound 3-4 is a poor PAM substrate but itself has good activity 
against DMS53 cells, similar to the parent agent 3-1, indicating compound 3-4 has 
potential in cancer therapy but not through the dual activity anticipated.  
 
A new bifunctional PAM assay with HPLC-MS system was developed, which enables 
simultaneous investigation of PHM and PAL activity. With this new assay, it was 
demonstrated that compound 1-143 has strong PAL inhibition and relatively low PHM 
inhibition. The results of structure-activity study show that the pyruvate moiety in 
compound 1-143 is responsible for PAL inhibition. The pH-dependent PAM inhibition 
assay with compound 1-143 implies that deprotonation of the enol form of compound 
1-143 results in a decrease of PAL inhibition by compound 1-143. The PAM inhibition 
assay with compound 1-143 also confirms that PAL activity dominates the conversion 
of hydroxylated intermediates to amidated products within two hours. The subsequent 
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stability study of compound 1-143 illustrated that compound 1-143 decomposes to 
compound 5-1 almost completely in aqueous solution over two days. This may inform 
the design of more stable PAL inhibitors in the future. 
 
The results that the intermediate HO-CTG in the culture medium of DMS53 cells is 
below the detection limit of fluorescence detector and over one hundred times lower 
than CTG and CT, suggests PAL catalysis is much better than PHM catalysis in human 
cells. Under these circumstances, the accumulation of CTG demonstrates that catalytic 
turnover by PHM limits the production of CT. In other words, PHM activity is the 
rate-limiting step of PAM activity. In future, the focus should be the cofactors of PHM 
activity such as ascorbate. Preliminary results in Appendix shows that ascorbate levels 
play a role in PHM activity through the isolated PAM competitive assay, and that SIN-
1 is likely to inactivate PHM activity through inhibiting semidehydroascorbate 
reductase (SDR) that is responsible for reducing semidehydroascorbate back to 
ascorbate during ascorbate recycling. 
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Chapter Eight 
Experimental 
8.1 General 
 
Melting points measuring method was established using a Stanford Research Systems 
MPA 100 OptiMelt automated melting point system with digital image processing 
technology operated with Meltview software.  
 
NMR spectra were recorded on Varian Mercury 300 (300 MHz for 1H and 75 MHz 
for 13C), Bruker AscendTM 400 (400 MHz for 1H and 100 MHz for 13C), and Bruker 
Avance 700 (700 MHz for 1H and 150 MHz for 13C) spectrometers. The NMR solvent 
Chloroform-D (99.8% D) and DMSO-D6 (99.9% D) were purchased from Cambridge 
Isotope Laboratories Inc, and D2O (99.8% D) and CD3OD (99.8%) were purchased 
from Sigma-Aldrich Co. 
 
The HPLC-MS method about isolated PAM assay was conducted on Waters Alliance 
2690 liquid chromatography (plus flow splitter) and Waters ACQUITY TQ mass 
detector. ESI mass spectra were recorded using a Micromass LC-ZMD single 
quadrupole liquid chromatograph mass spectromer for low resolution (LR).  
 
The DMS53 cell line were grown in GIBCO® RPMI-1640 medium supplemented with 
10% fetal bovine serum obtained from Invitrogen. The tripeptide substrate (R)-Tyr-
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(S)-Val-Gly-COOH used in isolated enzyme assays was obtained from Bachem AG. 
Fmoc-Gly-OH, Fmoc-(S)-Arg(Pbf)-OH, Fmoc-(S)-Phe-OH, Fmoc-(S)-Gln(Trt)-OH, 
Fmoc-(S)-Asp(OtBu)-OH, Fmoc-(S)-His(Bom)-OH, BOP and sodium were 
purchased from Merck Pty. Ltd. Bexarotene were purchased from Atomole Scientifica 
Co. Ltd. HBTU, Fmoc-(S)-Pro-OH, Fmoc-Ala-OH and BOP were purchased from 
Auspep Pty Ltd. NaOH, NaHCO3, NaCl, K2CO3, NH4Cl, Et3N, CuSO4 and ammonium 
acetate were purchased from Ajax Finechem Pty Ltd. Na2S2O5 were purchased from 
May & Baker Ltd. Ethyl glyoxalate solution (50% w/w in toluene) were purchased 
from Thermo Fisher Scientific Inc. HOBt, DMAP, DIC, DMAP, DIPEA, TIPS, 
TFA, NMO, TEMPO, EDC, PBA, Pd/C, Wang resins, piperidinethionyl chloride, 
diethyl oxalate, n-Butyl-lithium, lithium hydroxide monohydrate, NaClO2, NaClO, 
OsO4, MgSO4, NaBH3CN, Ac2O, (S)-Phe, NMM, N-Acetyl-(S)-Histidine, tert-butyl 
glycine hydrochloride, 4-Bromo-1-butene, tert-butyl bromoacetate, phenylacetic acid, 
N, O-Dimethylhydroxylamine hydrochloride, molecular sieves 3Å, dimethyl 
methylphosphonate, esterase from porcine liver, fumaric acid, benzyl alcohol, SIN-1, 
ascorbate, bovine liver catalase and fluorescamine were purchased from Sigma 
Aldrich Chemical Co. Glycyl-extended calcitonin and calcitonin were purchased from 
GL Biochem (Shanghai) Ltd. Unless otherwise noted, all reagents were obtained from 
commercial suppliers and used without further purification.  
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8.2 Experimental for Chapter 2: Study of Sequence Recognition by PAM 
 
8.2.1 Synthesis Work Described in Chapter 2 
 
Fmoc-Gly-Wang resin (2-1) 
 
          2-1 
Commercial dry Wang resin (339 mg, 0.40 mmol) was placed in a manual reaction 
vessel with DCM (4.5 mL) and DMF (0.5 mL) for 2 h. The organic solvent was then 
removed by filtration and the swollen Wang resin was treated with DMF (3 mL) 
containing Fmoc-Gly-COOH (297 mg, 1.00 mmol, 2.5 eq), DIC (160 µL, 1.00 mmol, 
2.5 eq), HOBt (135 mg, 1.00 mmol, 2.5 eq), and DMAP (5 mg, 0.04 mmol, 0.04 eq). 
The mixture was agitated gently with a nitrogen flow for 2 h. The solvent was then 
removed by filtration and the resin was washed with DMF (3 × 5 mL), MeOH (3 × 5 
mL) and dried in vacuo. A sample of the resin (10 mg) was used for testing the loading 
efficiency of Fmoc-Gly through Fmoc determination. It was added to piperidine in 
DMF (50 µL, 20%, v/v) to conduct Fmoc deprotection, followed by dilution with DMF 
(4.95 mL). The solution was analysed by UV-Vis spectroscopy at 278 nm against a 
blank sample that contained piperidine in DMF (50 µL, 20%, v/v) with DMF (4.95 
mL). The loading efficiency of Fmoc-Gly to the resin of 65% was calculated based on 
literature.[158] The loaded Fmoc-Gly-Wang resin 2-1 was again treated with DCM (4.5 
mL) and DMF (0.5 mL) for 2 h, then DMF (3 mL), Ac2O (80 µL, 0.80 mmol, 2.0 eq), 
and pyridine (70 µL, 0.80 mmol, 2.0 eq) were added. The mixture was agitated with a 
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nitrogen flow for 30 min. The solution was then filtered off and the resin was washed 
with DMF (3 × 5 mL). 
 
N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-14)  
 
                     2-14 
To Fmoc-Gly-Wang resin 2-1 was added piperidine in DMF (3.4 mL, 20%, v/v) and 
the mixture was agitated with a nitrogen flow at room temperature for 1 h to produce 
compound 2-2. The solvent was then filtered off and the resin was washed with DMF 
(3 × 5 mL). The glycine-substituted resin 2-2 was elongated to peptide 2-12 with the 
following protected amino acids: Fmoc-(S)-Phe-COOH, Fmoc-(S)-Arg(Pbf)-COOH, 
Fmoc-(S)-Gln(Trt)-COOH, Fmoc-(S)-Pro-COOH, and Fmoc-Gly-COOH. Each 
amino acid was used in 2-fold excess and was coupled in the presence of HOBt (108 
mg, 0.80 mmol, 2.00 eq), HBTU (303 mg, 0.80 mmol, 2.00 eq), and DIPEA (280 µL, 
1.60 mmol, 4.00 eq) in DMF (3.0 mL). Each coupling reaction mixture was agitated 
with a nitrogen flow at room temperature for 2 h, filtered in order to remove excess 
reagents, and then washed with DMF (3 × 5 mL). Fmoc deprotection was achieved by 
addition of piperidine in DMF (3.4 mL, 20%, v/v), agitation with a nitrogen flow at 
room temperature for 1 h, and washing with DMF (3 × 5 mL). After all the desired 
coupling and Fmoc deprotection reactions, to the crude compound 2-12 was added a 
mixture of excess Ac2O (500 µL), pyridine (500 µL), and DMF (5 mL), and the 
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mixture was agitated with a nitrogen flow at room temperature for 30 min to give 
acetylated peptide on the Wang resin 2-13. After filtration, the resin 2-13 was added 
to a mixture of TFA (3.2 mL), TIPS (0.1 mL) and H2O (0.1 mL) and then agitated at 
room temperature for 2 h. The mixture was filtered and the filtrate was transferred into 
cold Et2O (80 mL) in two Falcon tubes and placed in a -20 ºC freezer overnight. The 
tubes were then centrifuged at 5000 g, the supernatant was removed, and a sample 
(approx. 3 mg) of the product precipitate was dissolved in 10% aqueous MeOH 
solution (50 µL) and analysed by HPLC using an Alltima C18 5μ (22 × 250 mm) 
column, at a flow rate of 8 mL/min with a UV-Vis spectroscopy at 210 nm. The 
analysis was carried out with a linear gradient elution of 40:60 (MeOH: H2O (0.1% 
TFA), v/v) to 50:50 between 0-20 min, followed by a gradient elution of 50:50 to 95:5 
between 20-31 min and a gradient elution of 95:5 to 40:60 between 31-36 min. Finally, 
the solvent system was maintained at 40:60 for 4 min more. The resulting HPLC is 
reproduced in Figure 8.1, and showed two dominant peaks at 29.50 and 31.90 min. 
Samples corresponding to each of these two peaks were isolated through HPLC. Mass 
spectrometry of the peak at 29.50 min displayed ions at m/z 703.7, which corresponds 
to the [M+H]+ for hexapeptide 2-14; the peak at 31.90 min displayed ions at m/z 646.7, 
which is 57 less than that of the former peak, the difference being equal to the mass of 
a glycine residue. Based on this analysis, preparative HPLC was used to isolate 
compound 2-14. The column fractions were concentrated via freeze drying to give 
compound 2-14 (10 mg, 3.6%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ7.35 (m, 5H), 4.73 (dd, J = 9.6, 5.7 Hz, 1H). 4.43 (dd, J 
= 8.6, 5.0 Hz, 1H), 4.26 (m, 2H), 4.09 (s, 2H), 3.96 (d, J = 17.9 Hz, 1H), 3.92 (d, J = 
17.9 Hz, 1H), 3.65 (m, 2H), 3.23 (dd, J = 14.0, 5.7 Hz, 1H), 3.13 (t, J = 6.9 Hz, 2H), 
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3.00 (dd, J = 14.0, 9.6 Hz, 1H), 2.30 (m, 3H), 2.06 (m, 8H), 1.67 (m, 2H), 1.47 (m, 
2H); MS (ESI) (+ve): m/z 703.7 [M+H]+. HRMS (ESI) calcd. for C31H47N10O9 
[M+H]+ m/z 703.3527, found m/z 703.3528 (Figure 8.2). 
 
 
Figure 8.1 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-
Phe-Gly-COOH (2-14). 
 
2-14 
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Figure 8.2 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-
Phe-Gly-COOH (2-14). 
 
Figure 8.3 1H NMR of spectrum of compound 2-14. 
 
δ  
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N-Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-15) 
 
                  2-15 
 
Peptide 2-15 was synthesised using the same quantities and techniques described for 
compound 2-14. After the elongation from compounds 2-1 to 2-10 with Fmoc-(S)-
Phe-COOH, Fmoc-(S)-Arg(Pbf)-COOH, Fmoc-(S)-Gln(Trt)-COOH, and Fmoc-(S)-
Pro-COOH, compound 2-10 was acetylated, acidified, and precipitated in cold Et2O 
in exactly the same manner as described for compound 2-12. The analysis of a small 
amount of product precipitate was then carried out with a linear gradient elution of 
30:70 (MeOH: H2O (0.1% TFA), v/v) to 40:60 between 0-20 min. The resulting HPLC 
chromatogram is reproduced in Figure 8.4 and showed several dominant peaks. 
Samples corresponding to each of these were isolated through HPLC. Mass 
spectrometry of the peak at 11.40 min displayed ions at m/z 646.8, which corresponds 
to the [M+H]+ for pentapeptide 2-15; the peak at 12.70 min displayed ions at m/z 589.7, 
which is 57 less than that of the former peak, the difference being equal to the mass of 
a glycine residue. Based on this analysis, preparative HPLC was used to isolate 
compound 2-15. The column fractions were concentrated via freeze drying to give 
compound 2-15 (8 mg, 3.2%) as a colourless powder.  
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1H NMR (400 MHz, D2O): δ7.33 (m, 5H), 4.73 (dd, J = 9.4, 5.9 Hz, 1H), 4.38 (dd, J 
= 8.7, 4.9 Hz, 1H), 4.27 (m, 2H), 4.00 (d, J = 17.9 Hz, 1H), 3.96 (d, J = 17.9 Hz, 1H), 
3.65 (m, 2H), 3.23 (dd, J = 14.0, 5.9 Hz, 1H), 3.14 (t, J = 7.0 Hz, 2H), 3.00 (dd, J = 
14.0, 9.4 Hz 1H), 2.32 (m, 3H), 2.13 (s, 3H), 1.96 (m, 5H) 1.67 (m, 2H), 1.47 (m, 2H); 
MS (ESI) (+ve): m/z 646.8 [M+H]+. HRMS (ESI) calcd. for C29H44N9O8 [M+H]+ m/z 
646.3313, found m/z 646.3314 (Figure 8.5). 
 
 
Figure 8.4 HPLC chromatogram of crude N-Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-
Gly-COOH (2-15). 
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Figure 8.5 High resolution MS of isolated N-Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-
Gly-COOH (2-15). 
 
Figure 8.6 1H NMR of spectrum of compound 2-15. 
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N-Ac-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-16) 
 
                      2-16 
 
Peptide 2-16 was synthesised using the same quantities and techniques described for 
compound 2-14. After the elongation from compounds 2-1 to 2-8 with Fmoc-(S)-Phe-
COOH, Fmoc-(S)-Arg(Pbf)-COOH, and Fmoc-(S)-Gln(Trt)-COOH, compound 2-8 
was acetylated, acidified, and precipitated in cold Et2O in exactly the same manner as 
described for compound 2-12. The analysis of a small amount of product precipitate 
was then carried out with a linear gradient elution of 45:55 (MeOH: H2O (0.1% TFA), 
v/v) to 60:40 between 0-15 min, followed by maintenance of 95:5 between 15-20 min. 
The resulting HPLC chromatogram is reproduced in Figure 8.7 and showed several 
dominant peaks. Samples corresponding to each of these were isolated through HPLC. 
Mass spectrometry of the peak at 8.30 min displayed ions at m/z 549.7, which 
corresponds to the [M+H]+ for tetrapeptide 2-16. Based on this analysis, preparative 
HPLC was used to isolate 2-16. The column fractions were concentrated via freeze 
drying to give compound 2-16 (15 mg, 6.7%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ7.35 (m, 5H), 4.70 (dd, J = 9.4, 5.7 Hz, 1H), 4.29 (dd, J 
= 8.2, 6.1 Hz, 1H), 4.22 (dd, J = 8.4, 6.2 Hz, 1H), 3.99 (d, J = 17.9 Hz, 1H), 3.94 (d, 
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J = 17.9 Hz, 1H), 3.23 (dd, J = 13.9, 5.7 Hz, 1H), 3.14 (t, J = 6.9 Hz, 2H), 3.00 (dd, J 
= 13.9, 9.4 Hz, 1H), 2.27 (m, 2H), 2.03 (s, 3H), 1.93 (m, 2H), 1.68 (m, 2H), 1.48 (m, 
2H); MS (ESI) (+ve): m/z 549.7 [M+H]+. HRMS (ESI) calcd. for C24H37N8O7 
[M+H]+ m/z 549.2785, found m/z 549.2785 (Figure 8.8). 
 
 
Figure 8.7 HPLC chromatogram of crude N-Ac-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH 
(2-16). 
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Figure 8.8 High resolution MS of isolated N-Ac-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH 
(2-16). 
 
Figure 8.9 1H NMR of spectrum of compound 2-16. 
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N-Ac-(S)-Arg-(S)-Phe-Gly-COOH (2-17) 
 
                    2-17 
 
Peptide 2-17 was synthesised using the same quantities and techniques described for 
compound 2-14. After the elongation from peptides 2-1 to 2-6 with Fmoc-(S)-Phe-
COOH and Fmoc-(S)-Arg(Pbf)-COOH, compound 2-6 was acetylated, acidified, and 
precipitated in cold Et2O in exactly the same manner as described for compound 2-12. 
The analysis of a small amount of product precipitate was then carried out with a linear 
gradient elution of 5:95 (MeOH: H2O (0.1% TFA), v/v) to 40:60 between 0-50 min, 
followed by maintenance of 5:95 between 50-55 min. The resulting HPLC 
chromatogram is reproduced in Figure 8.10 and showed only one dominant peak at 
47.60 min. Sample corresponding to this peak was isolated through HPLC. Mass 
spectrometry of the peak displayed ions at m/z 421.7, which corresponds to the 
[M+H]+ for tripeptide 2-17. Based on this analysis, the whole precipitate was 
concentrated via freeze drying to give compound 2-17 (15 mg, 9.0 %) as a colourless 
powder.  
 
1H NMR (400 MHz, D2O): δ7.35 (m, 5H), 4.73 (m, 1H), 4.21 (dd, J = 7.9, 6.4 Hz, 
1H), 4.04 (d, J = 17.9 Hz, 1H), 3.99 (d, J = 17.9 Hz, 1H), 3.28 (dd, J = 14.0, 5.7 Hz, 
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1H), 3.14 (td, J = 7.0, 1.8 Hz, 2H), 3.01 (dd, J = 14.0, 9.6 Hz 1H), 2.02 (s, 3H), 1.63 
(m, 2H), 1.45 (m, 2H); MS (ESI) (+ve): m/z 421.1 [M+H]+. HRMS (ESI) calcd. for 
C19H29N6O5 [M+H]+ m/z 421.2199, found m/z 421.2206 (Figure 8.11). 
 
 
Figure 8.10 HPLC chromatogram of crude N-Ac-(S)-Arg-(S)-Phe-Gly-COOH (2-17). 
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Figure 8.11 High resolution MS of isolated N-Ac-(S)-Arg-(S)-Phe-Gly-COOH (2-17). 
 
 
Figure 8.12 1H NMR of spectrum of compound 2-17. 
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N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Asp-(S)-Phe-Gly-COOH (2-18) 
 
                        2-18 
 
Peptide 2-18 was synthesised and precipitated in Et2O in the same manner as described 
for compound 2-14, except that the Fmoc protected amino acid used for the third 
coupling was Fmoc-(S)-Asp(OtBu)-COOH instead of Fmoc-(S)-Arg(Trt)-COOH. The 
analysis of a small amount of product precipitate was carried out with a linear gradient 
elution of 5:95 (MeOH: H2O (0.1% TFA), v/v) to 60:40 between 0-50 min, followed 
by maintenance of 5:95 between 50-65 min. The resulting HPLC chromatogram is 
reproduced in Figure 8.13 and showed two dominant peaks. Samples corresponding 
to each of these were isolated through HPLC. Mass spectrometry of the peak at 48.10 
min displayed ions at m/z 663.4, which corresponds to the [M+H]+ for hexapeptide 2-
18; the peak at 23.20 min displayed ions at m/z 458.6, which is 204 less than that of 
the former peak, the difference being equal to a sum of the mass of glycine and 
phenylalanine residues. Based on this analysis, preparative HPLC was used to isolate 
compound 2-18. The column fractions were concentrated via freeze drying to give 
compound 2-18 (19 mg, 7.2%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ7.36 (m, 5H), 4.71 (m, 1H), 4.40 (dd, J = 8.7, 5.2 Hz, 
1H), 4.27 (dd, J = 9.4, 5.1 Hz, 1H), 4.12 (d, J = 17.6 Hz, 1H), 4.07 (d, J = 17.6 Hz, 
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1H), 3.99 (s, 2H), 3.64 (m, 2H), 3.26 (dd, J = 14.1, 5.7 Hz, 1H), 3.03 (dd, J = 14.1, 9.0 
Hz, 1H), 2.88 (dd, J = 17.0, 6.2 Hz, 1H), 2.75 (dd, J = 17.0, 7.7 Hz, 1H), 2.30 (m, 3H), 
2.05 (m, 8H); MS (ESI) (+ve): m/z 663.4 [M+H]+. HRMS (ESI) calcd. for 
C29H39N7O11Na [M+Na]+ m/z 684.2605, found m/z 684.2601 (Figure 8.14). 
 
 
Figure 8.13 HPLC chromatogram of N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Asp-(S)-Phe-
Gly-COOH (2-18). 
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Figure 8.14 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Asp-(S)-
Phe-Gly-COOH (2-18). 
 
Figure 8.15 1H NMR of spectrum of compound 2-18. 
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N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Ala-(S)-Phe-Gly-COOH (2-19) 
 
                       2-19 
 
Peptide 2-19 (5 mg) was generously given by Dr. Tim Altamore. The purity of this 
peptide was checked with a linear gradient elution of 5:95 (MeOH: H2O (0.1% TFA), 
v/v)) to 60:40 between 0-30 min, followed by maintenance of 5:95 between 30-35 min 
at 210 nm. The peak retention time of compound 2-19 was 32.70 min.  
 
1H NMR (400 MHz, D2O): δ7.33 (m, 5H), 4.68 (dd, J = 8.9, 5.8 Hz, 1H), 4.42 (dd, J 
= 8.6, 5.2 Hz, 1H), 4.27 (m, 2H), 4.10 (s, 2H), 3.90 (d, J = 17.6 Hz, 1H), 3.84 (d, J = 
17.6 Hz, 1H), 3.66 (m, 2H), 3.25 (dd, J = 14.0, 5.8 Hz, 1H), 3.02 (dd, J = 14.0, 8.9 Hz, 
1H), 2.33 (m, 3H), 2.06 (m, 8H), 1.30 (d, J = 7.2 Hz, 3H); MS (ESI) (+ve): m/z 640.6 
[M+Na]+. HRMS (ESI) calcd. for C28H39N7O9Na [M+Na]+ m/z 640.2707, found m/z 
640.2707 (Figure 8.17). 
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Figure 8.16 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Ala-(S)-
Phe-Gly-COOH (2-19). 
 
Figure 8.17 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Ala-(S)-
Phe-Gly-COOH (2-19). 
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Figure 8.18 1H NMR of spectrum of compound 2-19. 
 
N-Ac-Gly-(S)-Pro-(S)-Gln-Gly-(S)-Phe-Gly-COOH (2-20) 
 
                         2-20 
Peptide 2-20 was synthesised and precipitated in cold Et2O in the same manner as 
described for compound 2-14, except that the Fmoc protected amino acid used for the 
third coupling was Fmoc-Gly-COOH instead of Fmoc-(S)-Arg(Trt)-COOH. The 
analysis of a small amount of product precipitate was carried out with a linear gradient 
elution of 5:95 (MeOH: H2O (0.1% TFA), v/v) to 60:40 applied between 0-50 min, 
followed by maintenance of 5:95 between 50-65 min. The resulting HPLC 
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chromatogram is reproduced in Figure 8.19 and showed two dominant peaks. Samples 
corresponding to each of these were isolated through HPLC. Mass spectrometry of the 
peak at 21.70 min displayed ions at m/z 626.7, which corresponds to the [M+Na]+ for 
hexapeptide 2-20; the peak at 20.50 min displayed ions at m/z 422.5, which is 204 less 
than that of the former peak, the difference being equal to a sum of the mass of glycine 
and phenylalanine residues. Based on this analysis, preparative HPLC was used to 
isolate compound 2-20. The column fractions were concentrated via freeze drying to 
give compound 2-20 (20 mg, 8.4%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ7.35 (m, 5H), 4.69 (dd, J = 8.8, 5.9 Hz, 1H), 4.43 (dd, J 
= 8.6, 5.1 Hz, 1H), 4.33 (m, 1H), 4.12 (d, J = 17.2 Hz, 1H), 4.07 (d, J = 17.2 Hz, 1H), 
4.00 (d, J = 17.9 Hz, 1H), 3.95 (d, J = 17.9 Hz, 1H), 3.88 (m, 2H), 3.63 (m, 2H), 3.23 
(dd, J = 14.0, 5.9 Hz, 1H), 3.02 (dd, J = 14.0, 8.8 Hz, 1H), 2.49 (m, 1H), 2.37 (m, 2H), 
2.29 (m, 1H), 2.06 (m, 7H); MS (ESI) (+ve): m/z 626.7 [M+Na]+. HRMS (ESI) calcd. 
for C27H37N7O9Na [M+Na]+ m/z 626.2550, found m/z 626.2559 (Figure 8.20). 
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Figure 8.19 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-Gly-(S)-Phe-
Gly-COOH (2-20). 
 
Figure 8.20 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Gly-(S)-
Phe-Gly-COOH (2-20). 
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Figure 8.21 1H NMR of spectrum of compound 2-20. 
 
N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Pro-Gly-COOH (2-21) 
 
                         2-21 
 
Peptide 2-21 was synthesised and precipitated in cold Et2O in the same manner as 
described for compound 2-14, except that the Fmoc protected amino acid used for the 
second coupling was Fmoc-(S)-Pro-COOH instead of Fmoc-(S)-Phe-COOH. The 
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analysis of a small amount of product precipitate was carried out with a linear gradient 
elution of 5:95 (MeOH: H2O (0.1% TFA), v/v) to 35:65 between 0-32 min, followed 
by maintenance of 5:95 between 32-35 min. The resulting HPLC chromatogram is 
reproduced in Figure 8.22 and showed two dominant peaks. Samples corresponding 
to each of these were isolated through HPLC. Mass spectrometry of the peak at 19.20 
min displayed ions at m/z 653.3, which corresponds to the [M+H]+ for hexapeptide 2-
21; the peak at 13.30  min displayed ions at m/z 499.5, which is 154 less than that of 
the former peak, the difference being equal to a sum of the mass of glycine and proline 
residues. Based on this analysis, preparative HPLC was used to isolate compound 2-
21. The column fractions were concentrated via freeze drying to give compound 2-21 
(7 mg, 2.7%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ4.65 (m, 1H), 4.45 (m, 2H), 4.31 (m, 1H), 4.08 (s, 2H), 
4.05 (d, J = 18.1 Hz, 1H), 3.95 (d, J = 18.1 Hz, 1H), 3.81 (m, 1H), 3.64 (m, 3H), 3.22 
(t, J = 6.9 Hz, 2H), 2.38 (m, 2H), 2.30 (m, 2H), 2.06 (m, 12H), 1.69 (m, 3H); MS (ESI) 
(+ve): m/z 653.6 [M+H]+. HRMS (ESI) calcd. for C27H45N10O9 [M+H]+ m/z 653.3371, 
found m/z 653.3385 (Figure 8.23). 
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Figure 8.22 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-
Pro-Gly-COOH (2-21). 
 
Figure 8.23 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-
Pro-Gly-COOH (2-21). 
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Figure 8.24 1H NMR of spectrum of compound 2-21. 
 
N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-Gly-Gly-COOH (2-22) 
 
                             2-22 
 
Peptide 2-22 was synthesised and precipitated in cold Et2O in the same manner as 
described for compound 2-14, except that the Fmoc protected amino acid used for the 
second coupling was Fmoc-Gly-COOH instead of Fmoc-(S)-Phe-COOH. The analysis 
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of a small amount of product precipitate was carried out with a linear gradient elution 
of 5:95 (MeOH: H2O (0.1% TFA), v/v) to 22:78 between 0-20 min, followed by 
maintenance of 5:95 between 20-28 min. The resulting HPLC chromatogram is 
reproduced in Figure 8.25 and showed only one dominant peak at 25.60 min. Sample 
corresponding to the peak was isolated through HPLC. Mass spectrometry of the peak 
displayed ions at m/z 611.6, which corresponds to the [M-H]- for hexapeptide 2-22. 
Based on this analysis, the whole precipitate, was concentrated via freeze drying to 
give compound 2-22 (15 mg, 6.2%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ4.30 (m, 3H), 4.01 (s, 2H), 3.91 (m, 2H), 3.88 (d, J = 3.4 
Hz, 1H), 3.86 (d, J = 3.4 Hz, 1H), 3.56 (m, 2H), 3.14 (t, J = 6.9 Hz, 2H), 2.31 (m, 2H), 
2.20 (m, 1H), 1.98 (m, 8H), 1.71 (m, 1H), 1.58 (m, 2H); MS (ESI) (-ve): m/z 611.6 
[M-H]-. HRMS (ESI) calcd. for C24H39N10O9 [M-H]- m/z 611.2901, found m/z 
611.2900 (Figure 8.26). 
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Figure 8.25 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-Gly-
Gly-COOH (2-22). 
 
Figure 8.26 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-Gly-
Gly-COOH (2-22). 
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Figure 8.27 1H NMR of spectrum of compound 2-22. 
 
N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Pro-Gly-Gly-COOH (2-23) 
 
                            2-23 
 
Peptide 2-23 was synthesised and precipitated in cold Et2O in the same manner as 
described for 2-22, except that the Fmoc protected amino acid used for the third 
coupling was Fmoc-(S)-Pro-COOH instead of Fmoc-(S)-Arg(Trt)-COOH. The 
analysis of a small amount of product precipitate was carried out with a linear gradient 
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elution of 25:75 (MeOH: H2O (0.1% TFA), v/v) to 38:62 between 0-25 min, followed 
by maintenance of 25:75 between 25-30 min. The resulting HPLC chromatogram is 
reproduced in Figure 8.28 and showed only one dominant peak at 12.60 min. Sample 
corresponding to the peak was isolated through HPLC. Mass spectrometry of the peak 
displayed ions at m/z 576.6, which corresponds to the [M+Na]+ for hexapeptide 2-23. 
Based on this analysis, the whole precipitate was concentrated via freeze drying to 
give compound 2-23 (16 mg, 7.3%) as a colourless powder.  
 
1H NMR (400 MHz, D2O): δ4.48 (dd, J = 9.6, 4.7 Hz, 1H), 4.29 (m, 2H), 3.88 (m, 
6H), 3.65 (m, 1H), 3.53 (m, 1H), 3.47 (t, J = 6.6 Hz, 2H), 2.26 (t, J = 7.2 Hz, 2H), 2.13 
(m, 2H), 1.90 (m, 11H); MS (ESI) (+ve): m/z 576.6 [M+Na]+. HRMS (ESI) calcd. 
for C23H35N7O9Na [M+Na]+ m/z 576.2394, found m/z 576.2394 (Figure 8.29). 
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Figure 8.28 HPLC chromatogram of crude N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Pro-Gly-
Gly-COOH (2-23). 
 
Figure 8.29 High resolution MS of isolated N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Pro-Gly-
Gly-COOH (2-23). 
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Figure 8.30 1H NMR of spectrum of compound 2-23. 
 
8.2.2 Cell Culture Maintenance and PAM Enzyme Preparation  
 
Cell culture was performed using a modified literature procedure.[138] DMS53 cells 
(ATCC® CRL-2062TM) were seeded into fresh Nunc Cell Culture T25 flasks at 37 ºC 
under a moist atmosphere of 5% CO2 /95% air in a Memmert incubator, with RPMI 
medium (3 mL) that was changed every 48 h. Once cells were grown to about 80% density 
(estimated by microscope), they were washed thrice with Dulbecco’s phosphate-buffered 
saline (DPBS) (3 mL for each time), lifted with 0.05% trypsin-EDTA (1 mL) and 
incubation for 10 min. The resulting cell suspensions were then diluted with fresh medium 
(6 mL) and transferred into Nunc Cell Culture T175 flasks, followed by addition of 
more medium (40 mL) for further growth under the same temperature and air 
environment, as mentioned above. The cell medium (50 mL) was changed every 48 h. 
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Once cells were grown close to 90% density, the last batch of growth medium (which 
had been used for growing cells for 48 h) was collected, centrifuged at 5000 g for 20 
min by using a Millipore Amicon® Ultra YM-10 filter, and concentrated 100 times. 
The PAM enzyme concentrate was snap-frozen and stored at -80 °C for use later.  
 
8.2.3 Procedure for Determination of IC50 Values of Peptide Prohormones with 
PAM 
 
Assays were performed with 1.25 mM ascorbic acid, 10 μM copper sulphate, 
0.2 mg/mL bovine liver catalase, 1% EtOH, 1% DMSO, 50 μM tripeptide substrate 
(R)-Tyr-(S)-Val-Gly-COOH and 600-0 μM at 2X serial dilution of peptide 2-17 in 
150 mM MES buffer at pH 5.8. For the concentration selection of other peptides, 
compounds 2-18 and 2-19 were tested with the same concentration range as described 
above; peptides 2-14 - 2-16 and 2-20 were tested with 300-0 μM at 2X serial dilution; 
peptides 2-21 - 2-22 and 2-23 were examined with 2000-0 μM and 6000-0 μM at 2X 
serial dilution, respectively. Assays were initiated through the addition of concentrated 
medium PAM (5 μL) to give a final volume of 100 μL. The mixtures were incubated 
in a Lab Companion Model SI-600R open-air shaker at 37 ºC for 2 h, with agitation at 
80 rpm. At the end of the incubation, the reaction mixture was treated with 1 M NaOH 
(25 μL) and incubated at 37 ºC for 2 min, followed by neutralisation with 1 M HCl 
(25 μL). The solutions were then passed through Amicon® Ultra YM-3 filters using a 
centrifuge for 15 min at 12000 rpm at room temperature, and the filtrates were then 
analysed by using analytical HPLC. The competition assays were run at least in 
duplicate. 
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8.2.4 HPLC Method for Detection and Quantification of (R)-Tyr-(S)-Val-Gly-
COOH and (R)-Tyr-(S)-Val-NH2 in IC50 Assays 
 
HPLC detection of (R)-Tyr-(S)-Val-Gly-COOH and (R)-Tyr-(S)-Val-NH2 used a 
Waters Alliance 2695 separation module and a Waters 600E Pump connected to a two 
position, six port switching valve, a Waters Reagent Manager containing 
fluorescamine (30 mg/100 mL MeCN) and a Waters 2475 Fluorescence Detector. 
Injected sample underwent an online solid phase extraction on a YMC-Pack ODS AQ 
cartridge column S-5 µm (4.0 × 23 mm) with the switching valve open to waste. After 
5 min, flow was diverted to a YMC-Pack ODS-AQ column (4.6 × 150 mm) and a 
Phenosphere 5 µm CN 80Å column (4.6 × 250 mm) for 30 min. To allow fluorescent 
labelling of the N-terminus of substrate and product, a fluorescamine solution (0.33 
mg/mL in MeCN) was mixed with the eluent in a post-column Waters 1000 RXN coil 
at 25 ºC, before detection with a Waters 2475 Fluorescence Detector (λex.= 390 nm, 
λem.= 470 nm). The solvent and gradient system for the analysis is illustrated in Table 
8.1. A 30-minute cleaning routine was applied between each sample injection using 
the solvent and gradient system shown in Table 8.2.  
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Table 8.1 Solvent and gradient system for separation of (R)-Tyr-(S)-Val-Gly-COOH 
and (R)-Tyr-(S)-Val-NH2. 
Time (min) Flow (mL/min) MeCN (%) Buffer A ⃰ (%) 
0 3 0 100 
3 3 10 90 
30 3 10 90 
 
⃰ Buffer A: 100 mL Waters AccQ.Tagä and 1000 mL Water 
 
Table 8.2 Solvent and gradient system used for cleaning routine.  
Time (min) Flow (mL/min) MeCN (%) Buffer A ⃰ (%) 
0 0.5 50 50 
6 0.8 50 50 
16 0.8 50 50 
18 0.8 10 90 
24 0.8 10 90 
25 0.8 0 100 
30 0.8 0 100 
 
 ⃰ Buffer A: 100 mL Waters AccQ.Tagä and 1000 mL Water 
 
Data were collected and processed with Waters Empower 3 software wherein the peak 
areas of (R)-Tyr-(S)-Val-Gly-COOH and (R)-Tyr-(S)-Val-NH2 were determined and 
the proportion of (R)-Tyr-(S)-Val-NH2 was calculated as the percentage substrate 
turnover by PAM. For each peptide candidate 2-14 - 2-23, its concentration was 
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plotted as a function of percentage tripeptide substrate turnover using SciDAVis 0.2.4, 
and used to calculate IC50 values, as shown in Figure 8.31-Figure 8.40. 
 
 
 
 
Figure 8.31 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-
Gly-COOH (2-14) (µM) 
IC50 = 16 ± 3 µM 
R2 > 0.99 
 
IC50 = 20 ± 1µM 
R2 > 0.99 
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Figure 8.32 Determination of IC50 for N-Ac-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Phe-Gly-
COOH (2-15) (µM) 
IC50 = 17 ± 2 µM 
R2 > 0.99 
 
IC50 = 21 ± 5 µM 
R2 > 0.99 
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Figure 8.33 Determination of IC50 for N-Ac-(S)-Gln-(S)-Arg-(S)-Phe-Gly-COOH (2-
16) (µM) 
 
IC50 = 20 ± 2 µM  
R2 > 0.99 
 
IC50 = 17 ± 1 µM 
R2 > 0.99 
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Figure 8.34 Determination of IC50 for N-Ac-(S)-Arg-(S)-Phe-Gly-COOH (2-17) 
(µM) 
 
 
 
 
 
IC50 = 27 ± 1 µM 
R2 > 0.99 
 
IC50 = 26 ± 2 µM 
R2 > 0.99 
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Figure 8.35 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Asp-(S)-Phe-
Gly-COOH (2-18) (µM) 
 
 
 
IC50 = 69 ± 9 µM 
R2 = 0.99 
 
IC50 = 62 ± 8 µM 
R2 = 0.99 
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Figure 8.36 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Ala-(S)-Phe-
Gly-COOH (2-19) (µM) 
 
 
IC50 = 69 ± 10 µM 
R2 > 0.99 
 
IC50 = 71 ± 8 µM 
R2 > 0.99 
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Figure 8.37 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-Gly-(S)-Phe-Gly-
COOH (2-20) (µM) 
 
 
IC50 = 10 ± 1 µM 
R2 > 0.99 
 
IC50 = 12 ± 1 µM 
R2 > 0.99 
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Figure 8.38 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-(S)-Pro-
Gly-COOH (2-21) (µM) 
 
 
 
IC50 > 2000 µM 
IC50 > 2000 µM 
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Figure 8.39 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Arg-Gly-Gly-
COOH (2-22) (µM) 
 
 
IC50 = 1200 ± 200 µM 
R2 = 0.98 
IC50 = 1300 ± 200 µM 
R2 = 0.99 
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Figure 8.40 Determination of IC50 for N-Ac-Gly-(S)-Pro-(S)-Gln-(S)-Pro-Gly-Gly-
COOH (2-23) (µM) 
 
  
IC50 = 1500 ± 260 µM 
R2 = 0.96 
 
IC50 = 1400 ± 160 µM 
R2 = 0.96 
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8.3 Experimental for Chapter 3: Synthesis and Evaluation of Interactions 
of Glycine Derivatives of Medicinal Agents with Peptidylglycine α-
Amidating Monooxygenase 
 
8.3.1 Synthesis Work Described in Chapter 3 
 
tert-Butyl-(4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-
yl)vinyl)benzoyl)-glycinate (3-8) 
 
                3-8 
Bexarotene (250 mg, 0.72 mmol), tert-butyl glycine hydrochloride (130 mg, 
0.76 mmol, 1.06 eq) and BOP reagent (480 mg. 1.08 mmol, 1.50 eq) were combined 
and dissolved in DCM (10 mL). DIPEA (0.30 mL, 1.70 mmol, 2.36 eq) was added 
dropwise and the mixture was stirred for 24 h under nitrogen. The reaction mixture 
was concentrated under reduced pressure and subjected to silica gel flash column 
chromatography (EtOAc/n-hexane, 2:8, v/v). The appropriate fractions were 
combined and concentrated under reduced pressure to yield the compound 3-8 as a 
colourless amorphous solid (300 mg, 91%).  
 
m.p.: 137.8-138.8 ˚C; 1H NMR (300 MHz, CDCl3): δ7.73 (d, J = 8.5 Hz, 2H), 7.34 
(d, J = 8.5 Hz, 2H), 7.12 (s, lH), 7.07 (s, 1H), 6.61 (bt, J = 4.9 Hz, 1H), 5.79 (s, 1H), 
5.30 (s, 1H), 4.13 (d, J = 4.9 Hz, 2H), 1.94 (s, 3H), 1.70 (s, 4H), 1.50 (s, 9H), l.30 (s, 
6H), 1.27 (s, 6H); 13C NMR (75 MHz, CDCl3): δ169.2, 167.0, 149.0, 144.4, 144.3, 
196 
 
142.3, 138.0, 132.7, 132.6, 128.1, 128.0, 127.1, 126.7, 116.4, 82.5, 42.5, 35.2, 34.0, 
33.9, 31.9, 28.1, 19.9; MS (ESI) (+ve): m/z 484.6 [M+Na]+. HRMS (ESI) calcd. for 
C30H39NO3Na [M+Na]+ m/z 484.2828, found m/z 484.2831 (Figure 8.41). 
 
 
Figure 8.41 High resolution MS of compound 3-8. 
197 
 
 
Figure 8.42 1H NMR of spectrum of compound 3-8. 
 
(4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoyl)-
glycine (3-4) 
 
              3-4 
The glycine derivative 3-8 (100 mg, 0.22 mmol) was stirred in TFA (1 mL) for 2 h. 
Concentration under a nitrogen flow yielded the compound 3-4 as a colourless powder 
which was triturated from Et2O to give a colourless solid (80 mg, 91%). A sample 
(approx. 3 mg) of the product precipitate was dissolved in 10% aqueous MeOH 
solution (50 µL) and analysed by HPLC using an Alltima C18 5μ (22 × 250 mm) 
δ  
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column at a flow rate of 8 mL/min with a UV-Vis detector. The analysis was carried 
out with a gradient maintained at 75:25 (MeCN: H2O (0.1% TFA), v/v) for 5 min, 
followed by a linear gradient elution of 75:25 to 88:12 between 5-25 min and 
maintained at 75:25 for 5 min at 210 nm. The resulting HPLC chromatogram is 
reproduced in Figure 8.43, and showed that the resulting residue was pure, and the 
only dominant peak was at 22.30 min.  
 
m.p.: 164.1-167.0 ˚C; 1H NMR (300 MHz, CDCl3): δ7.73 (d, J = 8.2 Hz, 2H), 7.35 
(d, J = 8.2 Hz 2H), 7.11 (s, lH), 7.07 (s, 1H), 6.70 (bs, 1H), 5.79 (s, 1H), 5.31 (s, 1H), 
4.27 (bs, 2H), 1.93 (s, 3H), 1.70 (s, 4H), 1.30 (s, 6H), l.27 (s, 6H), 1.27 (s, 6H); 13C 
NMR (75 MHz, CDCl3): δ173.0, 168.1, 149.1, 145.1, 142.5, 138.1, 132.8, 132.0, 
128.2, 127.4, 116.8, 35.3, 34.2, 34.0, 32.1, 20.1; MS (ESI) (-ve): m/z 404.5 [M-H]-. 
HRMS (ESI) calcd. for C26H30NO3 [M-H]- m/z 404.2226, found m/z 404.2225 
(Figure 8.44).  
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Figure 8.43 HPLC chromatogram of compound 3-4. 
 
 
Figure 8.44 High resolution MS of compound 3-4. 
3-4 
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Figure 8.45 1H NMR of spectrum of compound 3-4. 
 
N-Ac-(S)-His(Bom)-Gly-COOH (3-6) 
 
             3-6 
To crude compound 2-2 (which was prepared in the exactly the same manner as 
described in Section 8.2.1) was added to Fmoc-(S)-His(Bom)-COOH (498 mg, 0.80 
mmol, 2.00 eq), HOBt (108 mg, 0.80 mmol, 2.00 eq), HBTU (303 mg, 0.80 mmol, 
2.00 eq), and DIPEA (280 µL, 1.60 mmol, 4.00 eq) in DMF (3.0 mL). The reaction 
mixture was agitated with a nitrogen flow at room temperature for 2 h, filtered in order 
to remove excess reagents, and then washed with DMF (3 × 5 mL). Fmoc deprotection 
δ  
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was then achieved by addition of piperidine in DMF (3.4 mL, 20%, v/v), agitation 
with a nitrogen flow at room temperature for 1 h, and washing with DMF (3 × 5 mL) 
to produce crude 3-10. To compound 3-10 was added a mixture of excess Ac2O (500 
µL), piperidine (500 µL), and DMF (5 mL) and the mixture was then agitated with a 
nitrogen flow at room temperature for 30 min. After filtration, to the residue was added 
a mixture of TFA (3.2 mL), TIPS (0.1 mL) and H2O (0.1 mL) and this was agitated 
manually at room temperature for 2 h. The reaction mixture was filtered and the 
resulting filtrate was transferred into cold Et2O (80 mL) with Falcon tubes placed into 
a -20 ºC freezer standing overnight for precipitation. After removing Et2O by filtration, 
crude N-Ac-(S)-His(Bom)-Gly-COOH (3-11) was obtained as a white solid (130 mg). 
The peptide with the Bom protecting group was hydrogenated using MeOH (10 mL) 
as solvent and Pd/C (5 wt%, 26 mg) as catalyst under a hydrogen atmosphere by using 
a balloon. After the mixture was stirred at room temperature for 4 h, the catalyst was 
removed by filtration, and the solvent was evaporated to produce a white solid (58 
mg). A sample (approx. 3 mg) of the precipitate was dissolved in 10% MeOH aqueous 
solution (50 µL) and subsequently analysed by preparative HPLC using an Alltima 
C18 5μ (22 × 250 mm) column, at a flow rate of 8 mL/min with a UV-Vis detector 
with peak detection at 210 nm. The analysis was carried out with an isocratic elution 
of 5:95 (MeOH: H2O (0.1% TFA), v/v) for 15 min. The resulting HPLC chromatogram 
is reproduced in Figure 8.46 and showed two dominant peaks. Samples corresponding 
to each of these were isolated through HPLC. Mass spectrometry of the peak at 12.30 
min displayed ions at m/z 255.5, which corresponds to the [M+H]+ for dipeptide 3-6; 
the peak at 10.50 min displayed ions at m/z 375.4, which corresponds to the [M+H]+  
for the starting material 3-11. Based on this analysis, preparative HPLC was used to 
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isolate 3-6. The column fractions were concentrated via freeze drying to give 
compound 3-6 (9.9 mg, 37%) as a colourless powder.  
 
m.p.: 159.1-163.0 ˚C; 1H NMR (400 MHz, CDCl3): 8.57 (s, 1H), 7.26 (s, 1H), 4.49 
(dd, J = 8.3, 5.0 Hz, 1H), 3.25 (dd, J = 15.3, 5.0 Hz, 1H), 3.08 (dd, J = 15.3, 8.3 Hz, 
1H), 1.99 (s, 3H); 13C NMR (75 MHz, CDCl3): δ173.3, 173.0, 172.5, 134.9, 131.0, 
118.6, 53.3, 41.8, 28.2, 22.5; MS (ESI) (+ve): m/z 255.5 [M+H]+. HRMS (ESI) calcd. 
for C10H15N4O4 [M+H]+ m/z 255.1093, found m/z 255.1093 (Figure 8.47).  
 
 
Figure 8.46 HPLC chromatogram of crude compound 3-6. 
3-6
 
 (3-10)  
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Figure 8.47 High resolution MS of compound 3-6. 
 
Figure 8.48 1H NMR of spectrum of compound 3-6. 
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N-Ac-(S)-His-NH2 (3-7) 
 
      3-7 
To a solution of N-Ac-(S)-histidine (200 mg, 0.99 mmol) in MeOH (5 mL) was added 
thionyl chloride (0.36 mL, 5.00 mmol, 5.00 eq), and the mixture was stirred at 0 ºC 
for 30 min under nitrogen. Thereafter, the reaction mixture was concentrated and the 
resulting residue was added to water (10 mL), followed by the extraction of EtOAc 
(3 × 10 mL). The combined organic layers were washed with saturated NaHCO3 
(3 × 20 mL), brine (1 × 20 mL), dried MgSO4, and concentrated to give the product 3-
13 as a colourless oil (175 mg, 83%). Thereafter, the ester 3-13 was treated with 
concentrated ammonia solution (40 mL) and stirred for 30 min. The reaction mixture 
was then concentrated under reduced pressure and purified by HPLC. Analysis of 
compound 3-7 was carried out using a Luna 5µ C18 analytical column (4.60 250 
mm) with an isocratic elution of 1:9 (MeOH: H2O (0.1% TFA), v/v) for 15 min at 
210 nm. As shown in Figure 8.49, there was one dominant peak at 10.00 min. Mass 
spectrometry of the peak displayed ions at m/z 197.3, which corresponds to the 
[M+H]+ for compound 3-7. Based on this analysis, preparative HPLC was used to 
isolate compound 3-7. The column fractions were concentrated via freeze drying to 
give compound 3-7 (80 mg, 41%) as a colourless powder.  
 
1H NMR (400 MHz, CDCl3): 8.62 (s, 1H), 7.31 (s, 1H), 4.67 (dd, J = 8.8, 5.6 Hz, 
1H), 3.29 (dd, J = 15.5, 5.6 Hz, 1H), 3.13 (dd, J = 15.5, 8.8 Hz, 1H), 1.99 (s, 3H); 13C 
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NMR (100 MHz, CDCl3): δ174.46, 174.12, 133.4, 128.6, 117.1, 52.3, 26.4, 21.7; MS 
(ESI) (+ve): m/z 197.3 [M+H]+. HRMS (ESI) calcd. for C8H13N4O2 [M+H]+ m/z 
197.1039, found m/z 197.1040 (Figure 8.50). 
 
 
Figure 8.49 HPLC chromatogram of crude compound 3-7. 
 
3-7 
 
 (3-10)  
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Figure 8.50 High resolution MS of compound 3-7. 
 
 
Figure 8.51 1H NMR of spectrum of compound 3-7. 
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8.3.2 Procedure for Determination of IC50 of Prodrug Candidates with PAM 
 
Assays were performed with 1.25 mM ascorbic acid, 10 μM copper sulphate, 
0.2 mg/mL bovine liver catalase, 1% EtOH, 1% DMSO, 50 μM tripeptide substrate 
(R)-Tyr-(S)-Val-Gly-COOH and 600-0 μM at 2X serial dilution of dipeptide 3-6 in 
150 mM MES buffer at pH 5.8. Compound 3-4 was initially tested with 600-0 μM at 
2X dilution, followed by 4800-0 μM at 2X dilution. Assays were initiated through the 
addition of concentrated medium PAM (5 μL) to give a final volume of 100 μL. The 
mixtures were incubated in a Lab Companion Model SI-600R open-air shaker at 37 ºC 
for 2 h, with agitation at 80 rpm. At the end of the incubation, the reaction mixture 
was treated with 1 M NaOH (25 μL) and incubated at 37 ºC for 2 min, followed by 
neutralisation with 1 M HCl (25 μL). The solutions were then passed through 
Amicon® Ultra YM-3 filters using a centrifuge for 15 min at 12000 rpm at room 
temperature, and the filtrates were then analysed by using the same HPLC method as 
described in Section 8.2.4. The competition assays were run at least in duplicate. 
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Figure 8.52 Determination of IC50 for Bex-glycine (3-4). 
 
IC50 = 1100 ± 240 µM 
R2 > 0.99 
 
IC50 = 1400 ± 300 µM 
R2 > 0.99 
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Figure 8.53 Determination of IC50 for N-Ac-Gly-(S)-His-Gly-COOH (3-6) (µM) 
 
 
IC50 = 67 ± 11 µM 
R2 > 0.99 
 
IC50 = 68 ± 11 µM 
R2 > 0.99 
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8.3.3 Procedure for Cytotoxicity Evaluation of Bexarotene (3-1) and Bex-glycine 
(3-4) 
 
Inhibition of growth proliferation was determined using CCK8 assays. At first, 
DMS53 cells were cultured, lifted as described before to give cell suspensions, a small 
amount of which were diluted with fresh medium and 0.4% trypan blue stain for cell 
counting with a BIO-RAD TC20TM automated cell counter. After cell counting, cell 
suspensions (5 × 103 cells mL-1) were made by dilution with fresh medium and 100 μL 
of the suspension was placed in a Nunclon 96-well plate and pre-incubated for 24 h in 
a Memmert incubator at 37 ºC under a moist atmosphere of 5% CO2/95% air. Following 
24 h of incubation, 160-0 μM at 2X serial dilution and 640 μM of bexarotene (3-1) and 
compound 3-4 (10 μL) was treated into the medium in the plate. The plate was 
incubated in the incubator for 72 h, followed by addition of CCK-8 solution (10 μL) 
for each well and further incubation for 4 h. The absorbance of each well was then 
measured using a Microplate reader at 450 nm and the cell viability percentage and 
concentration were plotted and calculated to give LD50 values using SciDAVis 0.2.4. 
 
8.3.4 Procedure for Standard PAM Assay with N-Ac-(S)-His-Gly-COOH (3-6) 
 
The assay was performed with 10 µM CuSO4, 1% DMSO, 1% EtOH, 75 µM N-Ac-
(S)-His-Gly-COOH (3-6), 1.25 mM ascorbic acid, and 0.2 mg/mL bovine liver 
catalase in 150 mM MES buffer at pH 5.8. Assay was initiated through the addition of 
5 µL medium PAM to give a final volume of 100 µL. The mixture was incubated at 
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neutralised with 1 M HCl (25 µL). The resulting solution was passed through 
Amicon® Ultra YM-3 filters using a centrifuge for 15 min at 12000 rpm at room 
temperature. The filtrates were then analysed through a Primesep 100 column (4.6 × 
100 mm) by using analytical HPLC under an isocratic gradient of MeCN and H2O 
(0.1% TFA) (5:95) for 15 min, which was monitored by UV-Vis spectroscopy at 220 
nm.  
  
212 
 
8.4 Experimental for Chapter 4: Investigation of the Subunit Activity of 
Peptidylglycine α-Amidating Monooxygenase 
 
8.4.1 Synthesis Work Described in Chapter 4 
 
N-Ac-(S)-Phe-COOH (4-1) 
 
         4-1 
(S)-Phenylalanine (6.60 g, 39.6 mmol) was suspended in aqueous NaHCO3 solution 
(5% w/v, 100 mL) cooled to 0 ºC. To this solution Ac2O (5.1 mL, 47.5 mmol, 1.20 eq) 
was added dropwise over a period of 1 h. The mixture was stirred at room temperature 
for 2 h followed by acidification to pH 2-3 with concentrated HCl, then it was cooled 
over ice water. The resulting white precipitate was filtered, washed with water, and 
dried to give compound 4-1 (5.50 g, 67%) as a colourless powder.  
 
m.p.: 172 ˚C;[222] 1H NMR (400 MHz, DMSO-d6) 8.17 (m, 1H), 7.32-7.14 (m, 5H), 
4.39 (dd, J = 9.5, 4.9 Hz, 1H), 3.03 (dd, J = 13.8, 4.9 Hz, 1H), 2.82 (dd, J = 13.8, 9.5 
Hz, 1H), 1.77 (s, 3H); MS (ESI) (-ve): m/z 206.1 [M-H]-. HRMS (ESI) calcd. for 
C11H12NO3 [M-H]- m/z 206.0817, found m/z 206.0811 (Figure 8.54).  
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Figure 8.54 High resolution MS of compound 4-1. 
 
Figure 8.55 1H NMR of spectrum of compound 4-1. 
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(S)-N-Acetylphenylalanyl glycine methyl ester (4-2) 
  
           4-2 
To a solution of N-Ac-(S)-Phe-COOH (4-1) (1.00 g, 4.78 mmol) in DCM (60 mL) was 
added BOP (2.18 g, 4.78 mmol, 1.00 eq) and DIPEA (3.36 mL, 19.11 mmol, 4.00 eq). 
The mixture was allowed to stir at room temperature under nitrogen for 30 min before 
the addition of glycine methyl ester hydrochloride (0.67 g, 5.26 mmol, 1.10 eq). 
Stirring of the reaction mixture was allowed to continue at room temperature under 
nitrogen for 16 h before it was diluted with EtOAc (150 mL). The organic layer was 
washed with 1 M HCl (3 x 30 mL), saturated NaHCO3 solution (3 × 30 mL) and brine 
(1 × 40 mL), dried over MgSO4, and concentrated in vacuo to give the title compound 
as a colourless solid (0.92 g, 69%). 
 
1H NMR (400 MHz, CDCl3) δ 7.25 (m, 5H), 6.37 (m, 1H), 6.12 (m, 1H), 4.70 (m, 
1H), 4.01 (dd, J = 18.2, 5.5 Hz, 1H), 3.90 (dd, J = 18.2, 5.2 Hz, 1H), 3.73 (s, 3H), 3.09 
(d, J = 7.2 Hz, 1H), 3.07 (d, J = 7.2 Hz, 2H), 1.98 (s, 3H); MS (ESI) (+ve): m/z 301.1 
[M+Na]+. HRMS (ESI) calcd. for C14H18N2O4Na [M+Na]+ m/z 301.1164, found m/z 
301.1157 (Figure 8.56).  
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Figure 8.56 High resolution MS of compound 4-2. 
 
(S)-N-Acetylphenylalanyl glycine (1-66) 
 
            1-66 
 
To a solution of 4-2 (200 mg, 0.71 mmol) in THF (10 mL) and H2O (10 mL) was 
added LiOH·H2O (121 mg, 2.85 mmol, 4.00 eq), and the mixture was stirred at room 
temperature for 24 h, after which the mixture was extracted with DCM (3 × 20 mL) to 
remove any unreacted 4-2. The mixture was acidified to pH 2 with 1 M HCl, and the 
aqueous layer was extracted with EtOAc (3 × 30 mL). The combined organic fractions 
were washed with brine (1 × 50 mL), dried over MgSO4, and concentrated in vacuo, 
216 
 
followed by purification by preparative HPLC using an Alltima C18 5μ (22 × 250 mm) 
column (6 mL/min). The analysis was carried out with an isocratic elution of 60:40 
(MeOH: H2O (0.1% TFA), v/v) between 0-30 min. The resulting HPLC is reproduced 
in Figure 8.57, and showed two dominant peaks. Sample corresponding to the first 
peak was isolated through HPLC. Mass spectrometry of the peak at 14.50 min 
displayed ions at m/z 263.2, which corresponds to the [M-H]- for compound 1-66. 
Based on this analysis, preparative HPLC was used to isolate 1-66. The column 
fractions were concentrated via freeze drying to give compound 1-66 (80 mg, 43%) as 
a colourless powder. 
 
m.p.: 155.5-159.6 ˚C; 1H NMR (400 MHz, CD3OD): δ 7.29-7.17 (m, 5H), 4.67 (dd, 
J = 9.5, 5.2 Hz, 1H), 3.90 (s, 2H), 3.20 (dd, J = 14.0, 5.2 Hz, 1H), 2.87 (dd, J = 14.0, 
9.5 Hz, 1H), 1.89 (s, 3H); 13C NMR (100 MHz, CD3OD): δ 174.1, 173.2, 172.7, 138.6, 
130.2, 129.4, 127.7, 55.9, 41.8, 38.8, 22.4; MS (ESI) (-ve): m/z 263.2 [M-H]-. HRMS 
(ESI) calcd. for C13H15N2O4 [M-H]- m/z 263.1032, found m/z 263.1032 (Figure 8.58).  
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Figure 8.57 HPLC chromatogram of crude compound 1-66. 
 
Figure 8.58 High resolution MS of compound 1-66. 
 
1-66 
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Figure 8.59 1H NMR of spectrum of compound 1-66. 
 
(S)-2-Acetamido-3-phenylpropanamide (4-3) 
 
          4-3 
 
To a solution of N-acetyl-(S)-Phe-COOH (4-1) (0.20 g, 0.96 mmol) in MeOH (5 mL) 
was added thionyl chloride (0.35 mL, 4.78 mmol). The mixture was stirred at 0 ºC for 
30 min under nitrogen. Thereafter, the reaction mixture was concentrated and the 
resulting residue was poured into water (10 mL) and the solution was extracted with 
EtOAc (3 × 10 mL). The combined organic layers were washed with saturated 
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NaHCO3 solution (3 × 10 mL), brine (3 × 10 mL), dried over MgSO4, and concentrated 
to provide the intermediate as a white solid. Thereafter, the material was treated with 
concentrated ammonia solution (10 mL) and stirred for 30 min. The reaction mixture 
was then concentrated under reduced pressure and purified by preparative HPLC using 
an Alltima C18 5μ (22 × 250 mm) column (6 mL/min). The analysis was carried out 
with a gradient elution of 40:60 (MeOH: H2O (0.1% TFA), v/v) to 65:35 between 0-
25 min, followed by maintenance at 40:60 for 10 min. The resulting HPLC is 
reproduced in Figure 8.60, and showed one dominant peak at 22.80 min. Sample 
corresponding to the main peak was isolated through HPLC. Mass spectrometry of 
this material displayed ions at m/z 229.1, which corresponds to the [M+Na]+ for 
compound 4-3. Based on this analysis, preparative HPLC was used to isolate 
compound 4-3. The column fractions were concentrated via freeze drying to give 
compound 4-3 (150 mg, 76%) as a colourless powder. 
 
m.p.: 177.2-177.6 ˚C; 1H NMR (400 MHz, CDCl3): δ 7.27 (m, 5H), 6.22 (m, 1H), 
5.78 (s, 1H), 5.46 (s, 1H), 4.68 (m, 1H), 3.12 (dd, J = 13.8, 6.2 Hz, 1H), 3.03 (dd, J = 
13.8, 7.9 Hz, 1H), 1.99 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 173.2, 170.3, 136.5, 
129.4, 128.9, 127.3, 54.3, 38.4, 23.3; MS (ESI) (+ve): m/z 229.1 [M+Na]+. HRMS 
(ESI) calcd. for C11H14N2O2Na [M+Na]+ m/z 229.0953, found m/z 229.0953 (Figure 
8.61).  
 
220 
 
 
Figure 8.60 HPLC chromatogram of crude compound 4-3. 
 
 
Figure 8.61 High resolution MS of compound 4-3. 
4-3 
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Figure 8.62 1H NMR of spectrum of compound 4-3. 
 
8.4.2 General Procedure for PAM assay using HPLC-MS 
 
PAM assays were performed through the addition of 1.25 mM ascorbic acid, 10 μM 
copper sulphate, 0.2 mg/mL bovine liver catalase, 1% EtOH, 1% DMSO, 50 μM 
substrate (R)-Tyr-(S)-Val-Gly-COOH or N-Ac-(S)-Phe-Gly-COOH (1-66) in 150 mM 
MES buffer at pH 5.8. Assays were initiated through the addition of concentrated 
medium PAM (5 μL) to give a final volume of 100 μL. The mixtures were incubated 
in a Lab Companion Model SI-600R open-air shaker at 37 ºC for 2 h, with agitation at 
80 rpm. The solutions were then passed through Amicon® Ultra YM-3 filters using a 
centrifuge for 15 min at 12000 rpm at room temperature, and the filtrates (25 µL) were 
then analysed using a Waters Alliance 2695 HPLC with a Waters Atlantis C18 column 
(4.6 × 150 mm) and flow splitter, followed by MS detection with a Waters ACQUITY 
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TQ detector. All the data were collected and processed with MassLynx 4.1 software. 
The solvent and gradient systems for analysis are illustrated in Table 8.3 and Table 
8.4 below. All assays were run at least in duplicate. 
 
Table 8.3 The gradient method for separation of (R)-Tyr-(S)-Val-Gly-COOH, HO-
(R)-Tyr-(S)-Val-Gly-COOH, and (R)-Tyr-(S)-Val-NH2. 
Time (min) Flow (mL/min) 
Waters (0.1% 
Formic acid) (%) MeCN (%) 
0 0.5 95 5 
0.5 0.5 95 5 
7 0.5 75 25 
10 0.5 75 25 
10.5 0.5 95 5 
 
Table 8.4 The gradient method for separation of N-Ac-(S)-Phe-Gly-COOH (1-66), 
OH-N-Ac-(S)-Phe-Gly-COOH, and N-Ac-(S)-Phe-NH2 (4-3). 
Time (min) Flow (mL/min) 
Waters (0.1% 
Formic acid) (%) 
MeCN (0.1% 
Formic acid) (%) 
0 1 97 3 
4 1 85 15 
9 1 80 20 
10.5 1 80 20 
11 1 97 3 
 
8.4.3 Procedure for pH-Dependent PAM Assay 
 
The pH-Dependent PAM Assays using (R)-Tyr-(S)-Val-Gly-COOH or N-Ac-(S)-Phe-
Gly-COOH (1-66) were performed in the same manner as described in Section 8.4.2, 
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except that four more pH conditions of MES buffer were used, which were pH 5.5, 
6.1, 6.4, and 6.7. All assays were run at least in duplicate. 
 
 
8.5 Experimental for Chapter 5: Structure-Activity Relationship Study for 
Peptidyl-α-Hydroxyglycine α-Amidating Lyase Inhibition 
 
8.5.1 Synthesis Work Described in Chapter 5 
 
N-(3-Oxo-1-phenylbutan-2-yl)acetamide (5-1) 
 
         5-1 
To a solution of (S)-Phe (1.00 g, 6.05 mmol) in pyridine (3.3 mL) was added Ac2O 
(5.0 mL, 52.89 mmol, 8.74 eq), and the resulting mixture was heated to 100 ºC for 5 
h under nitrogen. Thereafter, the reaction mixture was cooled to room temperature and 
stirred further. The reaction mixture was then concentrated in vacuo and the residue 
taken up in EtOAc (2 × 20 mL), washed with saturated aqueous NaHCO3 solution 
(3 × 20 mL), dried over MgSO4, filtered and the filtrate concentrated in vacuo. The 
residue was crystallised from Et2O and recrystallised from EtOAc to give long needle-
shape colourless crystals (0.68 g, 55%).  
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m.p.: 90-93 ˚C; 1H NMR (400 MHz, CDCl3): δ7.25 (m, 3H), 7.12 (m, 2H), 6.07 (s, 
1H), 4.89 (dd, J = 6.9, 5.6 Hz, 1H), 3.16 (dd, J = 14.1, 6.9 Hz, 1H), 3.08 (dd, J = 14.1, 
5.6 Hz, 1H), 2.15 (s, 3H), 1.98 (s, 3H); MS (ESI) (+ve): m/z 206.2 [M+H]+. HRMS 
(ESI) calcd. for C12H16NO2 [M+H]+ m/z 206.1181, found m/z 206.1181 (Figure 8.63). 
 
 
Figure 8.63 High resolution MS of compound 5-1. 
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Figure 8.64 1H NMR of spectrum of compound 5-1. 
 
Ethyl 5-acetamido-2,4-dioxo-6-phenylhexanoate (5-4) 
  
            5-4 
Na metal (90 mg, 3.90 mmol) was added to dry EtOH (5 mL) at room temperature 
under nitrogen. After the metal had dissolved, compound 5-1 (400 mg, 1.95 mmol, 
0.50 eq) and diethyloxalate (0.53 mL, 3.90 mmol, 1.00 eq) were added and the reaction 
mixture stirred for 4 h. The mixture was then concentrated in vacuo and water (10 mL) 
was added to the residue. The aqueous layer was extracted with EtOAc (2 × 20 mL) 
and subsequently acidified by addition of concentrated HCl until the pH was below 3. 
δ  
226 
 
The resulting aqueous phase was extracted with DCM (3 × 20 mL) and the organic 
layer was dried over MgSO4 and filtered. The residue was absorbed onto silica and 
purified through a plug of silica eluting with DCM followed by DCM: MeOH (95:5, 
v/v) to give a light yellow oil (520 mg). The ensuing residue was decoloured by 
decolourising carbon (3% w/w) and then subjected to silica gel flash column 
chromatography (EtOAc/n-hexane/MeOH, 1.5:8:0.5, v/v/v) to afford a colourless oil 
(280 mg, 47%). 
 
1H NMR (400 MHz, CDCl3): δ7.27 (m, 3H), 7.09 (m, 2H), 6.40 (s, 1H), 6.01 (m, 1H), 
4.98 (m, 1H), 4.35 (q, J = 7.1 Hz, 2H), 3.19 (dd, J = 14.0, 6.2 Hz, 1H), 3.09 (dd, J = 
14.0, 5.5 Hz, 1H), 2.00 (s, 3H), 1.37 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): 
δ201.9, 169.9, 164.2, 161.7, 135.4, 129.5, 128.7, 127.5, 101.0, 62.9, 57.9, 37.9, 23.3, 
14.2; MS (ESI) (+ve): m/z 306.2 [M+H]+. HRMS (ESI) calcd. for C16H20NO5 [M+H]+ 
m/z 306.1341, found m/z 306.1339 (Figure 8.65). 
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Figure 8.65 High resolution MS of compound 5-4. 
 
 
Figure 8.66 1H NMR of spectrum of compound 5-4. 
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5-Acetamido-2,4-dioxo-6-phenylhexanoic acid (1-143) (sodium salt) 
 
           1-143 
Lithium hydroxide monohydrate (30 mg, 0.72 mmol, 1.00 eq) was added to a solution 
of compound 5-4 (110 mg, 0.36 mmol, 0.50 eq) in THF/H2O (6 mL, 5:1, v/v). The 
mixture was stirred at room temperature for 1 h under nitrogen. Thereafter, the reaction 
mixture was concentrated and added to water (10 mL). The aqueous solution was 
washed with EtOAc (3 × 20 mL) and acidified by the addition of concentrated HCl 
until the pH was below 3. The resulting aqueous solution was extracted with DCM 
(3 × 20 mL). The organic layers were combined, dried over MgSO4, filtered and the 
filtrate concentrated in vacuo to give a yellow oil (72 mg). The resulting acid was 
dissolved in MeOH (5 mL) and converted to its sodium salt by addition of NaOH (10 
mg, 0.26 mmol). The reaction mixture was stirred under nitrogen at room temperature 
for 2 h, filtered to remove insoluble precipitate, and concentrated in vacuo. Thereafter, 
cold Et2O (2 mL) was added to precipitate a pale yellow solid (40 mg, 52%).  
 
m.p.: decomposes. 1H NMR (400 MHz, D2O): δ7.36 (m, 5H), 3.21 (dd, J = 14.0, 4.6 
Hz, 1H), 2.79 (dd, J = 14.0, 10.0 Hz, 1H), 1.82 (s, 3H). MS (ESI) (-ve): m/z 276.4 [M-
H]-. HRMS (ESI) calcd. for C14H14NO5 [M-H]- m/z 276.0872, found m/z 276.0872 
(Figure 8.67). 
 
229 
 
 
Figure 8.67 High resolution MS of compound 1-143. 
 
 
Figure 8.68 1H NMR of spectrum of compound 1-143. 
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N-Methoxy-N-methyl-2-phenylacetamide (5-5) 
 
       5-5 
To a solution of phenylacetic acid (2.00 g, 14.50 mmol) in DCM (25 mL) was added 
N,O-dimethylhydroxylamine hydrochloride (2.17 g, 21.80 mmol, 1.50 eq) and DMAP 
(2.72 g, 21.8 mmol, 1.50 eq) and the mixture was stirred overnight at room 
temperature. A saturated aqueous solution of NaCl was added and the mixture was 
extracted with DCM (2 × 20 mL). The combined organic layers were washed with 0.6 
M HCl solution (20 mL) and saturated NaCl solution (30 mL), dried over MgSO4 and 
the solvent was evaporated to afford a compound as a slightly yellow oil (2.40 g, 92%). 
 
1H NMR (400 MHz, CDCl3): δ7.25 (m, 5H), 3.74 (s, 2H), 3.57 (s, 3H), 3.16 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ172.6, 135.1, 129.4, 128.6, 126.9, 61.5, 39.6, 32.4; 
MS (ESI) (+ve): m/z 180.1 [M+H]+. HRMS (ESI) calcd. for C10H14NO2 [M+H]+ m/z 
180.1025, found m/z 180.1026 (Figure 8.69). 
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Figure 8.69 High resolution MS of compound 5-5. 
 
 
Figure 8.70 1H NMR of spectrum of compound 5-5. 
. 
δ  
232 
 
Ethyl 5-acetamido-1-phenylhex-5-en-2-one (5-6) 
 
 
         5-6 
 
An oven-dried flask equipped with a reflux condenser and a magnetic stir bar was 
cooled under nitrogen and charged with freshly activated magnesium turnings (0.55 g, 
22.32 mmol). Anhydrous Et2O (10 mL) was added to the flask as well as a piece of 
iodine (approx. 2 mg). 4-Bromo-1-butene (1.17 mL, 11.16 mmol, 0.50 eq) was slowly 
added to the reaction mixture dropwise. Self-reflux occurred after warming the flask 
with a warm water bath (60 ºC). After stirring for 30 min, the flask was cooled in an 
ice bath, after which compound 5-5 (1.00 g, 5.58 mmol, 0.25 eq) was added dropwise. 
The reaction mixture was stirred overnight at room temperature. Thereafter, a 
saturated solution of NH4Cl (20 mL) was added at 0 °C. After warming to room 
temperature, the mixture was extracted with EtOAc (3 × 20 mL). The combined 
organic layers were washed with saturated NaCl solution (30 mL) and dried over 
MgSO4. The organic layer was concentrated to afford a yellow oil (0.87 g, 89%) which 
was without further purification. 
 
1H NMR (400 MHz, CDCl3): δ7.25 (m, 5H), 5.76 (ddt, J = 17.1, 10.3, 6.5 Hz, 1H), 
5.01 (dd, J = 17.1, 1.7 Hz, 1H), 4.95 (dd, J = 10.3, 1.7 Hz, 1H), 3.69(s, 2H), 2.55 (t, J 
= 7.3 Hz, 2H), 2.30 (dt, J = 7.3, 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3): δ207.7, 
137.1, 134.3, 129.6, 128.9, 127.2, 115.4, 50.4, 41.2, 27.8; MS (EI) (+ve): 
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m/z 174.1. HRMS (EI) calcd. For C12H14O m/z 197.0942, found m/z 197.0937 
(Figure 8.71). 
 
Figure 8.71 High resolution MS of compound 5-6. 
 
Figure 8.72 1H NMR of spectrum of compound 5-6. 
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1-Phenylhex-5-en-2-amine (5-7) 
   
         5-7 
Compound 5-6 (0.60 g, 3.44 mmol) was dissolved in MeOH (2 mL) and then added 
to the solution of ammonium acetate (1.20 g, 15.49 mmol) and NaBH3CN (0.39 g, 
6.20 mmol) with activated molecular sieves 3Å. The resulting mixture was stirred at 
room temperature for 60 h. Afterwards the solution was transferred to a 100 mL-
round-bottom flask and then quenched by dropwise addition of concentrated HCl (5 
mL) until the pH was 1. The organic solvent was removed under reduced pressure, 
and the residue diluted with water (15 mL). The aqueous layer was washed with Et2O 
(2 × 25 mL) and treated by addition of KOH solution until the pH was 12. It was then 
extracted with Et2O (3 × 30 mL). The combined organic layers were dried over 
MgSO4, filtered, and the solvent was removed in vacuum to afford a slightly yellow 
oil (0.33 g, 55%). 
 
1H NMR (400 MHz, CDCl3): δ7.30 (m, 5H), 5.82 (ddt, J = 17.0, 10.3, 6.5 Hz 1H), 
5.10 (dd, J = 10.3, 1.7 Hz, 1H), 5.02 (dd, J = 17.0, 1.7 Hz, 1H), 3.60 (bs, 2H), 3.22 
(dd, J = 7.6, 5.8 Hz, 1H ) 2.91 (dd, J = 13.6, 5.8 Hz, 1H), 2.78 (dd, J = 13.6, 7.6 Hz 
1H), 2.25 (m, 2H), 1.67 (m, 2H); 13C NMR (100 MHz, CDCl3): δ138.2, 137.8, 129.7, 
129.5, 128.5, 126.8, 115.5, 52.7, 42.7, 34.7, 30.3; MS (ESI) (+ve): m/z 176.2 [M+H]+. 
HRMS (ESI) calcd. for C12H18N [M+H]+ m/z 176.1439, found m/z 176.1441 (Figure 
8.73). 
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Figure 8.73 High resolution MS of compound 5-7. 
 
Figure 8.74 1H NMR of spectrum of compound 5-7. 
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N-(1-Phenylhex-5-en-2-yl)acetamide (5-8) 
  
         5-8 
Compound 5-7 (330 mg, 1.88 mmol) was dissolved in anhydrous DCM (15 mL) in a 
round-bottom flask under nitrogen. The solution was cooled to 0 °C under stirring. 
Et3N (1.31 mL, 9.41 mmol, 5.00 eq) was added via a syringe followed by dropwise 
addition of Ac2O (0.53 mL, 5.65 mmol, 3.00 eq). The reaction mixture was then 
warmed up to room temperature and kept stirring overnight. The reaction mixture was 
washed with 0.12 M HCl solution (3 × 30 mL) and saturated NaHCO3 (3 × 30 mL). 
The organic layer was dried over MgSO4 and concentrated under reduced pressure and 
the ensuing residue obtained was subjected to silica gel flash column chromatography 
(EtOAc/n-hexane, 1:1, v/v) to afford a white solid (0.31 g, 76%). 
 
m.p.: 77.5-78.1 ˚C; 1H NMR (400 MHz, CDCl3): δ7.25 (m, 5H), 5.77 (ddt, J = 17.0, 
10.2, 6.6 Hz, 1H), 5.37 (s, lH), 5.00 (dd, J = 17.0, 1.27 Hz, 1H), 4.90 (dd, J = 10.2, 
1.27 Hz, 1H), 4.20 (m, 1H), 2.82 (dd, J = 13.8, 6.4 Hz, 1H), 2.78 (dd, J = 13.8, 6.5 Hz, 
1H), 2.10 (m, 2H), 1.94 (s, 3H), l.62 (m, 1H), 1.44 (m, 1H); 13C NMR (100 MHz, 
CDCl3): δ171.2, 137.8, 137.7, 129.5, 128.6, 126.7, 115.4, 51.3, 40.8, 33.2, 30.5, 22.5; 
MS (ESI) (+ve): m/z 240.2 [M+Na]+. HRMS (ESI) calcd. for C14H20NO [M+H]+ m/z 
218.1545, found m/z 218.1546 (Figure 8.75). 
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Figure 8.75 High resolution MS of compound 5-8. 
 
Figure 8.76 1H NMR of spectrum of compound 5-8. 
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N-(5,6-Dihydroxy-1-phenylhexan-2-yl)acetamide (5-9) 
  
          5-9 
The 25 mL-two-neck round-bottom flask was equipped with compound 5-8 (220 mg, 
1.01 mmol) and NMO (150 mg, 1.22 mmol, 1.21 eq), followed by addition of acetone 
(9 mL), H2O (1 mL), and OsO4 (4% w/w in H2O, 160 µL, 0.025 mmol, 0.25 eq). The 
reaction mixture was stirred under nitrogen for 5 h. Thereafter, saturated Na2S2O5 
solution (3 mL) was added to quench OsO4, and brine (25 mL) was then added. After 
extraction with EtOAc (3 × 20 mL), the combined organic phase was dried over 
MgSO4 and the ensuing residue was subjected to silica gel flash column 
chromatography (DCM/MeOH, 9:1, v/v) to afford a colourless oil (220 mg, 88%). 
 
1H NMR (400 MHz, CD3OD): (mixture of two diastereomers) δ7.23 (m, 10H), 4.08 
(m, 2H), 3.60 (m, 2H), 3.47 (m, 4H), 2.83 (dd, J = 13.6, 6.4 Hz, 1H), 2.82 (dd, J = 
13.6, 6.4 Hz, 1H), 2.77 (dd, J = 13.6, 7.6 Hz, 1H), 2.76 (dd, J = 13.6, 7.6 Hz, 1H), 1.88 
(s, 3H), 1.87 (s, 3H), 1.77 (m, 8H); 13C NMR (100 MHz, CD3OD): (mixture of two 
diastereomers) δ172.8, 140.0, 130.4, 129.3, 128.2, 127.3, 127.2, 73.3, 72.8, 67.4, 67.3, 
52.5, 52.0, 42.3, 42.2, 31.6, 31.4, 31.1, 30.8, 22.6; MS (ESI) (+ve): m/z 252.2 [M+H]+. 
HRMS (ESI) calcd. for C14H22NO3 [M+H]+ m/z 252.1600, found m/z 252.1602 
(Figure 8.77). 
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Figure 8.77 High resolution MS of compound 5-9. 
 
 
Figure 8.78 1H NMR of spectrum of compound 5-9 (The peak at d 5.49 is attributed 
to DCM).  
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5-Acetamido-2-hydroxy-6-phenylhexanoic acid (5-2) 
  
           5-2 
Diol 5-9 (18 mg, 0.073 mmol) was dissolved in EtOAc (0.66 mL), followed by 
addition of TEMPO (1.20 mg, 0.0074 mmol, 0.10 eq) in 1 M sodium phosphate buffer 
(0.47 mL, pH = 6.8) at room temperature. Then NaClO2 (80%, 50 mg, 0.44 mmol, 
6.00 eq) and NaClO solution (0.60 M, 6.2 µL, 0.0037 mmol, 0.05 eq) were added 
simultaneously in one minute. The mixture was stirred at 50 ºC for 24 h. Thereafter, 
the reaction was quenched with 1 M sodium phosphate buffer (pH = 2.1), followed by 
the extraction with EtOAc (3 × 10 mL). The combined organic layers were dried over 
MgSO4 and concentrated under reduced pressure. The ensuing residue was subjected 
to silica gel flash column chromatography (MeOH/DCM, 1:9, v/v and 
MeOH/THF/AcOH, 1:9:0.1, v/v/v) to afford a colourless oil (7 mg, 37%). 
 
1H NMR (400 MHz, D2O): (mixture of two diastereomers) δ7.31 (m, 10H), 4.21 (m, 
4H), 4.03 (m, 4H), 2.96 (dd, J = 13.4, 4.8 Hz 1H), 2.95 (dd, J = 13.4, 4.8 Hz, 1H), 2.68 
(dd, J = 13.4, 9.4 Hz, 1H), 2.67 (dd, J = 13.4, 9.4 Hz, 1H), 1.87 (s, 6H), 1.69 (m, 8H); 
13C NMR (175 MHz, D2O): (mixture of two diastereomers) δ178.6, 174.2, 139.4, 
130.2, 129.2, 127.2, 70.9, 70.5, 51.8, 51.5, 41.2, 41.0, 30.9, 30.7, 30.1, 30.0, 22.5; MS 
(ESI) (-ve): m/z 264.3 [M-H]-. HRMS (ESI) calcd. for C14H18NO4 [M-H]- m/z 
264.1236, found m/z 264.1235 (Figure 8.79). 
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Figure 8.79 High resolution MS of compound 5-2. 
 
Figure 8.80 1H NMR of spectrum of compound 5-2. 
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tert-Butyl-Oα-((S)-N-acetylphenylalanyl)-glycolate (5-10) 
 
           5-10 
To a solution of compound 4-1 (1.00 g, 4.78 mmol) in acetone (100 mL) was added 
potassium carbonate (1.32 g, 9.56 mmol, 2.00 eq) and tert-butyl bromoacetate (0.72 
mL, 4.78 mmol, 1.00 eq). The mixture was heated at reflux overnight under nitrogen, 
and evaporated under reduced pressure. The crude oil was partitioned between n-
hexane (100 mL) and water (100 mL). The organic fraction was dried over MgSO4, 
filtered, and evaporated under reduced pressure to give the title compound (1.35 g, 
88%) as a colourless oil.  
 
1H NMR (400 MHz, CDCl3): δ7.24 (m, 5H), 5.81 (d, J = 7.8 Hz, 1H), 4.97 (dt, J = 
7.8, 6.1 Hz, lH), 4.62 (d, J = 15.6 Hz, 1H), 4.50 (d, J = 15.6 Hz, 1H), 3.28 (dd, J = 
14.1, 5.7 Hz, 1H), 3.12 (dd, J = 14.1, 6.5 Hz, 1H), 1.96 (s, 3H), 1.49 (s, 9H); MS (ESI) 
(+ve): m/z 344.2 [M+Na]+. HRMS (ESI) calcd. for C17H23NO5Na [M+Na]+ m/z 
344.1474, found m/z 344.1471 (Figure 8.81). 
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Figure 8.81 High resolution MS of compound 5-10. 
 
Figure 8.82 1H NMR of spectrum of compound 5-10. 
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Oα-((S)-N-Acetylphenylalanyl)-glycolic acid (1-57) 
 
           1-57 
A solution of compound 5-10 (200 mg, 0.62 mmol) in neat TFA (2 mL) was stirred at 
room temperature under nitrogen for 30 min, before evaporation of solvent under 
reduced pressure. Et2O was added and the mixture was concentrated under reduced 
pressure to give the title compound (140 mg, 86%) as an oil. The purity was checked 
by preparative HPLC using the same method as described for compound 4-3. The 
resulting HPLC is reproduced in Figure 8.83, and showed one dominant peak at 27.90 
min. Sample corresponding to the peak was isolated through HPLC. Mass 
spectrometry of the peak at 27.90 min displayed ions at m/z 264.1, which corresponds 
to the [M-H]- for compound 1-57.  
1H NMR (400 MHz, CDCl3): δ7.23 (m, 5H), 6.15 (d, J = 7.7 Hz, 1H), 4.96 (m, lH), 
4.73 (d, J = 16.2 Hz, 1H), 4.68 (d, J = 16.2 Hz, 1H), 3.25 (dd, J = 14.1, 5.8 Hz, 1H), 
3.11 (dd, J = 14.1, 6.7 Hz, 1H), 1.99 (s, 3H); 13C NMR (100 MHz, CDCl3): δ171.5, 
171.1, 170.5, 135.5, 129.4, 128.9, 127.5, 61.1, 53.4, 37.4, 22.9; MS (ESI) (+ve): m/z 
264.1 [M-H]-. HRMS (ESI) calcd. for C13H14NO5 [M-H]- m/z 264.0872, found m/z 
264.0873 (Figure 8.84). 
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Figure 8.83 HPLC chromatogram of compound 1-57. 
 
 
Figure 8.84 High resolution MS of compound 1-57. 
1-57 
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Figure 8.85 1H NMR of spectrum of compound 1-57. 
 
Ethyl N-acetyl-(S)-phenylalaninate (5-11) 
 
         5-11 
To a solution of 4-1 (3.00 g, 14.30 mmol) in EtOH (72 mL) was added concentrated 
HCl (0.3 mL); the reaction mixture was refluxed overnight and then concentrated 
under reduced pressure. The residual solid was dissolved in EtOAc (10 mL), washed 
with saturated NaHCO3 solution (2 × 20 mL) and H2O (1 × 10 mL). The organic phase 
was dried over MgSO4 and concentrated under reduced pressure to give compound 5-
11 (2.77 g, 82%) as a white solid. 
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1H NMR (400 MHz, CDCl3): δ7.27 (m, 3H), 7.10 (m, 2H), 5.91 (bd, J = 7.8 Hz, 1H), 
4.87 (dd, J = 7.8, 5.8, 4.8 Hz, lH), 4.17 (q, J = 7.2 Hz, 2H), 3.15 (dd, J = 12.7, 4.8 Hz, 
1H), 3.15 (dd, J = 12.7, 5.8 Hz, 1H), 1.99 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H); MS (ESI) 
(+ve): m/z 258.2 [M+Na]+. HRMS (ESI) calcd. for C13H17NO3Na [M+Na]+ m/z 
258.1106, found m/z 258.1113 (Figure 8.86). 
 
 
Figure 8.86 High resolution MS of compound 5-11. 
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Figure 8.87 1H NMR of spectrum of compound 5-11. 
 
Dimethyl (S)-(3-acetamido-2-oxo-4-phenylbutyl)-phosphonate (5-12) 
 
          5-12 
n-Butyl-lithium (5.56 mL, 8.50 mmol) was slowly added, under nitrogen, to a solution 
of dimethyl methylphosphonate (0.95 mL, 8.50 mmol, 1.00 eq) in anhydrous THF (20 
mL) kept at -78 °C. The reaction mixture was stirred at -78 °C for 30 min, during 
which a white precipitate was formed, followed by the addition of compound 5-11 
(1.00 g, 4.25 mmol, 0.50 eq) in THF (1 mL). The mixture was slowly brought to room 
temperature, stirred overnight, monitored by TLC with eluting solvent EtOAc, and 
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quenched by the addition of H2O (5 mL), followed by the extraction with Et2O (3 
× 10 mL). The aqueous layer was acidified by the addition of concentrated HCl and 
extracted with DCM (3 × 10 mL); the extracts were dried over MgSO4, filtered, and 
concentrated under reduced pressure. The crude product 5-12 was subjected to silica 
gel flash column chromatography with the eluting solvent DCM/MeOH (20:1, v/v), to 
give a colourless oil (669 mg, 50%).  
 
1H NMR (400 MHz, CDCl3): δ7.23 (m, 5H), 6.44 (d, J = 7.8 Hz, 1H), 4.90 (m, 1H), 
3.75 (m, 6H), 3.23 (m, 2H), 3.02 (m, 2H), 1.98 (s, 3H); MS (ESI) (+ve): m/z 336.1 
[M+Na]+. HRMS (ESI) calcd. for C14H20NO5NaP [M+Na]+ m/z 336.0977, found m/z 
336.0991 (Figure 8.88). 
 
 
Figure 8.88 High resolution MS of compound 5-12. 
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Figure 8.89 1H NMR of spectrum of compound 5-12. 
 
Ethyl (S,E)-5-acetamido-4-oxo-6-phenylhex-2-enoate (5-13) 
 
          5-13 
 
To a 50 mL-round-bottom flask equipped with a magnetic stirring bar was added 
commercial ethyl glyoxalate solution (50% w/w in toluene, 10 mL). The solution was 
warmed to 50 °C at 35 mbar to remove most of toluene in vacuo. Afterwards, the flask 
was attached to distillation apparatus and warmed to 90 °C (observed 62 °C) to get rid 
of the rest of toluene. Then the pressure was reduced to 200 mbar and the oil bath was 
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slowly warmed to 115 °C to depolymerise and collect ethyl glyoxalate. To a mixture 
of compound 5-12 (373 mg, 1.19 mmol) and ethyl glyoxalate (freshly distilled) (147 
mg, 1.43 mmol, 1.20 eq) was added potassium carbonate (329 mg, 2.38 mmol, 2.00 
eq) in water (20 mL). The reaction mixture was stirred at 0 °C for 30 min, producing 
suspended white solid. After dried under freeze dryer, the solid was recrystallised from 
hot hexane to yield pure compound 5-13 (190 mg, 55%) as white needle-shape crystals.  
 
m.p.: 117.0-119.6 ˚C; 1H NMR (400 MHz, CDCl3): δ7.26 (m, 3H), 7.13 (d, J = 15.8 
Hz, 1H), 7.06 (m, 2H), 6.77 (d, J = 15.8 Hz, 1H), 6.06 (d, J = 7.2 Hz, 1H), 5.13 (ddd, 
J = 7.2, 6.7, 5.6 Hz, 1H), 4.27 (q, J = 7.1 Hz, lH), 3.21 (dd, J = 14.1, 6.7 Hz, 1H), 3.09 
(dd, J = 14.1, 5.6 Hz, 1H), 2.00 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, 
CDCl3): δ197.0, 169.8, 165.1, 136.3, 135.3, 132.9, 129.5, 128.9, 127.5, 61.7, 58.6, 
37.2, 23.3, 14.3; MS (ESI) (+ve): m/z 312.1 [M+Na]+. HRMS (ESI) calcd. for 
C16H19NO4Na [M+Na]+ m/z 312.1212, found m/z 312.1213 (Figure 8.90). 
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Figure 8.90 High resolution MS of compound 5-13. 
 
Figure 8.91 1H NMR of spectrum of compound 5-13. 
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4-Oxo-5-acetamido-6-phenyl-hex-2-enoic acid (1-39) 
 
            1-39 
 
To a solution of compound 5-13 (37 mg, 0.13 mmol) in MeOH (2 mL) was added 
0.1 M phosphate buffer (20 mL, pH 7.0) and pig liver esterase (370 units, 22 mg). The 
reaction mixture was shaken vigorously in the incubator at 30 °C for 18 h and washed 
with Et2O (2 × 20 mL). The aqueous layer was acidified by the addition of 
concentrated HCl (approx. pH 3, turned cloudy) and extracted with DCM (3 × 20 mL, 
emulsion). The combined organic extracts were dried over MgSO4, concentrated under 
reduced pressure and finally purified by preparative HPLC using an Alltima C18 5μ 
(22 × 250 mm) column (6 mL/min). The analysis was carried out with a linear gradient 
elution of 50:50 (MeOH: H2O (0.1% TFA), v/v) to 70:30 between 0-30 min, followed 
by maintenance of 50:50 between 30-35 min. The resulting HPLC is reproduced in 
Figure 8.92, and showed one dominant peak at 24.50 min. Sample corresponding to 
the peak was isolated through HPLC. Mass spectrometry of the peak at 24.50 min 
displayed ions at m/z 260.2, which corresponds to the [M-H]- for compound 1-39. 
Based on this analysis, preparative HPLC was used to isolate compound 1-39. The 
column fractions were concentrated via freeze drying to give compound 1-39 (16 mg, 
48%) as a colourless powder. 
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m.p.: decomposes; 1H NMR (400 MHz, DMSO-d6): δ8.41 (d, J = 7.4 Hz, 1H), 7.23 
(m, 5H), 7.09 (d, J = 15.8 Hz, 1H), 6.58 (d, J = 15.8 Hz, 1H), 4.71 (ddd, J = 9.5, 7.4, 
5.2 Hz, lH), 3.05 (dd, J = 13.9, 5.2 Hz, 1H), 2.78 (dd, J = 13.9, 9.5 Hz, 1H), 1.79 (s, 
3H); 13C NMR (100 MHz, DMSO-d6): δ197.8, 169.5, 166.4, 137.5, 136.4, 132.1, 
129.2, 128.2, 126.4, 58.5, 34.9, 22.2; MS (ESI) (+ve): m/z 260.2 [M-H]-. HRMS (ESI) 
calcd. for C14H14NO4 [M-H]- m/z 260.0923, found m/z 260.0923 (Figure 8.93). 
 
 
Figure 8.92 HPLC chromatogram of compound 1-39. 
 
1-39 
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Figure 8.93 High resolution MS of compound 1-39. 
 
Figure 8.94 1H NMR of spectrum of compound 1-39. 
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(E)-4-(Benzyloxy)-4-oxobut-2-enoic acid (5-3) 
 
            5-3 
 
Fumaric acid (1.00 g, 8.62 mmol) and benzyl alcohol (890 µL, 8.62 mmol, 1.00 eq) 
were dissolved in anhydrous DMF (10 mL). NMM (0.97 mL, 8.62 mmol, 1.00 eq) was 
added at 0 ºC followed by EDC (1.65 g, 8.62 mmol, 1.00 eq) after 30 min. The reaction 
was stirred for 16 h at room temperature. Thereafter, the reaction mixture was 
concentrated in vacuo and dissolved in EtOAc (10 mL), followed by extraction with 
saturated aqueous NaHCO3 solution (3 × 40 mL). The combined aqueous layer was 
then acidified with concentrated HCl to pH 2. The product was extracted with EtOAc 
(2 × 20 mL), and the organic phase was washed with H2O (2 × 20 mL) and dried over 
MgSO4. The ensuing residue was subjected to silica gel flash column chromatography 
(EtOAc/n-hexane/AcOH, 5:4.9:0.1, v/v/v) to afford a white solid (0.89 g, 50%).  
 
m.p.: 113.5-114.7 ˚C; 1H NMR (400 MHz, CDCl3): δ7.38 (m, 5H), 6.98 (d, J = 15.8 
Hz, 1H), 6.88 (d, J = 15.8 Hz, 1H) 5.25 (s, 2H); 13C NMR (100 MHz, CDCl3): δ169.2, 
164.6, 135.6, 135.2, 132.9, 128.8, 128.7, 128.6, 67.5; MS (ESI) (+ve): m/z 229.1 
[M+Na]+. HRMS (ESI) calcd. for C11H10O4Na [M+Na]+ m/z 229.0477, found  m/z 
229.0482 (Figure 8.95). 
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Figure 8.95 High resolution MS of compound 5-3. 
 
Figure 8.96 1H NMR of spectrum of compound 5-3. 
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8.5.2 Procedure for PAM Inhibition Assay 
 
Assays were performed with 1.25 mM ascorbic acid, 10 μM copper sulphate, 
0.2 mg/mL bovine liver catalase, 1% EtOH, 1% DMSO, 50 μM tripeptide substrate 
(R)-Tyr-(S)-Val-Gly-COOH and 0.4-0 µM (for PAL inhibition assay) and 100-0 µM 
(for PHM inhibition assay) at 2X serial dilution of compound 1-143 in 150 mM MES 
buffer at pH 5.8. For the concentration selection of other compound candidates, 
compounds 5-1 and 5-2 were tested with 400-0 µM at 10X serial dilution; compound 
1-57 was tested with 100-0 µM (for PAL inhibition assay) and 2000-0 µM (for PHM 
inhibition assay) at 2X serial dilution; compound 1-39 was tested with 100-0 µM at 
2X serial dilution; compound 5-3 was tested with 150-0 µM at 2X serial dilution; 
compound 1-17 was tested with 20-0 µM at 2X serial dilution and 100 µM. Assays 
were initiated through the addition of concentrated PAM (5 μL) to give a final volume 
of 100 μL. The mixtures were incubated in a Lab Companion Model SI-600R open-
air shaker at 37 ºC for 2 h, with agitation at 80 rpm. The solutions were then passed 
through Amicon® Ultra YM-3 filters using a centrifuge for 15 min at 12000 rpm at 
room temperature. All prepared samples were analysed using HPLC-MS system 
except that the samples of compound 5-3 were analysed using HPLC with a 
fluorescence detector, of which the solvent system and column conditions were 
exactly same as described in Section 8.2.4. In the trace reproduced by HPLC with a 
fluorescence detector, the peak of hydroxylated tripeptide appears at 18.63 min. The 
data for all assessment that not shown in Chapter 5 are illustrated below in Figure 
8.97 – Figure 8.101. 
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Figure 8.97 Determination of IC50 against PHM for N-Ac-Phe-glycolate (1-57) (µM) 
IC50 = 151 ± 20 µM 
R2 > 0.99 
 
IC50 = 126 ± 25 µM 
R2 > 0.99 
 
N-Ac-Phe-glycolate (1-57) (µM) 
N-Ac-Phe-glycolate (1-57) (µM) 
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Figure 8.98 Data of PAL inhibition using N-Ac-Phe-glycolate (1-57) (µM) 
 
No PAL inhibition 
 
No PAL inhibition 
 
N-Ac-Phe-glycolate (1-57) (µM) 
N-Ac-Phe-glycolate (1-57) (µM) 
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Figure 8.99 Determination of IC50 against PHM for compound 1-39 (µM) 
 
 
IC50 = 3.0 ± 1.0 µM 
R2 > 0.99 
 
IC50 = 3.1 ± 1.0 µM 
R2 > 0.99 
 
Compound 1-39 (µM) 
Compound 1-39 (µM) 
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Figure 8.100 Determination of IC50 against PHM for the fumaric acid 5-3 (µM) 
 
IC50 = 30 ± 1 µM 
R2 > 0.99 
 
IC50 = 33 ± 1 µM 
R2 > 0.99 
 
The fumaric acid 5-3 (µM) 
The fumaric acid 5-3 (µM) 
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Figure 8.101 Determination of IC50 against PHM for PBA (1-17) (µM) 
 
 
IC50 = 17 ± 6 µM 
R2 > 0.99 
 
IC50 = 11 ± 4 µM 
R2 > 0.99 
 
PBA 
PBA (1-17) (µM) 
PBA (1-17) (µM) 
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8.5.3 Procedure for pH-Dependent PAL Inhibition Assay Using N-Ac-Phe-
pyruvate (1-143) 
 
The pH-dependent PAL Assays using N-Ac-Phe-pyruvate (1-143) were performed in 
the same manner as described in Section 8.5.2, except that four more pH conditions 
of MES buffer were used, which were pH 5.5, 6.1, 6.4 and 6.7. All assays were run at 
least in duplicate. Data related to pH 5.5, 6.1, 6.4 and 6.7 were shown below (Figure 
8.102 – Figure 8.105). 
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Figure 8.102 Determination of IC50 against PAL for N-Ac-Phe-pyruvate (1-143) 
(µM) at pH 5.5 
 
 
 
IC50 = 0.08 ± 0.01 µM 
R2 > 0.99 
 
IC50 = 0.08 ± 0.01 µM 
R2 > 0.99 
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Figure 8.103 Determination of IC50 against PAL for N-Ac-Phe-pyruvate (1-143) 
(µM) at pH 6.1 
 
 
 
 
 
IC50 = 0.10 ± 0.01 µM 
R2 > 0.99 
 
IC50 = 0.11 ± 0.01 µM 
R2 > 0.99 
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Figure 8.104 Determination of IC50 against PAL for N-Ac-Phe-pyruvate (1-143) 
(µM) at pH 6.4 
 
 
 
 
IC50 = 0.12 ± 0.02 µM 
R2 > 0.99 
 
IC50 = 0.11 ± 0.02 µM 
R2 > 0.99 
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Figure 8.105 Determination of IC50 against PAL for N-Ac-Phe-pyruvate (1-143) 
(µM) at pH 6.7  
IC50 = 0.18 ± 0.02 µM 
R2 > 0.97 
 
IC50 = 0.19 ± 0.02 µM 
R2 > 0.99 
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Appendix 
 
Ascorbate-concentration-dependent isolated PAM assay was performed by using 
substrate tripeptide (R)-Tyr-(S)-Val-Gly-COOH. Except concentrations of ascorbate, 
other assay conditions are similar to that described in Section 8.4.2. The substrate 
turnover were analysed by using HPLC with a fluorescence detector as described in 
Section 8.2.4. Figure A1 shows that when the concentration of ascorbate is below 
0.31 mM, the substrate turnover is below two percent. The increasing of concentration 
from 0.31 mM to 2.5 mM increases the substrate turnover. The continuously 
increasing concentrations of ascorbate then decrease substrate turnover. 
 
 
Figure A1 Substrate turnover in ascorbate concentration-dependent assay.  
 
 
 
270 
 
In PAM activity, the product from the oxidation of ascorbate in PAM has been 
confirmed as semidehydroascorbate (SD), which requires semidehydroascorbate 
reductase (SDR), a type of NADH oxidase, to reduce back to ascorbate to form a 
recycling of ascorbate.[99] The NADH oxidase activity is a major source of superoxide 
anion and is inhibited by peroxynitrite (ONOO-).[223] Based on this, our hypothesis is 
that if SDR is inhibited by addition of ONOO- the level of ascorbate participating in 
PAM activity is expected to decrease and thus decrease the level of amidated product. 
Considering the complexity of the environment of the medium of DMS53 cells, it is 
convenient to get a quick answer on whether doping ONOO- in the whole cell assay 
could accumulate the level of CTG and decrease the level of CT. Due to the short 
biological half-life of ONOO- (can be < 0.1 s), chronic exposure to micromolar 
ONOO- was simulated by treatment of 3-morpholinosydnonimine hydrochloride 
(SIN-1) with repetitive pulses of ONOO- in the micromolar range.[223-224] The whole 
cell assay with SIN-1 was performed by adding 0, 1mM, and 2 mM SIN-1 every 12 h 
for 24 h after DMS53 cells growing to about 80 % density. The medium samples were 
collected and injected onto HPLC with fluorescence detection. The number of cells 
was counted in the same way as the whole cell PAL inhibition assay did. The HPLC 
traces were shown in Figure A2 below.  
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Figure A2 HPLC trace of (A) DMS53 medium sample; (B) DMS53 medium sample 
with 1 mM SIN-1; (C) DMS53 medium sample with 2 mM SIN-1.  
A 
B 
C 
CT  CTG  
CTG  
CT  
CT  
CTG  
Retention time Area % Area 
CTG 75.507 1181185 44.82%
CT 81.279 1454320 55.18%
Retention time Area % Area 
CTG 75.467 1224203 65.40%
CT 81.201 647560 34.60%
Retention time Area % Area 
CTG 75.317 814722 68.55%
CT 81.042 373716 31.45%
CTG/CT = 0.81, Cell number: 32 M 
  
CTG/CT = 1.89, Cell number: 34 M 
  
CTG/CT = 2.18, Cell number: 23 M 
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Compared with the level of CTG and CT in the blank sample (Figure A2A), the level 
of CTG in 1mM SIN-1 sample slightly increases while the CT level decreases 
significantly (Figure A2B), where CTG/CT value in Figure A2A was 0.81 while the 
value in Figure A2B increased to 1.89. This indicates that SIN-1 inhibits PHM activity, 
which is consistent with our hypothesis. When the concentration of SIN-1 is 2 mM, 
CTG/CT value is similar to that in 1 mM sample, but CTG and CT levels dropped 
about 33% and 50%, respectively. It is likely that SIN-1 with 2 mM shows cytotoxic 
against DMS53 cells, which is consistent with the fact that counted cell number 
decreases by around 33%.   
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